







Helicobacter pylori is a gram negative, microaerophilic bacteria that plays an
important role in chronic gastritis and peptic ulcer disease. Multiple antimicrobial
therapies including combinations of clarithromycin, metronidazole or amoxycillin
and proton pump inhibitor have been used to eradicate H. pylori. Antimicrobial
resistance in H. pylori has been associated with treatment failure. In this study,
antimicrobial susceptibility patterns of amoxycillin, ciprofloxacin, clarithromycin,
erythromycin, tetracycline and metronidazole were evaluated in 110 H. pylori strains
isolated from 454 antral biopsies of patients undergoing endoscopy at the Royal
Infirmary, Edinburgh. The MICs were determined by E-test. Resistance to
clarithromycin and erythromycin was found in 8.2% (9/110) and 9.1% (10/110)
respectively. Metronidazole resistance was demonstrated in 8 isolates (7.3%).
Tetracycline resistance was found in one of the isolates (0.9%). Two isolates were
resistant to ciprofloxacin (1.8%). Resistance to amoxycillin was not detected.
Molecular mechanisms of fluoroquinolone, macrolide and metronidazole resistance
in H. pylori were investigated. Resistant to fluoroquinolone has been associated with
alterations in the Quinolone Resistance-Determining Region (QRDR) of gyrA gene.
Mutation at position 91, leading to an amino acid change from Aspartic acid to
Asparagine was found in 2 ciprofloxacin-resistant isolates. One isolate had a
mutation at Asparagine-87 to Lysine. Mutations in the 23S rRNA conferring
macrolide resistance were investigated. Mutations at position 2143 (A to G) were
shown in seven of the ten macrolide-resistant isolates. Two of the seven isolates
carried an additional T to C mutation at either position 2182 or 1934. Of the ten
macrolide-resistant isolates, two had a single mutation at either position 2182 or
2195. Mutation at position 2182, however, has previously been identified not to be
associated with macrolide resistance. The mutations at position at 1934 (T to C) and
position 2195 (C to T) have not previously been reported. One of the ten isolates
(MIC>256 mg/L) had no alteration in the 23S rRNA. The results indicate that
different mechanisms play a role in macrolide resistance in these H. pylori strains.
Metronidazole resistance has been reported to be associated with mutations in the
rdxA gene, encoding oxygen-insensitive nitroreductase. To investigate the role of
rdxA, sequencing analysis of rdxA of metronidazole-resistant isolates was
determined. The results showed that no particular amino acid substitution was
associated with metronidazole resistance. One isolate contained a nonsense mutation,
generating a stop codon. However, two metronidazole-sensitive strains had
alterations in rdxA by insertions of a mini-IS605 sequence. These results suggest that
alterations in rdxA are not the sole mechanism of metronidazole resistance and other
mechanisms are required in the development of resistance.
Since the prevalence rate of metronidazole resistance is variable, ranging from 11 to
70%, it is possible that some variation in reported resistance levels derives from
difficulties in the method of sensitivity testing. To set a standard for susceptibility
testing for metronidazole in H. pylori, the optimum conditions for sensitivity testing
were evaluated. Activation of metronidazole requires an anaerobic environment. It
was found that incubation under microaerophilic conditions elevated metronidazole
MIC, suggesting that microaerophilic conditions cannot activate metronidazole to its
active form. Pre-incubation of H. pylori in anaerobic conditions for 24 hours prior to
incubation under microaerophilic conditions for 72 hours was found to be necessary
to achieve accurate susceptibility results. This can explain why some centres report
high levels of metronidazole resistance.
To investigate the development of fluoroquinolone resistance in H. pylori,
ciprofloxacin-resistant mutants were selected in vitro by exposing sensitive strains to
serial increments of ciprofloxacin in Columbia blood agar plate. The QRDR of gyrA
gene was analysed for mutations. Reduced susceptibility to ciprofloxacin was
associated with either a single or double amino acid changes in gyrA gene. Mutations
at position 85, 87 and 91 were found to be associated with ciprofloxacin resistance.
The results also demonstrated that gyrA mutations are not sole contributors for the
mechanism of ciprofloxacin resistance in H. pylori. As no parC gene has not yet
been identified in H. pylori, any contribution from topoisomerase IV cannot be
quantified. To investigate the DNA gyrase activity in H. pylori, gyrA and gyrB were
separately cloned and overexpressed by using a T7 promoter vector, which contain a
fusion tag of six histidine residues. GyrA and GyrB were purified by affinity
chromatography using nickel-chelating resins. The ability of DNA gyrase to
supercoil relaxed DNA was determined.
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Since Helicobacter pylori was first isolated in 1982 by Marshall and Warren (Marshall
and Warren, 1984), it has been recognized as the principal cause of peptic ulcer disease
and as a risk factor in the development of gastric cancer (Parsonnet et al., 1991). The
discovery of the role of H. pylori infection has led to a breakthrough in medical care.
Successful eradication of H. pylori infection requires a combination of two or three
antibiotics and proton pump inhibitors. However, antibiotic resistance has emerged and
is a principal cause of treatment failure. Understanding the mechanism of resistance will
lead to better antibiotic administration and may lead to a design of novel and more
effective drugs for a new successful treatment of H. pylori. Furthermore, identification
and characterization of resistant gene will provide a sensitive and rapid method to detect
antibiotic-resistant strains.
1.2 Discovery of H. pylori
The discovery of these bacteria was revealed by a series of unrelated observations.
These were not obvious indicators at the time but are now clear demonstration of H.
pylori. In 1893, Bizzozero first described the presence of spiral-shaped bacteria in the
gastric glands and parietal cells of dogs. Krienitz, in 1906, noted that gastric
spirochaetes were found in human stomach. In 1938, Doenges reported spirochaetes
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present in 43% of 242 samples from autopsy stomachs. In 1975, spiral bacteria were
demonstrated in 80% of gastric samples from patients with gastric ulceration (Steer,
1975). In 1979, Fung et al. described endoscopic, histological and ultrastructural
correlations of chronic gastritis and showed that spiral bacteria were on the lumen
surface of epithelial cells (Fung et al., 1979).
It was almost one century after Bizzozero described spiral-shaped bacteria that Warren
and Marshall, in 1982, were the first able to culture spiral organisms from gastric
biopsies obtained from patients with upper gastrointestinal complaints. They used
methods for the isolation of Campylobacter species and incubated the cultures under
microaerophilic conditions for 48 hours. The initial cultures were unsuccessful. During
the Easter weekend, the plates were unintentionally incubated for 5 days and colonies
were seen. Subsequently, other biopsy samples were also cultured for 3-4 days and the
organisms were isolated. These organisms were characterized and called Campylobacter
pyloridis since they were resembled other Campylobacter species in morphological
characteristics and guanine/cytosine content (Marshall and Warren, 1984).
Subsequently, the species name was changed to C. pylori. In 1989, Goodwin suggested
that C. pylori should be transferred to the new genus Helicobacter on the basis of
comparison of 16S rRNA sequences, fatty acid contents, biochemical reactions and
ultrastructure features (Goodwin et al, 1989). Following publication by Marshall and
Warren (1984), the presence of these organisms in the gastric mucus was rapidly
confirmed (Jones et al., 1984; McNulty and Watson, 1984).
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In an effort to prove that these curved bacteria were the cause of upper gastrointestinal
disease, Marshall conducted an ingestion study by infecting himself and developed
gastritis afterwards (Marshall et al., 1985). Koch's postulates were, therefore, fulfilled
and the association between H. pylori and upper gastrointestinal disease has been
established. Since the discovery of H. pylori, the perception of peptic ulcer disease has
subsequently altered from chronic, recurring disease of uncertain origin to a disease,
caused by bacteria, which can be cured by antibiotic-based treatments.
In 1994, the International Agency for Cancer Research stated that H. pylori was a
grade I carcinogen of humans and a consensus conference convened by the National
Institutes of Health concluded that H. pylori was a major cause of peptic ulcer disease
and strongly recommended that patients with H. pylori infection and gastric or duodenal
ulcers should be treated to eradicate the bacterium (NIH Consensus Conference, 1994).
H. pylori infection also has been associated with the development of gastric non-
Hodgkin's lymphomas (Parsonnet et al., 1991) and gastric mucosa-associated lymphoid
tissue (MALT) lymphoma (Eidt et al., 1994; Wotherspoon et al., 1991). H. pylori,




H. pylori organisms are curved to spiral-shaped, Gram-negative bacteria that colonise
the gastric lumen of primates, including human. After prolonged culture, coccoid forms
typically predominate (Bode et al., 1993) and are metabolically active but cannot be
cultured in vitro. H. pylori is found to be 2.5 to 5.0 pm long and 0.5 to 1.0 pm wide
with four to six unipolar sheathed flagella in gastric biopsy samples (Goodwin and
Armstrong, 1990; Goodwin et al., 1985). Flagella are important for bacterial motility. H.
pylori are mostly actively motile but may appear to be non-motile in hanging drop
preparations in some cultures (Owen, 1998). H. pylori are microaerophilic bacteria,
growing best in an atmosphere of 5% oxygen, however, after laboratory passages, some
strains can grow in 10% CO2 (Goodwin and Armstrong, 1990). H. pylori requires
complex basal medium with supplementation such as whole blood, serum, haem,
cornstarch, charcoal, or egg yolk emulsion (Hachem et al., 1995; Henriksen et al.,
1995). Colonies of H. pylori with circular (l-2mm), convex and translucent on blood
agar normally take 3-5 days at 37°C to appear for the primary isolation. H. pylori does
not oxidise or ferment carbohydrates. It produces catalase, oxidase and high level of
urease and alkaline phosphatase (Owen, 1998).
The genome size of H. pylori ranges from 1.6 to 1.73 Mb, with an average of 1.67 Mb
(Taylor et al., 1992). The G+C content ranges from 34.1 to 37.5mol% with an average
value of 35.2 mol% (Beji et al., 1988). H. pylori exhibits considerable re-arrangements
in gene order and sequence variation within gene (Jiang et al., 1996), including genes
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that encode urease (Foxall et al., 1992) and accessory proteins, flagellin (Forbes et al.,
1995), vacuolating cytotoxin (VacA) (Cover et al., 1994), and Cytotoxin-associated
protein (CagA) (Garner and Cover, 1995; Kato et al., 1996; Miehlke et al., 1996).
Although, plasmids are present in about 40% of H. pylori strains with the size ranging
from 1.5 to 23.3 kb, they do not have known virulence factors (Kleanthous et al., 1991;
Minnis et al., 1995). The lipopolysaccharide (LPS) expresses Lewis blood group
antigens (Appelmelk et al., 1997), which may play a role in pathogenesis.
1.4 H. pylori Infection
H. pylori colonise the stomachs and cause continuous inflammation (Dooley et al.,
1989), leading to increasing risk for a wide range of clinical outcomes. H. pylori
infection is recognised as a cause of chronic active gastritis and peptic ulcer disease. It is
considered to be a risk factor for gastric cancer and MALT lymphoma (Parsonnet et al.,
1991; Parsonnet et al., 1994; Peterson, 1991). The majority of infected persons do not
develop clinically apparent disease. It is likely that a combination of several factors,
such as strain pathogenicity, environmental conditions and individual host response
influences the disease outcome (Cremonini et al., 2001).
H. pylori produces a variety of substances and enzymes that cause injury to the epithelial
cells, such as urease (Labigne et al., 1991), superoxide dismutase (Spiegelhalder et al.,
1993) and phospholipases (Mauch et al., 1993). Vacuolating cytotoxin (VacA) and
cytotoxin-associated protein (CagA) are produced by only some clinical isolates
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(Covacci et al., 1993; Cover et al., 1995; Cover et al., 1994; Phadnis et al., 1994).
Although vacA is present in nearly all H. pylori strains, only 40-60% of the strains have
cytotoxin activity (Cover et al., 1990; Weel et al., 1996). The vacA gene type si is
associated with enhanced gastric inflammation and more severe diseases (Atherton et
al., 1997). H. pylori strains (60%) carrying the cagA gene have been reported to be
associated with enhanced expression of interleukin-la(IL-1 a), interleukin-lp (EL-lp)
and interleukin-8 (IL-8) and mucosal inflammation (Peek et al., 1995). The release of
IL-8, which has potent chemotactic activity for neutrophils, plays a role in gastric
inflammation and cell damage (Censini et al., 1996). There is a close association
between the presence of cagA and vacA type si. Most si strains are cagA positive
(Atherton et al., 1995). Autoimmunity may play a role in epithelial cell destruction and
mucosal damage as Lewis blood antigen has been found to be expressed on the
lipopolysaccharide of H. pylori (Appelmelk et al., 1996).
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1.5 Epidemiology of H. pylori Infection
H. pylori is one of the commonest bacteria in humans. It has been found in the stomachs
of humans in all parts of the world. In developing countries, 70 to 90% of the population
carries H. pylori. The prevalence of infection is lower in developed countries, ranging
from 25 to 50%. The acquisition seems to occur predominantly in childhood (Goodman
and Correa, 1995; Mendall and Northfield, 1995).
Most studies suggest that males and females have the same risk of becoming infected in
all age groups considered. In developed countries, H. pylori infection rate is lower in
individuals with higher socioeconomic status although the rate of infection is high
among certain ethnic groups despite economic advancement (Graham et al., 1991;
Mendall et al., 1992)
I.5.1 Transmission
Since H. pylori is a bacterium restricted to humans and other primates, its route of
transmission remains unclear. Various pathways have been discussed, favoring a person-
to-person mode of transmission. It is suggested that both fecal-oral and oral-oral
transmission is predominant in childhood (Thomas, 1994). In particular, H. pylori has
been isolated from the faeces of infected children (Thomas et al., 1992), indicating that
shedding is intermittent. Faecally contaminated water may be a source of infection
(Klein et al., 1991). H. pylori can reach the oral cavity. Oral-oral transmission has been
7
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reported in the case of African women who premasticated foods given to their infants
(Megraud, 1995). Sexually transmission has not been identified (Perez-Perez et al.,
1991; Polish et al., 1991).
Childhood is thought to be the primary period of risk for H. pylori acquisition (Malaty
and Graham 1994). H. pylori can be found in saliva, dental plaque (Ferguson et al.,
1993; Krajden et al., 1989) and faeces (Leverstein-van Hall et al., 1993) which could be
the vehicle of transmission through anything contaminated by them.
1.6 Diagnosis of infection
Many diagnostic tests are available for the diagnosis of H. pylori infection including
invasive methods requiring endoscopy and biopsy and non-invasive methods (Table




Table 1.1 Diagnostic tests for detection of H. pylori infection
Invasive method Noninvasive methods
Culture Serology
Histology Urea breath test





H. pylori culture is definite proof of infection. However, it is the most technically
demanding of the diagnostic techniques. The optimum conditions of isolation,
transportation and culture media are required. The sensitivity of culture in experience
laboratories is greater than 90% (Megraud et al., 1999) but it can vary extensively
between centres because of local expertise. The lengthy incubation period is also
required for H. pylori culture (3-12 days). Although considered a tedious, time-
consuming, and expensive procedure, culture is the standard technique used in most
laboratories for the isolation of H. pylori from gastric biopsy samples. The advantage of
culture is that it allows the determination of antimicrobial susceptibility testing and the
strains can be analysed in detail. The antibiotic susceptibility profiles are needed
particularly after treatment failure. However, the standard protocol for H. pylori
9
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susceptibility testing has not yet been established. It also demands money, time and
personnel and is mainly used in research centres.
Culture of gastric biopsy samples provides the best yield of H. pylori. Biopsies from the
antrum are mainly used since H. pylori usually colonises at this site. Transport has to be
rapid and the transport media such as normal saline, 20% glucose or Stuart's medium are
required (Soltesz et al., 1992). Saline and 20% glucose are a simple and acceptable for a
short time period (<4 hours) and should be maintained at 4°C. For a longer period (24
hours), Stuart's medium must be used and maintained at 4°C. The biopsy samples can be
kept at -70°C or in liquid nitrogen (Han et al., 1995).
Many different media, such as Dent's medium and Skirrow's medium, can be used to
grow H. pylori. It mainly consists of an agar base such as Columbia or brain heart
infusion agar, a growth supplement such as horse blood or serum and a selective
supplement, including a mixture of antimicrobial agents such as vancomycin,
trimethoprim, cefsulodin and amphotericin B, which prevents the growth of other
organisms. The use of both selective and non-selective media may increase sensitivity.
H. pylori requires a microaerophilic environment with high humidity. The incubation
time should be for a maximum of 7-10 days at 37°C. Positive cultures are usually
observed three to five days after plating the biopsies. The small, round, smooth and
translucent colonies on the selective media can be identified as H. pylori. Gram-strain
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(Gram-negative, curved rods) and biochemical tests, including urease, catalase and
oxidase, which give strong positive results, should be carried out to complete the
identification.
1.6.1.2 Histology
Several staining method, such as modified Geimsa and Warthin-Starry, are used to
detect H. pylori. In experienced hands, histological identification is highly sensitive and
specific (Cutler et al., 1995) and provides the assessment of morphological changes of
the gastric mucosa. Immunohistochemistry, which is a sensitive and specific staining
method, has been established to detect H. pylori (Ashton-Key et al., 1996). The
sensitivity of the histology is generally 90-95% and the specificity is 95-98%
(Nedenskov-Sorensen et al., 1991). Factors affecting the capability of test include
bacterial density, type of stain used, and the expertise and enthusiasm of the pathologist.
1.6.1.3 Rapid Urease Test
Since H. pylori produces large amount of urease enzyme, the indirect detection of the
organism has been developed. The sensitivity of the tests depends on the number of
bacteria in the biopsy. There are different types of rapid urease tests commercially
available, including the gel test (CLOtest, Hpfast), paper tests (PyloriTex®) and tablet
test. In pre-treatment, the sensitivity of the tests varies from 80-95% whereas the
specificity range is 95-100% (Midolo and Marshall, 2000). In post-treatment and in
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bleeding patients, it has been reported the low sensitivity and specificity (Archimandritis
et al., 2000; Tu et al., 1999). The CLOtest was the first commercial available urease
test for biopsy samples. It consists of an agar gel containing phenol red and urea. In the
presence of urease, the urea is hydrolysed and forms ammonia, leading to an increase in
pH, which is detected by the change of the indicator, phenol red, from yellow to red. The
test is interpreted up to 24 hours.
6.1.1.4 PCR
Polymerase chain reaction (PCR) can be used for the detection of H. pylori in gastric
tissue samples. It is a rapid and highly sensitive and specific method to identify H. pylori
infection. The accuracy of the technique varies widely depending on the primers and
target gene sequences, specimen preparation, bacterial density (Ashton-Key et al., 1996;
Wong et al., 2001). There are no special requirements in the handling, transport and
storage of the gastric biopsy samples and the results can be obtained in a short period of
time. It can identify low numbers of bacteria present in specimens such as in saliva and
faeces (Li et al., 1996) or when the bacteria is no longer alive. PCR-based techniques
have been developed to detect clarithromycin-resistant H. pylori strains from gastric
biopsy samples by identification of mutations in the 23S rRNA gene (Chisholm et al.,
2001). However, it has a high risk of contamination resulting in false-positive results and





H. pylori infection induces cellular and humoral immune responses. There are various
methods developed for the detection of antibodies to H. pylori in whole blood, serum,
saliva and urine. Several antigens have been used such as whole cell sonicates and
urease-enriched fractions. The measurement of specific antibodies in serum has been
extensively used to determine colonisation status and can be used for the diagnosis of H.
pylori infection as a screening procedure, or to follow the efficacy of eradication
regimen. Specific IgM antibodies can be detected shortly after the infection is acquired,
but IgA and IgG titres indicate chronic infection. Serological tests are commercially
available, quick, easy to perform and inexpensive and have been recommended for the
diagnosis of H. pylori infection in adults (Malfertheiner et al., 1997). Among the various
serological tests available, Enzyme-linked immunosorbent assay (ELISA) is the most
widely used and has produced consistent and reliable results. Most assays detect specific
IgG. Near-patient test kits provide a rapid diagnosis of H. pylori infection, which are
based on latex agglutination or immunochromatography. They have low sensitivities
compared with laboratory-based tests.
ELISA has low sensitivity for diagnosis of H. pylori infection in children, particularly
the younger ones. The specific IgG antibody levels have been reported to be higher in
older children (Raymond et al. 1996). Immunoblotting appears to be more sensitive and
can detect low levels of antibodies that are not detected by ELISA (Nilsson et al., 1997;
13
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Rocha et al., 2000). Furthermore, it allows the detection of antibodies to virulence
factors such as CagA and VacA proteins. However, immunoblotting is expensive and
time-consuming.
Antibodies to H. pylori persist in the blood for long periods of time. The reduction in the
IgG antibody titre is not significant until the 6th month (Kosunen et al., 1992). Therefore,
the determination of the efficacy of therapy for H. pylori infection by serology requires
several months for accurate detection of a significant fall in antibody titre. A
preliminary study demonstrated that antibody to the heat shock protein (Hsp) hsp60 in
serum declines rapidly after successful eradication and is useful for early assessment
(4 weeks) of the eradication therapy (Yunoki et al., 2000).
1.6.2.2 Urea Breath Test (UBT)
Urea breath test is currently the standard non-invasive test for the detection of H. pylori
infection. It is a simple, safe and highly accurate method ideal to evaluate, in pre- and
post-treatment conditions (Bazzoli et al., 1997; Logan, 1998). The sensitivity and
specificity are in the range of 97% and 95%. The test is based on the identification of
urease activity of H. pylori. Urea labelled with either 13C or 14C is ingested by patients.
In the presence of H. pylori, urease hydrolyses urea into ammonia and labelled
bicarbonate, which is exhaled as labelled CO2. The 13C is detected by mass
spectrophotometer while the 14C is detected by scintillation counter. 13C-UBT is widely
14
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used than l4C-UBT as 13C is non-radioactive isotope. Since the 13C-UBT is high cost, it
is restricted to research centres. I4C-UBT has been reported to give unreliable result if
the patients who had gastric surgery or have been treated with proton pump inhibitors or
ranitidine (Chey et al., 1997). To avoid false-negative results, a period of 7-14 days of
PPI or H2 antagonist treatment withdrawal is recommended before performing the UBT
(Savarino et al., 2000).
1.6.2.3 Stool Antigen Test
The stool antigen detection is rapid, simple and easy for sample collection. The detection
of H. pylori antigen in stool (HpSA) determined by ELISA has become commercially
available. It is highly sensitive and specific. The accuracy of HpSA test is comparable to
that of the urea breath test (Vaira et al., 1999) and can be considered as an accurate and
rapid method. It is easy for sample collection and can be used both in untreated patients
and in the confirmation of H. pylori eradication after treatment. Since the antigen
disappears quite rapidly, the measurement of HpSA is useful to assess the success of H.
pylori eradication, which could be made as early as 2 weeks after treatment (Odaka et
al., 2002).
1.7 Treatment
The association between H. pylori and gastritis and peptic ulcer disease led to
therapeutic attempts to eradicate this bacterium. In vitro, H. pylori is susceptible to
various antimicrobial agents including penicillin, cephalosporins, macrolides,
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tetracyclines, chloramphenicol, quinolones, rifampicin, carbapenems, nitroimidazoles,
nitrofuran (Goodwin et al., 1986; McNulty et al., 1985; McNulty and Dent, 1988).
Despite good in vitro activities, these antimicrobial agents, when they are used as single
drugs, are ineffective in vivo. Treatment failure may be due to the lack of diffusion into
the mucus, reduced activity in the acid environments (McNulty et al., 1988) and
acquired resistance to antibiotics such as quinolone and nitroimidazole (Glupczynski et
al., 1987; Goodwin et al., 1988). Therefore, combination of antimicrobial agents is
required for successful eradication. Triple therapy has been the best available and
effective for H. pylori eradication.
Bismuth salts, such as bismuth subcitrate, are active against H. pylori but relapse of
infection is common when used alone (Marshall et al., 1987). Bismuth-based triple
therapy, involving the administration of a bismuth salt plus metronidazole and either
amoxycillin or tetracycline for 2 weeks, achieves eradication rates of up to 90% (Chiba
et al., 1992). However, this regimen is complicated, associated with adverse effects and
partially overcome by metronidazole resistance.
The best current triple therapy involves proton pump inhibitor (PPI) or ranitidine
bismuth citrate (RBC) with clarithromycin and either amoxicillin or metronidazole,
which is considered as the first-line therapy (Malfertheiner et al., 2002). Proton pump
inhibitors (PPIs), such as omeprazole and lansoprazole, are active against H. pylori in
vitro and inhibit acid secretion, leading to the increase of intragastric pH. Ranitidine
bismuth citrate (RBC) is a new compound, which combines the antisecretory activity of
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ranitidine with mucoprotective and H. pylori suppressive effects of bismuth. The
second-line treatment, quadruple therapy, the addition of a PPI to bismuth triple therapy,
has been recommended when the first-line treatment is unsuccessful. The regimen
includes PPI, bismuth, tetracycline and metronidazole.
1.8 Macrolides
Macrolides have been widely used to treat various infections for over 40 years.
Erythromycin, introduced in 1953, was the first macrolide antibiotic discovered and has
been used for the treatment of respiratory tract and skin infections. It is also effective in
the treatment of some intracellular pathogen infections caused by Legionella,
Mycoplasma and Chlamydia species. Newer macrolides, such as clarithromycin, and
azithromycin, have a broader spectrum of activities and better acid stability and
phamacokinetic profiles. They have excellent activity against Haemophilus influenzae,
Mycobacterium avium complex (MAC), nontuberculous mycobacteria, and Chlamydia
trachomatis.
1.8.1 Structure-Activity Relationships
Macrolides, originally isolated from Streptomyces species, are composed of various
amino sugars attached to a lactone ring of variable size (See Figure 1.1). Clinically
useful macrolides consist of a 14-, 15-, and 16-membered lactone ring. Erythromycin is
represented the first generation of the 14-membered ring macrolides. Modification of the
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core erythromycin structure leads to differences in pharmacokinetic properties and in
responses to bacterial resistant mechanisms (McFarland et al., 1997). For instance, the
semi-synthetic derivatives of erythromycin, clarithromycin, roxithromycin, and the 15-
membered ring azithromycin, have better acid stability, broader spectrum of action and
more potent activity against H. influenzae (Carbon, 1995). Ketolides, the latest
generation of macrolides, are modified by replacing cladinose hydroxyl group with a
ketone group. They exhibit an enhanced antibacterial activity and show a significant
activity against some macrolide-resistant strains (Nilius et al., 2001). Loss of
bactericidal activity was, however, observed when the lactone ring of macrolides was
cleaved. In addition, the absence of cladinose sugar in erythromycin or the tertiary amine
groups of desosamine sugar in 14- and 15-membered ring macrolides (mycaminose




Figure 1.1. Chemical structures of 14-membered ring macrolides, erythromycin,
and clarithromycin, a 15-membered ring macrolide, azithromycin, and a ketolide,
telithromycin.
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1.8.2 Mechanism of Antibiotic Action
Macrolides are bacteriostatic agents that bind to the 50S ribosomal subunit and inhibit
protein synthesis in the transpeptidation/translocation process by stimulating
dissociation of the peptidyl-tRNA molecule from the ribosomes during elongation (Pruss
et al., 1999; Riesenfeld et al., 1997) (See Figure 1.2). The precise mechanism of
macrolide interaction with bacterial rRNA and the location of drug binding site have not
yet been established. The peptidyltransferase loop of domain V and the hairpin 35 from
domain II, two segments in the 23S rRNA, are assumed to be the major components of
the macrolide binding site on the ribosome. The binding site of macrolides,
chloramphenicol and clindamycin are overlapped (Cocito et al., 1997; Vannuffel and
Cocito, 1996).
Most of the 14-member-ring macrolides, including erythromycin and its derivatives,
consist of three structural components: the lactone ring, the desosamine sugar, and the
cladinose sugar. The hydrogen-bond interactions of macrolides with the peptidyl
transferase region are mediated by the reactive groups of the desosamine sugar and the
lactone ring (Gasc et al., 1991; Steinmetz et al., 1992). Schlunzen et al. showed that
macrolides interacted with ribosome by seven hydrogen bonds and suggested that van
der Waals forces, hydrophobic interactions and the geometry of the rRNA surrounding
the macrolide molecules may involve in macrolide binding. The nucleotide A2058
appears to be crucial for drug binding since hydrogen bonds are formed between 2' OH
of the desosamine sugar and N1 and N6 of A2058 (Schlunzen et al., 2001). This can
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Figure 1.2. Inhibition of bacterial protein synthesis by macrolides.
nascent polypeptide chain









give explanation why the N6 dimethylation and rRNA mutations at A2058 confer
macrolide resistance (Sigmund et al., 1984; Weisblum, 1995).
Peptide bond synthesis occurs in the peptidyl transferase centre of the 50S subunit.
Macrolides of erythromycin class do not inhibit peptidyl transferase activity. They bind
to the 50S subunit at the entrance of the nascent peptide exit tunnel. It is thought that
macrolides block the tunnel and cause dissociation of peptidyl-tRNA from the ribosome
and subsequent cell death (Milligan and Unwin, 1986; Nissen et al., 2000). Small
peptides (up to 8 residues) are allowed to form before the nascent protein chain reaches
the bound macrolides (Tenson et al., 1996).
The interaction of macrolides with the 50S subunit is studied by RNA footprinting. It
has been demonstrated that macrolides interact with hairpin 35 in domain II and the
peptidyl transferase loop in the domain V of the 23S rRNA (Hansen et al., 1999; Xiong
et al., 1999) (See Figure 1.3). Several studies demonstrated that macrolides protected
A2058 and A2059 of the 23S rRNA from chemical modification (Beauclerk and
Cundliffe, 1987; Hansen et al., 1999; Moazed and Noller, 1987; Xiong et al., 1999). It
has also been revealed that macrolides interact with the helix 35 in domain II of the 23S
rRNA , suggesting that peptidyl transferase cavity and hairpin 35 involve in drug
binding and may be folded closed together in the 23S rRNA tertiary structure (Hansen
et al., 1999; Xiong et al., 1999). However, by using the high-resolution X-ray structure
of the 50S rRNA, Schlunzen et al. demonstrated that macrolides bound to the peptidyl
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Figure 1.3. Secondary-structure models of 23S rRNA (A) the hairpin 35 (B) and
the peptidyl transferase centre in domain V of 23S rRNA (C) are shown in enlarged
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transferase cavity of the 23S rRNA at the entrance of the tunnel and no direct interaction
was found between macrolides and helix 35. It was indicated that the footprinting effect
at A752, in Domain n, might be of an allosteric effect (Schlunzen et al., 2001).
Mutations in two ribosomal proteins, L4 and L22 confer resistance (Arevalo et al., 1988;
Chittum and Champney, 1994), 23S rRNA, (Tait-Kamradt et al., 2000; Wittmann et al.,
1973). It is still unclear, however, whether these ribosomal proteins directly play a role
in the drug binding or the mutations perturb the conformation in the drug-binding site
(Gabashvili et al., 2001; Gregory and Dahlberg, 1999). In spite of these advances in the
understanding of the mode of action of macrolides, the exact process remains unknown.
1.8.3 Mechanism of Macrolide Resistance
Erythromycin resistance was described in bacterial pathogens a few years after
erythromycin was introduced in the 1950s. Resistance to macrolides can occur by
several mechanisms, including alterations in the drug target site, drug inactivation and
active efflux.
1.8.3.1 Target Site Alterations
1.8.3.1.1 Mutations in Ribosomal Proteins
Mutations in ribosomal proteins, L4 and L22, have been linked to erythromycin
resistance (Wittmann et al., 1973). However, evidence from structural study by
Schlunzen demonstrated that there was no direct interaction between the drugs and
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ribosomal proteins (Schlunzen et al., 2001). Mutations in these two ribosomal proteins
conferring resistance is, presumably mediated by perturbing the conformation of the 23S
rRNA (Gregory and Dahlberg, 1999).
1.8.3.1.2 Posttranscriptional Methylation of A2058 in the 23S rRNA
Different bacterial species can produce an enzyme, encoded by erythromycin-resistant
methylase (erm) genes, which methylate the N-6 position of adenosine 2058 (E. coli
numbering) of the 23S rRNA to form either mono- or dimethyladenine. This results in
conformational changes in the P site of the rRNA and prevents the macrolide binding.
The modification by methylase leads to cross-resistance in the macrolides lincosamides
and streptogramin B antibiotics. This phenomenon was termed the macrolide-
lincosamide-streptogramin B (MLSB) antibiotic resistance phenotype. Macrolide,
lincosamide and streptogramin antibiotic are chemically distinct but have similar mode
of action (See Figure 1.4). These antibiotics act as protein synthesis inhibitors by
blocking the peptidyl transferase region of the 50S subunit of the bacterial ribosome.
MLSb cross-resistance phenotype is probably due to the overlapping binding sites of the
MLSb antibiotics. The MLSb resistance has been identified in Staphylococcus spp.,
Streptococcus spp., Enterococcus spp., Corynebacterium diptheriae, Bacteroides spp.,
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Figure 1.4. The MLS superfamily antibiotics. Chemical structures of erythromycin,





Clostridium spp., Bacillus spp., Lactobacillus spp., Mycoplasma pneumoniae,
Campylobacter spp., and recently, Propionibacterium spp., and members of family
Enterobacteriaceae (Leclercq and Courvalin, 1991).
Some erm genes are inducible. The 15- and particularly the 14-membered ring
macrolides are strong inducers. It was demonstrated that the basal levels of ribosomal
methylation varied from strain to strain in erm-bearing S. pneumoniae clinical isolates
(Rosato et al., 1998). This is due to the different ability of the macrolides and
structurally related antibiotics to induce rRNA methylation. Nine erm genes from
various clinically important bacterial species, belonging to four hybridisation classes,
have been recognised (Table 1.2) (Pechere, 2001).
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Table 1.2. Erythromycin-resistant methylase (erm) genes in clinically important
bacteria
Gene Bacterial species
ermA S. aureus, coagulase-negative staphylococci
ermP C. perfringens, C. difficile, E. faecalis
ermZ C. difficile, E. faecalis
errnBC L. reuteri, E. coli
ermAM S. sanguis, S. pneumoniae
S. agalactiae, S. pyogenes
ermB S. aureus, B. subtilis
ermC S. aureus, coagulase-negative staphylococci
ermM S. epidermidis
ermF B. fragilis, B. avatus
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1.8.3.1.3 Mutations in the 23S rRNA
The 23S rRNA mutations confer macrolide resistance by altering the structure of the
drug binding site and reducing the interaction between macrolides and ribosomes.
Mutations conferring macrolide resistance are listed in Table 1.3 (Vester and
Douthwaite, 2001).
The 23S rRNA mutation at A2058, the same site for methylation, leads to MLSB
resistance. It was first identified in Mycobacterium intracellulare (Meier et al., 1994).
Mutational alteration in 23s rRNA has been reported in Mycobacterium avium (Sander
et al., 1996) and H. pylori (Versalovic et al., 1996) , and other organisms containing
only one or two 23S rRNA genes (Tait-Kamradt et al., 2000). It is unusual to find this
type of mutation in clinically resistant isolates carrying multiple copies (i.e. more than
four) of the 23S rRNA gene such as staphylococci and streptococci (Davies et al., 2000;
Gasc et al., 1991). Mutations at A2058, or at A2059 confer the highest levels of
resistance. Mutations at positions 2057, 2452, and 2611 have lower-level drug
resistance. Despite being slightly outside the central point of macrolide interaction, these
positions are close by in the secondary structure.
Macrolide resistance was observed during antibiotic therapy for eradication of H. pylori.
Mutations at positions A2058 or A2059 in the 23S rRNA were identified in
clarithromycin-resistant isolates (Versalovic et al., 1996). Taylor et al. reassigned the
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positions 2058 and 2059 as positions 2142 and 2143 based on the precise location in the
23 s rRNA of H. pylori (Taylor et al., 1992). Other macrolide-resistant mechanism
including erm genes or macrolide efflux systems has not yet been reported in H. pylori
(Debets-Ossenkopp et al., 1996; Hulten et al., 1997). Mutations at A2058 and A2059
conferring erythromycin-resistance were reported in Mycoplasma pneumoniae isolates
(Lucier et al., 1995). These mutations were also observed in propionibacteria clinical
isolates while a G2057 mutation was found in some isolates (Ross et al., 1997).
In domain II, mutation at position 754 in hairpin 35 confers low-level macrolide
resistance in an E. coli laboratory strain, suggesting the proximity of this hairpin and the
peptidyl transferase region in the 23S rRNA tertiary structure (Xiong et al., 1999).
Douthwaite demonstrated that deletion of selected nucleotides in domain II in laboratory
mutants confers erythromycin resistance and suggested that rRNAs in domains II and V
interact through aribosomal protein (Douthwaite, 1992).
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Table 1.3. 23S rRNA mutations reported to confer macrolide resistance
































Macrolide-modifying enzymes including erythromycin esterase (Barthelemy et al.,
1984) and macrolide 2'-phosphotransferase (O'Hara et al., 1989) are produced by the
strains inactivating the lactone ring of the 14-membered macrolides. Two types of
esterases, I and n, encoded by ereA (Ounissi and Courvalin, 1985) and ereB (Arthur et
al., 1986) has been identified. Esterase genes have been reported in E. coli, Klebseilla,
Citrobacter, Proteus and Enterobacter spp. A clinical isolate of S. aureus was found to
inactivate 14- and 16-membered-ring macrolides (Wondrack et al., 1996). The products
of inactivation were identical to products produced by E. coli, encoded for either EreA
or EreB esterase.
1.8.3.3 Active Efflux
Efflux is one of the resistance mechanisms for macrolides mediated by actively
transporting the antibiotic out of the cell, thus keeping the intracellular concentration
low and ribosomes free from antibiotic. Different efflux systems conferring macrolide
resistance have been described. The msrA efflux pump, encoded by plasmid-borne
msr{A) genes, is responsible for macrolide and streptogramin B resistance in
staphylococci. It is a member of the ATP-binding-cassette (ABC) transporter
superfamily (Ross et al., 1990). The mef genes have been found in a variety of Gram-
positive bacteria, including corynebacteria, enterococci, micrococci, and streptococci
(Kataja et al., 1998; Luna et al., 1999; Shortridge et al., 1996). Two mef genes,
including mef (A)(Clancy et al., 1996) and mefiE) (Tait-Kamradt et al., 1997), have
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been described. The Mef protein belongs to the major facilitator superfamily (MFS),
which is fuelled by the proton motive force. This efflux appears to be chromosome-
mediated and affects only macrolides but not lincosamide and streptogramins. The
mef{A) gene was described in Streptococcus pyogenes (Clancy et al., 1996) while the
meflE) gene was reported in S. pneumoniae (Tait-Kamradt et al., 1997).
1.8.4 Mechanism of Macrolide Resistance in the Clinic
In the USA, over two-thirds of the macrolide-resistant S. pneumoniae strains harboured
the efflux mechanism (Gay et al., 2000; Shortridge et al., 1999). The other third of the
resistant isolates contained the rRNA modification mechanism. A study conducted in
Canada (Johnston et al., 1998) demonstrated that the mefE gene was detected more
frequently than erm genes in S. pneumoniae. In most S. pneumoniae strains isolated in
Belgium and Italy, macrolide resistance is caused by the presence of the erm genes
(Descheemaeker et al., 2000; Oster et al., 1999). In Japan, it was described that
approximately 60% of erythromycin-resistant S. pneumoniae strains harboured the ermB
gene, whereas 40% carried the mefE gene (Nishijima et al., 1999). In Western Europe,
efflux mechanism was observed in the majority of the erythromycin-resistant S.




Mutations at A2058 (or neighboring nucleotides) in the 23S rRNA have been
demonstrated in macrolide-resistant clinical strains of Mycobacterium avium (Sander et
al., 1996) and H. pylori (Versalovic et al., 1996), and other organisms harbouring only
one or two 23S rRNA genes (Tait-Kamradt et al., 2000). Resistance in bacteria with
multiple 23S rRNA operons, such as Enterococcus, Streptococcus, and Staphylococcus
species, is generally conferred by Erm methylation of A2058 or by efflux (Kataja et al.,
1999; Ross et al., 1990). Antibiotic resistance in clinical strains can be linked to
alterations of specific nucleotides of the 23S rRNA within the peptidyl transferase centre
(Vester and Douthwaite, 2001). Mutations of A2058 (E. coli numeration) and several
neighboring positions in the central loop of domain V confer resistance to macrolides
(Sigmund and Morgan, 1982).
1.8.5 Clarithromycin Resistance in H. pylori
Macrolides are essential component for H. pylori eradication regimen. Among the
macrolides available, clarithromycin is currently widely used. It has a low MIC against
H. pylori and good diffusion in the gastric mucosa. The antimicrobial activity is less
affected by a decreased in pH than that of the other compounds in this group. The
antimicrobial effect of clarithromycin, in common with that of established macrolides,
has been attributed to binding to the 50S ribosomal subunit within the bacterial cell, thus
inhibiting translocation of aminoacyl transfer-RNA and consequent protein synthesis.
Clarithromycin resistance in H. pylori is associated with mutations in the peptidyl
transferase region of the 23S ribosomal RNA genes (Versalovic et al., 1996). Mutations
34
Chapter 1 Introduction
in the 23S rRNA decrease the affinity of clarithromycin for the ribosome and thus
interfere with antimicrobial activity (Occhialini et al., 1997).
Mutations conferring macrolide resistance were first described in two genes positions
2142 or 2143, formerly named 2058 and 2059, respectively, which are the cognates in E.
coli, then 2143 and 2144 before to be revised as it is now (Taylor et al., 1997). The point
mutation can be a transition (A to G) or a transversion (A to C). Versalovic et al. found
that mutation from A to G at position 2142 is the most frequent (Versalovic et al., 1997),
whist Domingo et al. demonstrated that the A to G mutation at postion 2143 is the most
frequent mutation (Domingo et al., 1998). A number of studies reported mutations
conferring macrolide resistance in H. pylori and at least five distinct point mutations
(G2115 to A, G2141 to A, A2142 to G, A2142 to C, and A2143 to G) have been
reported (Debets-Ossenkopp et al., 1998; Garcia-Arata et al., 1999; Hulten et al., 1997;




Figure 1.5 Comparison of the domain V loops of the 23 S rRNA from H. pylori and
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Metronidazole, l-(2-hydroxyethyl)-2-methyl-5-nitroimidazole) is a synthetic
antibacterial and antiprotozoal agent that belongs to the nitroimidazole class (See Figure
1.6). It was first introduced for the treatment of gynaecological infections caused by
Trichomonas vaginalis in 1959. Metronidazole has been found to be active against
anaerobic and some microaerophilic bacteria such as H. pylori. It is now widely used for
treatment of infections with anaerobic microorganisms (Edwards, 1993; Ingham et al.,
1980; Muller, 1983).
1.9.1 Mechanism of Action
Metronidazole is amebicidal, bactericidal and trichomonicidal. The drug itself is not
toxic. It has to enter the cell and requires reductive activation of the nitro group of the
imidazole ring to form a hydroxylamine derivative. The reduced product causes DNA
degradation and strand breakage (Edwards, 1993; Lindmark and Muller, 1976).
Metronidazole needs an extremely low redox potential to be converted itself into an
active form. Therefore, the selective toxicity of metronidazole for anaerobic bacteria
and protozoa is due to the low redox potential of the components of their electron
transport proteins, such as ferredoxin and flavodoxin, which have sufficiently low redox
potential to reduce metronidazole to its toxic nitroradical. In anaerobic organism,
electrons derived from oxidative decarboxylation of pyruvate, catalysed by POR
(pyruvate oxidoreductase) are transferred to ferredoxin or flavodoxin. By having very
low redox potential, metronidazole accepts electron from the reduced electron carrier
proteins and is then activated (Edwards, 1993; Edwards et al., 1973) (See Figure 1.7).
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Figure 1.7. Scheme of the interaction of metronidazole with electron transport
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Anaerobic organisms develop metronidazole resistance by reducing or abolishing
activity of elements of this series of electron transport reactions, particularly POR and
ferrodoxin, with appropriate compensatory modifications of the normal fermentative
pathway (Edwards, 1993; Moreno et al., 1983; Narikawa, 1986; Quon et al., 1992).
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An alternative mechanism of action of metronidazole in anaerobic bacteria exposed to
aerobic conditions has been proposed. The presence of molecular oxygen may oxidise
the nitro anion radicals generated from the reduction of metronidazole, resulting in a
one-electron transfer step back to the parent compound (Moreno et al., 1983) (Figure
1.8). Regeneration of the parent compound would then lead to further cycles of
reduction and oxidation. Although this process, term 'futile cycling' results in
detoxification of the drug, it also generates superoxide radical anions that may be toxic
to the microorganism. Under normal circumstance, superoxide dismutase converts
superoxide anions to hydrogen peroxide, which is further reduced to water by the action
of catalase. In the presence of transition metals, such as iron or copper, superoxide ions
and hydrogen peroxide may react to generate the highly reactive, DNA damaging
hydroxyl free radical (Edwards, 1993). Increased expression of superoxide dismutase
has been reported in metronidazole-resistant amoebae and appears to contribute to the
resistant phenotype, rather than the result of a general stress response.
Figure 1.8. Futile cycling (Figure taken from Edwards, 1993)
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1.9.2 Resistance to Metronidazole in H. pylori
Since metronidazole is used for the treatment of many infections caused by anaerobic
bacteria and protozoa, an increase of metronidazole-resistant H. pylori strains has been
generated. The mechanism of resistance is still unclear. Several mechanisms have been
proposed including reduced uptake and/or increased efflux of metronidazole (Lacey et
al., 1993), inactivation of metronidazole through 'futile cycling' (Cederbrant et al.,
1992), increased repair of radical-induced damage (Chang et al., 1997; Jorgensen et al.,
1998; Smith and Edwards, 1995) and mutation in metronidazole-reducing enzymes
(Goodwin et al., 1998; Hoffman et al., 1996; Kaihovaara et al., 1998).
Since H. pylori live in microaerobic environment, it was proposed that the reactive
oxygen species generated by 'futile cycling' were responsible for cell death (Edwards,
1993; Lacey et al., 1993). In the presence of oxygen, reduced metronidazole can convert
back to its parent compound by 'futile cycling' process, generating superoxide anions
instead of hydroxylamine. The increased synthesis of superoxide dismutase and catalase
has been hypothesised to explain metronidazole activity in H. pylori (Cederbrant et al.,
1992). However, the presence of this process has not yet been successfully demonstrated
(Jorgensen et al., 1998).
Smith and Edwards (Smith and Edwards, 1995) demonstrated that superoxide dismutase
and catalase were not induced by metronidazole and there was no correlation between
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enzyme levels and resistance patterns. Jorgensen found that in the presence or absence
of catalase activity has no effect on the susceptibility of strains to this antibiotic
(Jorgensen et al., 1998). Little evidence has been demonstrated that futile cycling
contributes to the mode of action of metronidazole. Therefore, futile cycling does not
occur in H. pylori.
Microaerophilic bacteria oxidise pyruvate via pyruvate:ferredoxin/flavodoxin
oxidoreductase (POR), metabolic feature found in anaerobic bacteria (Hughes et al,
1995). Both anaerobic and microaerophilic bacteria are susceptible to 5-nitroimidazole
drugs (Hof et al., 1984; Lockerby et al., 1985; Smith and Edwards, 1995). These drugs,
when reduced by low-potential ferredoxins or flavodoxins, form hydroxylamine
derivatives, which damage DNA (Kedderis et al., 1988; Krieg and Hoffman, 1986;
Lindmark and Muller, 1976; Muller, 1983; Smith and Edwards, 1995).
The loss of resistance in metronidazole-resistant H. pylori strains on exposure to
anaerobic environment was demonstrated (Smith and Edwards, 1995). It is suggested
that the mechanism of resistance is probably mediated through the activation of
anaerobic metabolic pathways, which function less or not at all under microaerophilic
conditions, causing the reduction of metronidazole, thus accounting for the increased
sensitivity to drug (Smith and Edwards, 1995).
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Furthermore, Smith and Edwards studied the ability of metronidazole susceptible and
resistant strains to scavenge oxygen from intracellular environment and found that
metronidazole resistant H. pylori strains had reduced activity of NADH oxidase, an
oxygen scavenger (Smith and Edwards, 1997). Metronidazole resistance may be
mediated through an inability of metronidazole-resistant strains to remove O2 from the
site of metronidazole reduction, thus preventing metronidazole activation. Jorgensen
demonstrated that metronidazole-resistant H. pylori reduced metronidazole more slowly
than their sensitive counterparts. These results strongly suggest that H. pylori is capable
of reducing metronidazole to its active form at the relative high redox potentials
encountered in microaerobic conditions and that this process is reduced or inactive in
resistant strains. Hoffman et al. demonstrated an association between metronidazole
resistance and repression of the pyruvate oxidoreductase and a-ketoglutarate
oxidoreductase activities in response to low levels of metronidazole in H. pylori
(Hoffman et al., 1996).
H. pylori contains a NADPH nitroreductase, encoded by rdxA gene, which reduce
metronidazole through sequential two-electron reductions to generate toxic metabolites
that cannot be transformed to its parent compound under aerobic or microaerophilic
conditions by the 'futile cycling' process. Goodwin et al. demonstrated that that the loss
of oxygen-insensitive NADPH nitroreductase activity was responsible for the
mechanism of metronidazole resistance in H. pylori, and mutational inactivation of the
rdxA gene conferred resistance (Goodwin et al., 1998).
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Debets-Ossenkopp also confirmed that rdxA gene was disrupted in metronidazole-
resistant H. pylori strain NCTC11637 and no mutation was detected in any other genes
suggested to be linked to the mechanism of resistance (Debets-Ossenkopp et al., 1999).
Jenk et al. studied the role of rdxA in a mouse model and demonstrated that 25 out of 27
metronidazole-resistant strains isolated from mice had mutations in the rdxA gene (Jenks
et al., 1999). Tankovic et al. reported mutation in the rdxA gene in 12 of 13
metronidazole-resistant clinical isolates (Tankovic et al., 2000).
The rdxA gene of some metronidazole-resistant strains appears to be unchanged (Jenks
et al., 1999; Tankovic et al., 2000). This suggests that other mechanisms of resistance
may exist in H. pylori. The contribution of other mechanisms responsible for resistance
is still unknown. Mutations in the genes regulating the expression of the rdxA gene or in
the promoter sequence of the rdxA gene have been postulated (Van Der Wouden et al.,
2000). Metronidazole efflux or reduced uptake, deficiency of other enzymes involved in
the reduction of metronidazole to its active form, target modification or increased DNA
repair may play a role in the mechanism of resistance.
More recently, inactivation of other reductase-encoding genes, including frxA, encoding
NADPH flavinoxidoreductase, and fdxB, encoding ferredoxin-like protein, have been





Fluoroquinolones are a series of synthetic antibacterial compounds used in the treatment
of a wide range of bacterial infections. Nalidixic acid, the first clinically useful
quinolone, was discovered as a by-product of the purification process of the anti¬
malarial drug chloroquine (Lesher et al., 1962). It had good activity against certain
Gram-negative bacteria, particularly the Enterobacteriaceae but showed only poor
activity against Gram-positive bacteria. As a result of its limited spectrum of activity and
poor serum and tissue concentrations, the clinical applications of nalidixic acid was
restricted. It was not until almost 20 years later that the substitution of a fluorine atom at
position C-6 of the quinolone core structure was synthesised, leading to the construction
of fluoroquinolones (Koga et al., 1980). Since then hundreds of quinolones have been
synthesised and this significant breakthrough generated a new spectrum of compounds
with improved absorption and enhanced antibacterial potency. Figure 1.9 shows the
structures of nalidixic acid and fluoroquinolone core.
Structures of quinolones (Figure 1.10) have developed along two major pathways: the
naphthyridones, which contain original naphthyridine core of nalidixic and the
fluoroquinolones, which have a carbon atom substituted for nitrogen at the 8-position of
the naphthyridine core (Domagala, 1994). All of them contain a fluorine substitution at
position 6. The C-7 position is the most adaptable site for chemical change. The
characteristics of quinolone generations are shown in Table 1.4 (Ball, 2000).
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Table 1.4. Characteristics of quinolone generations. (Adapted from Ball et al., 2000)
Core structure Characteristics
Generation Fluoroquinolone Naphthyridone
flumequine nalidixic acid predominantly used for the

















trovafloxacin enhanced activity against
Gram-positive pathogens





The second-generation fluoroquinolones, such as ciprofloxacin, have predominantly
activity against Gram-negative bacteria but less effective against Gram-positive bacteria
including S. pneumoniae and methicillin-resistant S. aureus. The development of
enhanced Gram-positive activity has been shown in the generation lib compounds such
as grepafloxacin and sparfloxacin. The third-generation fluoroquinolones, such as
gatifloxacin (Perry et al., 1999) and moxifloxacin (Dalhoff et al., 1996), have enhanced
activity against Gram-positive pathogens and are very active against S. pneumoniae.
They are highly effective in lower respiratory tract infection treatment. Gemifloxacin
has markedly better activity against Gram-positive bacteria, particularly S. pneumoniae,
than any other quinolones (Cormican and Jones, 1997).
Fluoroquinolones are potent broad-spectrum antimicrobial drugs that target two essential
enzymes in the bacterial cell, type II topoisomerases, DNA gyrase and topoisomerase IV
(Levine et al., 1998). They have bactericidal activities as DNA gyrase and




Topoisomerases fall into two categories: Type I and Type EI. All topoisomerases have
the abilities to change the topology of DNA through breakage and reunion of DNA
strands. They have, however, different activities. Type I topoisomerases comprise
topoisomerase I and HI which are able to relax and decatenate interlocked DNA circles
by catalysing single stranded DNA cleavage and strand passage in the absence of ATP.
Type IT topoisomerases include DNA gyrase and topoisomerase IV which are multi-
subunit enzymes and ATP dependent. Unlike type I topoisomerases, DNA gyrase and
topoisomerase IV alter DNA topology by introducing a double-strand breakage with the
passage of another helix through the transient break and religating the broken ends
(Drlica and Zhao, 1997). This process is essential in maintaining the appropriate state of
DNA supercoiling and decatenation of DNA during cell replication. DNA gyrase and
topoisomerase IV are targets of fluoroquinolones.
1.10.2 DNA Gyrase
DNA gyrase consists of two-subunits (an A2B2 tetramer), encoded by the gyrA and gyrB
genes (Swanberg and Wang, 1987). DNA Gyrase introduces negative supercoils into
relaxed DNA, and thus relieves topological stress arising from the translocation of
transcription and replication complexes along DNA (Reece and Maxwell, 1991). It can
also unlink the knots and catenanes generated by recombination. Gyrase, however, does
not play a major role in unlinking catenanes formed during replication and
topoisomerase IV is principally responsible for this function.
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In E. coli, GyrA, a 97 kDa fragment, mediates strand breakage and reunion. The active
sites, tyrosine 122, bind to the DNA phosphate backbone and perform cleavage and
religation (Horowitz and Wang, 1987). GyrB, a 90-kDa fragment in E. coli, functions by
supporting DNA relaxation and is responsible for ATP binding and hydrolysis (Reece
and Maxwell, 1991). The N-terminal region of GyrA interacts with GyrB, whereas the
C-terminal domain is responsible for DNA supercoiling. Similarly, the N-terminus of
GyrB contains the ATP-binding domain, and the C-terminus contains the GyrA
interaction region.
1.10.3 Topoisomerase IV
Topoisomerase IV, a C2E2 complexes, consists of parC and parE genes. ParC and ParE
are homologous to the A and B subunits of DNA gyrase, respectively. Topoisomerase
IV, a decatenating enzyme, resolves interlinked daughter chromosomes following DNA
replication. It can relax negatively supercoiled DNA at a much slower rate than
decatenation (Hiasa and Marians, 1996). ParC is 36% identical to GyrA, while Par E is
40% identical to GyrB (Kato et al., 1990). The active sites, tyrosine 120 in ParC, bind to
the DNA phosphate backbone and perform cleavage and religation, as GyrA activity.
ParE provides similar activities as GyrB, responsible for ATP binding and hydrolysis.
DNA gyrase and topoisomerase IV use a double-strand-passage mode of action (Roca,
1995) but have a difference in DNA wrapping. Gyrase wraps DNA around itself
whereas topoisomerase IV does not (Peng and Marians, 1995). Topoisomerase IV favors
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intermolecular strand passage reactions such as decatenation while gyrase favor
intramolecular strand passage reaction such as supercoiling.
1.10.4 Drug-Target Interaction
Since mutations in the gyrA gene confer quinolone resistance, it was believed that
quinolone bound directly to GyrA (Gellert et al., 1977). The occurrence of gyrB
mutations suggested that the quinolone binding site may include both subunits
(Yamagishi et al., 1986). Shen et al. proposed a cooperative drug-binding model in
which a quinolone binds to bases of single-stranded DNA and self-associates in a pocket
created by gyrase (Shen et al., 1989) (Figure 1.11). However, this model cannot explain
why mutation changes in the gyrase genes can cause quinolone resistance. The
quinolones are believed to interact with the bases through hydrogen bonds between the
3-carboxy and 4-oxo groups. At least 4 molecules are thought to bind per binding site
and ring stacking and hydrophobic interactions contribute to their cooperativity. Shen et
al. postulated that gyrase interacts with the C-7 position of the drug (Shen et al., 1989),
however, Maxwell later pointed out that the C7 group is variable in the quinolones
(Maxwell, 1992). Yoshida et al proposed a quinolone pocket model in which quinolones
exerts their action through their interaction in a pocket of the gyrase-DNA complex that
appears during DNA cleavage-reunion reactions and the quinolone binding affinities for
the complex are mediated by both GyrA and GyrB (Yoshida et al., 1993).
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Palumbo et al. proposed an alternative model, involving drug binding to phosphate
groups in DNA via a Mg2+ bridge, stacking interactions between the quinolone and a
DNA base in a single stranded region, stabilised with metal ion (Palumbo et al., 1993)
(Figure 1.12).
Figure 1.11. Quinolone-DNA binding model for gyrase inhibition.(Figure taken
from Shen et al., 1989)
Figure 1.12. The Quinolone-DNA binding via a Mg2+ bridge (Figure taken from






Critchlow and Maxwell demonstrated that DNA gyrase mutants which have tyrosine -
122 replaced with either phenylalanine or serine can bind quinolone drugs. It implies
that DNA cleavage is not crucial for drug binding (Critchlow and Maxwell, 1996), thus
contesting the model proposed by Shen et al. (Shen et al., 1989). The precise mechanism
of quinolone, topoisomerase and DNA binding is still unknown. A high-resolution
structure study, which is extremely difficult by the large size of DNA gyrase (-400 kDa)
is required.
It has been demonstrated that inactivation of DNA gyrase severely inhibits DNA
synthesis and results in cell death. In contrast, DNA synthesis is not significantly
affected in topoisomerase IV mutants despite having defects in chromosome partitioning
(Adams et al., 1992; Khodursky et al., 1995). This is validated in nature where
Mycobacterium spp and H. pylori (Hooper, 1998) do not possess topoisomerase IV,
suggesting that either DNA gyrase or an equivalent of the enzyme compensate for the
absence of topoisomerase IV.
Topoisomerase IV has found to be inhibited by quinolones but it is not as sensitive to the
drugs as DNA gyrase (Hoshino et al., 1994; Peng and Marians, 1993). It is thought that
DNA gyrase is a primary target of quinolones as its superior topoisomerase activity.
However, in Gram-positive bacteria, such as S. aureus and S. pneumoniae,




1.10.5 Mechanism of Quinolone Action
Quinolones target gyrase or topoisomerase IV by trapping the enzymes on DNA as
ternary drug-enzyme-DNA complexes (Drlica, 1999), containing broken DNA. DNA
fragmentation is described as gyrase-mediated strand passage (Figure 1.13). Gyrase
wraps around DNA and produces a pair of single-stranded breaks. The quinolones trap
the DNA-gyrase complex after DNA cleavage. These cleavable complexes block
replication fork movement (Hiasa et al., 1996), leading to inhibition of DNA synthesis
and subsequent cell death. The ternary complex formation is crucial for cytotoxicity.
The complexes are reversible and the DNA strand can be religated. Hiasa et al. purposed
that the collision of a replication fork with a topoisomerase-quinolone-DNA complex
converts the cleavable complex to an unreversible form and a double-strand break is
probably generated by subsequent denaturation of the topoisomerase, resulting from an
aborted attempt at repair of the complex, signaled by the termination of DNA replication
(Hiasa et al., 1996). Figure 1.12 shows the intracellular action of quinolones that
mediate cell death.
Chen et al showed that the lethal effects of oxolinic acid, releasing of DNA breaks and
cell death, were blocked by chloramphenicol, an inhibitor of protein synthesis. It is
suggested that synthesis of additional protein activity is required to release the DNA
ends from the quinolone-gyrase-DNA complexes. Although, chloramphenicol is very
effective at blocking the lethal effect of oxolinic acid, it has only partial effect on
ciprofloxacin, a potent fluoroquinolone. This indicates that the second lethal mode arises
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from dissociation of gyrase subunits, constraining DNA ends in ciprofloxacin-gyrase-
DNA complexes. Furthermore, it was demonstrated that ciprofloxacin has two
intracellular targets, DNA gyrase and topoisomerase IV, and DNA gyrase is the major
quinolone target in E. coli (Chen et al., 1996).
55
Chapter 1 Introduction
Figure 1.13. Schematic representation of events involved in quinolone-mediated cell
death. Gyrase and DNA interact (a) in such a way that 4-quinolone compounds can trap
(b) a reaction intermediate that blocks DNA synthesis and cell growth. The DNA ends
can be released by two pathways, leading to cell death. Pathway c is inhibited by
chloramphenicol. It is postulated that pathway c is mediated by a repair factor, removing
quinolone-gyrase complexes from DNA. At high concentrations of quinolones, the
DNA ends can be released by a chloramphenicol-insensitive pathway (d). This pathway

















Cell death Cell death
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1.10.6 Mechanism of Quinolone Resistance
The quinolones are a group of synthetic antibiotics, including nalidixic acid and
fluorinated quinolones. Different mechanisms are involved in the development of
quinolone resistance. Alterations in DNA gyrase and topoisomerase IV and mutations
affecting the accumulation of quinolones including either reduced expression of porins
or lipopolysaccharide, or active efflux are associated with the mechanism of resistance.
1.10.6.1 Mutations in Quinolone Targets
Quinolones target the enzyme DNA gyrase in the bacterial cell (Yoshida et al., 1988).
Sequencing analysis of DNA from many bacterial species has demonstrated that
mutations near the active site (Tyr 122 in E. coli) of the A subunit ofDNA gyrase confer
resistance. The mutations are located in a region of gyrA known as the quinolone
resistance-determining region (QRDR) at the amino acid terminus between amino acid
67 and 106, which is highly conserved within bacterial species. A single amino acid
substitution at positions 67, 81, 83, 84, 87 or 106 has been involved in the resistant
mechanism. Alterations in the QRDR have been reported in a variety of bacterial species
such as E. coli, Salmonella spp., Acinetobacter spp, S. aureus, S. pneumoniae and N.
gonorrheae. Mutations of Serine 83 and Aspartic acid 87 in GyrA of E. coli confer
high-level quinolone resistance. Amino-acid substitutions at Serine 83 to a hydrophobic
amino acid normally confer more resistance than does mutation at Aspartic acid 87.
57
Chapter 1 Introduction
Alterations in the gyrB gene have been reported to contribute to resistance in some
isolates and these changes are associated with a specific QRDR (Nakamura et al., 1989).
Mutations at position 426 and 447 in the gyrB gene also confer resistance. The drug-
enzyme interactions are involved in gyrase sensitivity to quinolones (Yoshida et al.,
1991). The frequency of gyrB mutations, however, is much lower in comparison with
the frequency of gyrA mutations.
Mutations in topoisomerase IV are involved in quinolone resistance. It has been
demonstrated that topoisomerase IV is a secondary target of the quinolone in Gram-
negative bacteria such as E. coli and A. baumannii (Khodursky et al., 1995; Vila et al.,
1997). Topoisomerase IV appears to be the primary target of the quinolones in Gram-
positive bacteria (Ferrero et al., 1995; Tankovic et al., 1996).
Resistance to quinolones most commonly involves alterations of the DNA gyrase and
topoisomerase IV, however, other mechanisms including decreased drug permeability or
active efflux have been linked to the mechanism of resistance.
1.10.6.2 Reduction of Quinolone Accumulation
Quinolones enter the bacterial cell wall either directly through the lipid bilayer
(hydrophobic quinolones such as nalidixic acid) or through water filled protein pores,
the porins (hydrophilic compounds such as ciprofloxacin, ofloxacin) (Hirai et al, 1986).
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Quinolone resistance due to reduced drug accumulation involves reduced expression of
porin proteins and overexpression of active efflux system.
OmpF and OmpC are two major outer membrane porins in E. coli. In E. coli, OmpF
porins are the major gate for the entry of hydrophilic quinolones. Mutations in ompF
have less effect on the penetration of hydrophobic compounds. Since OmpF is an
unspecific porin, several unrelated drugs such as tetracycline, chloramphenicol and some
(3-lactam, can enter into the cell by this porin. Loss of OmpF porin leads to resistance to
all these antibiotics. In addition to mutations in the ompF gene, a decreased in OmpF
porin appears to be linked to the alterations in unrelated loci such as marRAB and
soxRS loci (Ariza et al., 1994; Miller et al., 1994).
Another mechanism involved in quinolone resistance is the expression or overexpression
of efflux system that remove antimicrobial agents from the cell. Efflux of quinolones is
an energy-requiring transport process. NorA efflux pump are associated with quinolone
resistance in S. aureus. Mutations in the promotor region of the norA confer resistance to
hydrophilic fluoroquinolones such as ciprofloxacin and norfloxacin (Kaatz et al., 1993;
Ng et al., 1994). PmrA, the efflux pump in S. pneumoniae, involves in fluoroquinolone
resistance (Gill et al., 1999). Inactivation of pmrA gene leads to increased susceptibility
to norfloxacin and ciprofloxacin but has no effect on sparfloxacin and moxifloxacin




1.10.7 Resistance to Fluoroquinolones in H. pylori
Fluoroquinolones are not routinely included in current regimens used to treat H. pylori
infection as they show a significant decrease of their activity at low pH. Resistance to
fluoroquinolone (MIC > 4mg/L) was found in the clinical trial that examine the efficacy
of ciprofloxacin in the treatment ofH. pylori infection (Moore et al., 1995). Mutations
in the QRDR of the gyrA gene, encoding the A-subunit of DNA gyrase, confer
ciprofloxacin resistance. Moore et al. demonstrated that resistance were associated with
four groups of point mutations in the gyrA gene with substitutions at amino acid 87, 88
and 91 and a double amino acid substitution at position 91 and 97 (Table 1.5). The most
common mutation in H. pylori was at Aspartic acid-91 (Asp-87 in E. coli) whereas a
substitution at Serine-83 is the most frequently reported in some other bacteria such as
E. coli and C. jejuni.
Table 1.5. Mutations in the QRDR of gyrA in H. pylori (Moore et aL, 1995)
Amino acid changes Comparable change in E. coli MIC (mg/L)
None - 0.0625-0.25
Asn-87 to Lys Ser-83 to Ala 8
Ala-88 to Val Ala-84 to Pro 4
Asp-91 to Gly, Asp-87 to Val or to Asn 4-8
to Tyr or to Asn
Asp-91 to Asn and Asp-87 to Val or to Asn 8
Ala-97 to Val
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1.11 Aims of this thesis
Chapter 1 Introduction
1. To determine the antibiotic susceptibility patterns of H. pylori strains isolated in
Scotland.
2. To determine the optimal conditions for metronidazole susceptibility testing
3. To investigate the mechanism of fluoroquinolone resistance in the laboratory
mutants and in clinical isolates.
4. To investigate the mechanism of macrolide resistance in clinical isolates.
5. To investigate the role of rdxA gene in metronidazole resistance in clinical isolates.
6. To investigate the DNA gyrase activity in H. pylori by cloning, expression and
purification of GyrA and GyrB.
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Chapter 2 Materials and Methods
2.1 Bacterial Strains and Plasmids
One hundred and ten isolates of H. pylori were isolated from 454 gastric biopsies from
patients undergone endoscopy at the Royal Infirmary between 1999-2001 (Dr. R.
Heading and F. Paton, Royal Infirmary, Edinburgh). All strains were single isolates from
individual patients and used for antibiotic susceptibility patterns and mechanisms of
resistance studies. A culture collection of 20 clinical isolates of H. pylori collected in
1997 was received from Dr. A. Alkout (Infection and Immunity laboratory, University
of Edinburgh) and were used for metronidazole susceptibility testing study and selection
of fluoroquinolone-resistance mutants. E. coli BL21-DE3 pLysS and E. coli TopF', used
for cloning and overexpression of GyrA and GyrB, were supplied by Invitrogen (USA).
Standard strains used in this study were H. pylori NCTC 11637, supplied by the Central
Public Health Laboratory (Colindale), and H. pylori NCTC 11916, received from Dr. A.
Alkout.
The plasmids used for overexpression of GyrA and GyrB was pCR T7/NT-TOPO,
supplied by Invitrogen (USA). pBR322, supplied by GibcoBRL (Life Technology Ltd.,
Paisley, UK) was used for supercoiling activity experiment.
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2.2 Antimicrobial Agents
Antimicrobial agents, manufacturers and solubility information are listed in Table 2.2.
Fresh stock solutions of all antibiotics were prepared on the day of use.
Table 2.1 Antimicrobial agents and their solvents
Antimicrobial agent Solvent Manufacturer/Supplier
Ciprofloxacin Water Bayer pic
Chloramphenicol Water/Ethanol Sigma-Aldrich
Ampicillin Water Sigma-Aldrich
Vancomycin Water Eli Lilly and Company
Cefsulodin Water Sigma-Aldrich
Trimethoprim Water/0.5M HC1 10% of
final volume
Sigma-Aldrich
Amphotericin B Water E.R. Squibb & Son Ltd.
2.3 Chemicals, Buffers and Enzymes
All chemicals are purchased from Sigma-Aldrich Company Ltd. (Poole, UK) unless
otherwise stated. Acetic acid and hydrochloric acid were purchased from BDH (Poole,
UK). Saline was made up with 0.85% (w/v) NaCl and sterilized before used by
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autoclaving. Buffers were made according to data for Biochemical Research (1974). All




Media used in this study were Columbia agar, Brain Heart Infusion Broth and Muller
Hinton agar, supplied by Oxoid (Basingstoke, UK). LB (Luria-Bertani) broth and LB
agar were supplied by GibcoBRL (Life Tecnologies Ltd., Paisley, UK). All media were
made up with distilled water according to the manufacturer's instructions. Prior to use
all media were sterilized by autoclaving at 121°C and 15psi for 15 minutes to destroy all
vegetative cells and spores.
2.4.2 Transport Media
Gastric biopsy samples were transported on ice to the laboratory in 0.5ml sterile saline.
The samples were kept on ice and processed in the laboratory within 4 hours.
2.5 Bacterial Identification
Gastric biopsy samples from the antrum were obtained from the patients, who consented
to take part in this study. A single antral biopsy specimen was taken from each patient
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and kept in sterile saline on ice before processed in the laboratory. Gastric biopsies were
ground and grown on selective and non-selective media. Columbia agar supplemented
with 7% horse blood was used as non-selective media whereas Columbia agar,
containing 7% horse blood, lOmg/L vancomycin, 5mg/L trimethoprim, 5mg/L
amphotericin B and 5mg/L cefsulodin was used as selective media. The plates were
incubated in anaerobic jar under microaerophilic conditions (6% O2 and 10% C02)
provided by gas generating kit (Campylobacter system BR60, Oxoid, Unipath Ltd.,
Basingstoke, UK) at 37°C for 3-7 days. The strains were identified as H. pylori by gram
stain, colony morphology and positive urease, catalase and oxidase activity. All H.
pylori strains were stored at -70°C in brain heart infusion broth containing 20% glycerol
and were subcultured onto Columbia agar plates supplemented with 7% horse blood
before use.
2.6 Antimicrobial Susceptibility Testing
2.6.1 Minimum inhibitory Concentrations (MICs)
The colonies on the Columbia agar, supplemented with 7% horse blood were harvested
and suspended in brain heart infusion broth to the density equal to that of No.3
MacFarland Standard to give 109 cfu/ml. Minimum inhibition concentrations (MICs)
were performed on Columbia agar, supplemented with 7% horse blood. A multipoint
inoculator (Denley, Billinghurst, Surrey) was used to inoculate the tested organisms onto
Columbia blood agar, containing serially diluted antibiotics. The plates were incubated
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under microaerophilic conditions at 37°C for 72 hours. The MIC was determined to be
the lowest concentration with no growth.
2.6.2 Epsilon Test (E-test)
The E-test (AB Biodisk, Cambridge, UK) comprises a plastic strip embedded with an
antibiotic gradient and employed a more stringent and convenient method for
determining susceptibility of bacteria. The colonies on the Columbia agar, supplemented
with 7% horse blood were harvested and suspended in brain heart infusion broth to the
density equivalent to No.3 MacFarland Standard turbidity. The suspensions were flood-
seeded onto Columbia agar containing 1% horse blood. The plastic strips were
impregnated on the surface of the agar plates. The plates were incubated for 72 hours at
37°C under microaerophilic conditions. For metronidazole susceptibility testing only, the
plates were pre-incubated under anaerobic conditions for 24 hours, followed by
microaerophilic conditions for 72 hours. The manufacturer's instructions were followed
in the interpretation of the results.
2.7 Selection of Fluoroquinolone-Resistant Mutants
Stepwise selection of ciprofloxacin-resistant mutants was performed by plating
approximately 108cfu of H. pylori onto Columbia blood agar containing increasing
concentrations of ciprofloxacin. After 72 hours of incubation at 37°C under
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microaerophilic conditions, first-step ciprofloxacin-resistant mutants were selected.
Second-step mutants were obtained by plating the first-step mutants onto Columbia
blood agar containing increasing concentrations of ciprofloxacin. Third-step mutants
were obtained in the similar manner to the second-step mutants. MICs were determined
by E test and agar dilution on Columbia agar containing 7% horse blood.
2.8 Preparation of DNA for PCR
Chromosomal DNA was extracted for PCR by using a Puragene DNA isolation kit
(Gentra system kit, USA) according to the manufacturer's instructions.
2.9 Phenol:Chloroform:lsoamyl Alcohol DNA Extraction
Phenol:chloroform:isoamyl alcohol (25:24:1) were used to cleanup pBR322 for
supercoiling assay. Sample containing pBR322 was mixed gently with equal volume of
phenol/chroloform/isoamyl alcohol. The upper aqueous layer was removed to the new
tube after centrifugation at 13,000g for 5 minutes. An equal volume of ice-cold
isopropanol was added and mixed. The DNA was pelleted by centrifugation at 13,000g
for 10 minutes. The supernatant was discarded and the pellet was dried and resuspended
in distilled water.
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2.10 Mutation Detection by the Polymerase Chain Reaction
(PCR)
Mutations in the QRDR of gyrA, 23S rRNA and rdxA were detected by PCR
amplification and DNA sequencing. The primers used for each PCR are shown in Table
2.3. All reactions were prepared in 100 pi volumes in a Techne Cyclogene Thermal
cycler (Cambridge Biosciences, Cambridge). The products were analysed by agarose gel
electrophoresis.
2.10.1 Amplification of the QRDR of gyrA.
Oligonucleotides primers 5'AATTAGGCCTACTTCCAAAGTCGCTTACA-3' and 5'-
TCTTCACTCGCCTTAGTCATTCTGGC-3'(Moore et al, 1995) were used to amplify a
238bp fragment. Reactions comprised lxPCR buffer, 1.5mM MgCh, 200pM each
dNTP, 0.25pM of each primer (Oswel DNA services Ltd., Southampton), 2U of Taq
DNA polymerase. Cycling parameters were as follows: i) one cycle of 94 °C for 60s; ii)
35 cycles of 94°C for 60s, 55 °C for 30s, 72 °C for 60s, iii) one cycle of 4 °C for 24
hours.
2.10.2 Amplification of the Peptidyltranferase Region of the 23S
rRNA
The 23S rRNA primers were derived from the sequence published by Occhialini et al.
(1997). Oligonucleotides primers 5'-CCACAGCGATGTGGTCTCAG-3' and 5'-
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CTCCATAAG AGCCAAAGCCC-3' (Occhialini et al, 1997) were used to amplify a
425bp fragment. Reactions consist of lxPCR buffer, 1.5mM MgCh, 200pM each dNTP,
0.25pM each primer (Oswel), 2U of Tag DNA polymerase. Cycling parameters were as
follows: I) one cycle of 94 °C for 60s; ii) 35 cycles of 94°C for 60s, 54 °C for 60s, 72 °C
for 60s, iii) one cycle of 72 °C for 10 minutes, iv) one cycle of 4 °C for 24 hours.
2.10.3 Amplification of rdxA
Oligonucleotides primers 5'ATGGGTTGCTGATTGTGGTTTATGG3' and 5'CGTTG
AAAACACCCCTAAAAGAGCG-3' (Pual et al, 1995) were used to amplify a 947bp
fragment of the rdxA gene. Reactions consist of lxPCR buffer, 1.5mM MgCh, 200pM
each dNTP, 0.25pM of each primer (Oswel), 2U of Taq DNA polymerase. Cycling
parameters were as follows: i) one cycle of 94 °C for 60s; ii) 35 cycles of 94°C for 60s,
55 °C for 60s, 72 °C for 60s, iii) one cycle of 72 °C for 10 minutes, iv) one cycle of 4 °C
for 24 hours.
2.11 Analysis of DNA by Gel Electrophoresis
DNA was visualised by electrophoresis on 1-1.5% agarose gel (Gibco BRL, Paisley,
UK) in TAE buffer [40mM Tris-acetate (pH8.0), 2mM EDTA]. Electrophoresis was
performed on horizontal gels utilising a minisubcell GT (Bio-Rad, Hemel, Hemstead
UK). The DNA samples were mixed with loading buffer [0.25%(w/v) bromphenol blue,
0.25% (w/v) xylene cyanol, 30% (w/v) sucrose] at a ratio 5:1 prior to gel loading.
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Samples were electrophoresed at a constant voltage between 70 and 90V (Powerpac 300,
Bio-Rad, UK) for a time length depending on DNA fragment size (30-50 min). Samples
were electrophoresed alongside a suitable molecular weight marker, generally lOObp
ladder (Promega), lkb ladder and lambda HindlU DNA (Promega).
2.12 Staining and Visualisation of DNA
Following electrophoresis, gels were stained in a 0.5pg/mL ethidium bromide solution
and visualised on a UV trans-illuminator (UV products, Cambridge). The Bio-Rad
GelDoc 20000 system (BioRad) was also used to visualise and photograph gels.
2.13 DNA Quantification
A rapid method to estimate DNA concentration was perform by electrophoresising lpl
of DNA sample alongside 2pl of 0.5pg Lambda///mdEtI DNA (Promega), each band of
which is known to contain a specified DNA concentration. The gel was stained in
ethidium bromide solution. The intensity of the sample bands were compared with
Lambda///mdIII DNA bands to estimate the concentration of DNA.
2.14 Sequencing of PCR Products
The PCR products were purified by using a QIAquick PCR purification kit (Qiagen,
Germany) according to the manufacturer's instructions. The purified products were
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eluted from the column into 30 pi of elution buffer to concentrate the DNA to ensure
that it contained 30-90ng DNA to run on an automatic sequencer. The PCR primers used
for PCR amplification were also used for DNA sequencing, with 3.2 pmole of primer
per sequencing reaction. All the sequences were processed in the Department of
Haematology, Royal Infirmary of Edinburgh. The DNA sequence was determined by
chain termination method developed by Sanger et al (1997). Individual PCR fragments
were set up in the ready reaction format for fluorescence based on dideoxy cycle
sequencing (PE Applied System, UK). DNA sequences were analysed by Chromas
Version 1.56 software and compared to the published sequences by using the BLAST
online search (http://www.ncbi.nlm.nih.gov/ BLAST). The amino acid sequences were
translated using EXPASY translate website (http:www.expasy.ch.tools/DNA/html).
Multi-alignment of DNA and amino acid sequences were performed with the online
website multalin (http://www.toulous.inra.fr/multalin.html).
2.15 PCR Cloning and Expression of GyrA and GyrB
PCR cloning and expression of GyrA and gyrB were carried out with the pCR T7 TOPO
TA Expression kit (Invitrogen, USA), according to the manufacturer's instructions All
reagents, competent cells and plasmids were supplied by the kit unless otherwise stated.
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2.15.1 Primer Design
The forward primers hybridised at the beginning of the genes and the reverse primers
were designed to hybridise downstream of the stop codon and the forward primers
hybridised at the beginning of the genes. The actual sizes of gyrA and gyrB are 2478bp
and 2322bp, respectively. The PCR products, amplified by Taq polymerase, had 3' A-
overhangs, which were able to ligate to the pCR-T7/NT vector, a T7 expression vector
containing 3' T-overhangs (Figure 2.1). The proteins overexpressed by this vector
contained His-tagged at the N terminal, thus enabling the expressed protein to be
purified by affinity chromatography.
Figure 2.1 pCR-T7/NT vector map
PCR Product
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2.15.2 Amplification of Complete Sequences gyrA and gyrB
The gyrA and gyrB primers were derived from the sequences of H. pylori 26695 from
GenBank (Accession No. AE000583), by using Primer 3 software
(http:www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi). Chromosomal DNA was
obtained from H. pylori NCTC 11637 as previously described. Two oligonucleotide
primers, 5' -ATGCAAGATAATTCAGTCAATGAA-3' and 5' -TTCAAGCGGTACGA
AATTAAAAA-3' were used for gyrA amplification. Oligonucleotide primers 5'-ATGC
AAAATTACCAGAGCCATAGT-3' and 5'-CCCCTAAATTCACGCTCTCT-3' were
used for gyrB amplification. Temperature cycling was performed on a GeneAmp PCR
system 9600 (Perkin-Elmer).
For gyrA amplification, a PCR reaction (lOOpJ) of lxPCR buffer, 2mM MgCl2, 200uM
each dNTP, 0.25p,M of each primer, 2U of Taq DNA polymerase in MilliQ water were
cycled at the following parameters: 2 minutes at 94°C followed by 30 cycles of 94°C for
1 minute, 55 °C for 1 minute and 72 °C for 3 minutes with the final extension of 72 °C
for 10 minutes producing a product of 2590bp.
For gyrB amplification, a PCR reaction (100pl) of lxPCR buffer, 3mM MgCl2, 200uM
each dNTP, 0.25pM of each primer, 2U of Taq DNA polymerase in MilliQ water were
cycled at the following parameters: 2 minutes at 94°C followed by 30 cycles of 94°C for
1 minutes, 55 °C for 1 minutes and 72 °C for 3 minutes with the final extension of 72 °C
for 10 minutes producing a product of 2380bp.
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2.15.3 Cloning of PCR Products
PCR products of gyrA and gyrB were excised and purified with a Gel Extraction Kit
(Qiagen) according to the manufacturer's instruction. The gyrA and gyrB genes were
separately cloned into pCR-T7/NT vector (Invitrogen), which encodes an N-terminal
6xHis-G tag thus enabling the expressed protein to be purified by affinity
chromatography on a ProBond resin column (Invitrogen). The recombinant plasmids
were transformed into competent E. coli TOPlOF'cells and selected on LB agar
containing lOOmg/L ampicillin. Plasmids from the positive clones were extracted and
purified with Wizard Plus SV Minipreps DNA purification system (Promega), according
to the manufacturer's instruction. The plasmids were further analysed by HindUl
restriction analysis and DNA sequencing.
2.15.4 Restriction Analysis of Recombinant Plasmids
Plasmids of the transformants were extracted and analysed for the orientation of the
inserts by HindJE. A 4|il of plasmid was added to 2 fxl restriction enzyme buffer (6mM
Tris-HCl, 6mM Mg CI2, lOOmM NaCl, ImM DTT, pH 7.5), 0.2|il bovine serum
albumin (lOmg/ml) and 5U (Promega), final volume 20 |il. The reaction mixtures were
incubated at 37C for 4 hours and run on a 1.5% agarose gel and visualised as previously
described. If the restriction sites are cut with this enzyme, the plasmid containing gyrA
gives the products of 4459bp, 537bp and 450bp and that of gyrB was 367 lbp, 1023bp,
480bp and 90bp.
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2.15.5 Sequencing of Plasmids Containing gyrA and gyrB Inserts
The orientation and its insertion in frame with the vector's 6xHis tag were verified by
DNA sequencing, using the vector's forward and reverse primers and primers chosen
from the internal sequences of the gyrA and gyrB genes. The plasmids were sent to the
Department of Haematology, Royal Infirmary of Edinburgh for DNA sequencing. The
sequencing primers are shown in Table 2.2
Table 2.2 Oligonucleotide primers used for DNA sequencing for gyrA
Primer Sequence
HP-WA2 5'-TTT AGT CAA TGG GGC TAA TGG-3'
HP-WA3 5'-CGC GAT GAG TGA AAT TGT CTT-3'
HP-WA4 5'-CTC CAA GGC GCA CTG AAA T-3'
HP-WA5 5'-GAA AAA TGG CGT GGT GAA G-3'
T7 5'-TAA TAC GAC TCA CTA TAGGG-3'
T7 Reverse 5'-TAG TTA TTG CTC AGC GGTGG-3'
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Table 2.3 Oligonucleotide primers used for DNA sequencing for gyrB
Primer Sequence
GyrB-Fl 5'- ATGC AAAATTACCAGAGCCATAGT-3'
GyrB-F2 5'-CGT GAT GGA AGT CGT TGA ATT T-3'
GyrB-F3 5'-GCC AGA GAG CTT ACA AGG AAA A-3'
GyrB-F4 5'-GGT GGA TAT TGA AGG GAT TGG-3'
T7 5'-TAA TAC GAC TCA CTA TAGGG-3'
T7 Reverse 5'-TAG TTA TTG CTC AGC GGTGG-3'
2.15.6 Overexpression of GyrA and GyrB
Plasmids of the positive clone were overexpressed in BL21(DE3)-pLysS cells. The
bacteria was selected on LB broth containing lOOmg/L ampicillin and 37mg/L
chloramphenicol at 37 °C overnight. A 20ml of overnight culture was used to inoculate
1L of LB broth containing lOOmg/L ampicillin and 37mg/L chloramphenicol at 37°C. At
an OD600 of 0.5, the cells were induced with ImM isopropyl thio-(3-D-galactoside
(IPTG) for 4 hours at 37°C. Cells were collected by centrifugation at lOOOg for 30
minutes, resuspended in sonication buffer (20mM phosphate buffer, 500mM NaCl,
pH7.8) and lysed by sonication. The cell lysate was centrifuged at 3000g for 30 minutes
to obtain cell-free extracts. The lysate was passed through a 0.8pm syringe filter and was
stored on ice or at -20 °C. This was then purified on an affinity column.
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2.16 SDS-PAGE
The GyrA and GyrB proteins were separated by SDS-PAGE (Laemmli, 1970). The
samples were boiled in sample buffer (62.5mM Tris-HCl pH 6.8, 0.2% SDS, 10%
glycerol, 1% 2-mercaptoethanol, 0.01% bromphenol blue) for 5 minutes before loading
onto a 4% stacking gel and 12% separating gel (Bio-Rad) in electrode buffer (25mM
Tris-HCl pH 8.3, 192mM Glycine, 0.2% SDS). A constant voltage of 180 V was
applied. Molecular weights were determined from standard bands using Precision
Protein Standards (Bio-Rad) and were detected with Coomassie brilliant blue (40% v/v
methanol, 10% v/v acetic acid, 0.25% w/v Coomassie blue R-250) for 45 mins and
destained by destaining solution (40% v/v methanol, 10% v/v acetic acid in distilled
water). All gel anlysis was carried out using Quantity One software (Bio-Rad).
2.17 Western Blot
The GyrA and GyrB proteins were resolved on an SDS-PAGE gel. Equilibrate the gels,
membranes, filter papers and fiber pads in transfer buffer for 30 minutes. The PVDF
(polyvinylidine difluoride) membranes were wetted in 100% methanol before soaking in
the buffer. Pre-wetted PVDF membranes were applied to an SDS gel containing the
separated proteins. The proteins were transferred while a constant voltage of 100V was
applied for 1 hour in the cold room by the Trans-Blot electrophoretic transfer cell (Bio-
Rad). The transfer buffer was 25mM Tris, 192 mM glycine, pH 8.3.
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The blots were washed with TBS-T (20mM Tris-HCl pH7.6, 137mM NaCl, 0.1%
Tween 20) for 15 minutes and then blocked with 5% skimmed milk powder in TBS-T
for 1 hour at room temperature. The membranes were incubated with specific antibody
to HisG conjugated with HRP at 1:5000 dilution at room temperature for 2 hours. The
membranes were washed extensively with TBS-T at room temperature 4 times, 15
minutes each. The TMB substrate kit (Vector Laboratories, USA) was used to detect
labelled proteins, according to the manufacturer's instructions.
2.18 Purification of GyrA and GyrB
GyrA and GyrB were purified by ProBond Purification System (Invitrogen). The
recombinant protein with contains six tandem histidine residues at the N-terminal has a
high affinity for ProBond resin. The sample was loaded onto a ProBond column,
previously equilibrated with Native binding buffer (20mM sodium phosphate, 500mM
NaCl, pH 7.8). The column was washed with Native binding buffer pH 6.0 (20mM
sodium phosphate, 500mM NaCl, pH 6.0) until the OD28o is less than 0.01. The protein
was eluted by gradient imidazole (50mM, 200mM, 350mM and 500mM) according to
the manufacturer's instruction.
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2.19 Supercoiling Relaxed DNA Activity
DNA gyrase catalyses the ATP-dependent introduction of supercoils into relaxed DNA.
Relaxed DNA was prepared by treating pBR322 DNA with DNA topoisomerase I. The
supercoiling assay was carried out using relaxed DNA as a substrate.
2.19.1 Relaxed DNA Preparation
Standard reaction mixtures (20pl) containing 35mM Tris-HCl, pH 8.0, 72mM KC1,
5mM MgCl2, 5mM DTT, 5mM spermidine, 0.01% bovine serum albumin, 0.5pg
supercoiled pBR322 DNA (Gibco, BRL) and 1 Unit of topoisomerase I (Armersham
Phamacia Biotech, UK) were incubated at 37 °C for 1 hour. The mixtures were then
extracted with an equal volume of phenol-chloroform-isoamyl alcohol (25:24:1). After
centrifugation at 13,000g for 5 minutes, the aqueous layer was added to an equal volume
of ice cold isopropanol. The DNA was pellet by centrifugation at 13,000g for 10
minutes and resuspended in 50 pi of sterile distilled water.
2.19.2 Assay of DNA Supercoiling
Supercoiling activities were carried out in 40pl of 35mM Tris-HCl, pH 7.5, 25mM KC1,
4mM MgCl2, 2mM DTT, 1.8mM spermidine, ImM ATP, 6.5%glycerol, O.lmg/ml
bovine serum albumin, 0.2pg relaxed pBR322 DNA. E. coli DNA gyrase (Sigma, UK)
was used as a positive control. Serial dilutions of partially purified GyrA and GyrB were
determined for the optimal activity. The samples were electrophoresed in a 1% agarose
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gel for 45 minutes at 80V. The gel was stained with 0.5(a,g/ml ethidium bromide and
visualised on a UV transluminator.
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Chapter 3 Results: Antibiotic Susceptibility of
H. pylori
3.1 Introduction
H. pylori has been recognised as a causative agent of gastritis and peptic ulcer diseases.
The potential for antimicrobial therapy in the treatment of H. pylori infection has
resulted in the reported on in-vitro susceptibilty of H. pylori to antimicrobial agents.
Many antibiotics have excellent in-vitro activity against H. pylori, however, when
antibiotics are used alone, the development of resistance usually occurs. Multi-drug
antimicrobial therapies including combinations of clarithromycin, metronidazole or
amoxycillin and proton pump inhibitors are widely used to eradicate H. pylori.
The prevalence of antibiotic resistance varies between countries. It is important to
update the antibiotic resistant profile of individual area. Susceptibility patterns of
antibiotics against H. pylori have not yet been reported in Scotland. This study
investigated the prevalence of antibiotic resistance of H. pylori and the in-vitro activity
of amoxycillin, ciprofloxacin, clarithromycin, erythromycin, tetracycline and
metronidazole against H. pylori clinical isolates.
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3.2 Collection of Clinical Strains of H. pylori in Scotland
H. pylori isolates were obtained from antral biopsies from the 454 patients undergoing
routine endoscopy at the Centre for Liver and Digestive Disorders, Royal Infirmary,
Edinburgh, Scotland. The specimens were collected during the period December 1999 -
March 2001. This project was a prospective study and was approved by the ethical
committee. Sample collection and patient consent were a source of delay. One biopsy
sample from antrum per patient was used to isolate H. pylori.
Of the 454 gastric biopsies, 110 H. pylori strains were isolated. The isolates were
identified as H. pylori by oxidase, catalase production, rapid positive urease test and
Gram-stain. The H. pylori isolation rate was low at 24.2% (110/454). This can be
explained by the fact that biopsies were obtained from patients undergoing routine
endoscopy, not only the patients with gastritis or peptic ulcer disease. Only one biopsy
sample was obtained from each patient, which could also reduce the H. pylori isolation
rate.
3.3 Antibiotic Susceptibility Testing
Susceptibility profiles of 110 H. pylori strains were determined by E-test to amoxycillin,
ciprofloxacin, clarithromycin, erythromycin, tetracycline and metronidazole. The range
of MICs, MIC50, MIC90 of amoxycillin, ciprofloxacin, clarithromycin, erythromycin,
tetracycline and metronidazole against 110 clinical isolates are shown in Table 3.1,
Figure 3.1 and Figure 3.2 The MICs of all strains are shown in Appendix I. The MIC
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break points are >8mg/L for amoxycillin, >2mg/L for ciprofloxacin, >2mg/L for
clarithromycin, >2mg/L for erythromycin, >2mg/L for tetracycline and >4mg/L for
metronidazole.
Table 3.1 MICs of 6 antibiotics against 110 H. pylori clinical isolates
Antibiotic MIC50 (mg/L) MIC90 (mg/L) Range (mg/L)
Amoxycillin <0.016 0.016 <0.016-0.047
Ciprofloxacin 0.032 0.064 0.003->32
Clarithromycin <0.016 0.023 <0.016->256
Erythromycin 0.023 0.125 <0.016->256
Tetracycline 0.023 0.064 <0.016-1
Metronidazole 0.016 0.75 <0.016->256
83
Chapter 3 Results: Antibiotic Susceptibility of H. pylori
















































































c c c C 0 0
= 0 0 O C O

































Chapter 3 Results: Antibiotic Susceptibility of H. pylori
Analysis of the MIC data (Table 3.1) showed that amoxycillin was the most potent
antibiotic against H. pylori as the MIC90 is 0.016mg/L and no resistance was found in all
of these isolates. Clarithromycin (MIC90 = 0.023mg/L) was the second most potent,
followed by tetracycline and ciprofloxacin with the MIC90 of 0.064mg/L. Metronidazole
was the least active antibiotic (MIC90 = 0.75mg/L). Erythromycin was the next least
active (MIC90 = 0.125mg/L). The MIC50 and MIC90 values of all antibiotics are below
the breakpoints.
Figure 3.3 gives an overview of the distribution of the MICs of amoxycillin,
ciprofloxacin, clarithromycin, erythromycin, tetracycline and metronidazole. For all
strains, the MIC of amoxycillin was <0.064mg/L. Most of the isolates (84.5%) had very
low MICs (<0.016mg/L). The distribution of the MIC peaked at <0.016mg/L and
gradually declined to 0.047mg/L (Figure 3.3 a).
For ciprofloxacin, the distribution of the MICs showed a set of the sensitive strains with
the MIC range 0.003 - 0.19mg/L. The peak was at 0.032mg/L and then declined from
both sides. The majority of the sensitive strains (94.4%) had the MIC of <0.064mg/L.
Two strains exhibited ciprofloxacin resistance with MICs of 16 and >32mg/L (Figure
3.3 b).
For clarithromycin, most of the strains (72.7%) had a clarithromycin MIC of
<0.016mg/L (Figure 3.3 c). The distribution of the MICs had a peak at the MIC of
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The susceptibility patterns of amoxycillin, ciprofloxacin, clarithromycin, erythromycin,
tetracycline and metronidazole against H. pylori isolated in Scotland demonstrated that
all antibiotics tested are active against H. pylori (MIC90 range 0.016-0.75mg/L) and all
isolates exhibit the MIC90 below the breakpoints for all antibiotics. However,
metronidazole and clarithromycin resistance has frequently been reported as they are
widely used to eradicate H. pylori. Metronidazole was found to be the least potent drug
tested in this study with the MIC90 of 0.75mg/L. Metronidazole resistance was observed
in 8 strains with the MIC range 4 - >256mg/L. Clarithromycin has excellent activity
against II. pylori with the MIC90 of 0.023mg/L. However, eight isolates (MIC range 3 -
>256mg/L) were found to be resistant to clarithromycin and one isolate was
intermediate resistant (MIC = 1.5mg/L). All of these isolates were cross-resistant to
erythromycin. Two isolates were resistant to both metronidazole and clarithromycin,
suggesting that these resistances were developed after H. pylori treatment with these
antibiotics and antibiotic susceptibility testing should be performed for the successful
eradication therapy.
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<0.016mg/L and then tailed off. The sensitive strains had the MIC range 0.016 -
0.125mg/L). A cluster of clarithromycin-resistant isolates was demonstrated with the
MICs in the range 1.5- >256mg/L and the distribution of the MICs was in line. The MIC
breakpoint for clarithromycin is >2mg/L and the MIC of 1.5mg/L is intermediate
resistant.
For erythromycin, the distribution of the MICs showed that all the sensitive strains had
the MIC in the range of <0.016 - 0.19mg/L, with the peak at 0.023mg/L (Figure 3.3 d).
Of the 100 isolates, 77 strains (77%) had the MIC of < 0.032mg/L. All of the resistant
strains had high-level MIC of >256mg/L.
For tetracycline, a cluster of sensitive isolates with the MIC range of <0.016 - 0.19mg/L
was shown (Figure 3.3 e). The peak was at 0.016mg/L. Of the 109 sensitive strains, 91
(83.4%) had the MIC of < 0.032mg/L. One isolate had the MIC of lmg/L, which was
defined as intermediate resistant.
For metronidazole, most of the strains (38.2%) had the MIC of <0.016mg/L (Figure 3.3
f). The distribution of MICs showed a peak at the MIC of <0.016mg/L and then tailed
off. A cluster of the sensitive strains with MICs in the range < 0.016 - 1.5mg/L) was
observed. One isolate had the MIC of 4mg/L (cut-off level). A cluster of metronidazole-
resistant isolates was shown, with the MIC range 12 - >256mg/L.The distribution of the
MIC of this cluster was in line.
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Figure 3.3 Distribution of the MICs of 110 H. pylori isolates against amoxycillin (a),
ciprofloxacin (b), clarithromycin (c), eryhromycin (d), tetracycline (e) and
metronidazole (f).
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3.4 Prevalence of Antibiotic Resistance in H. pylori in Scotland
Resistance to macrolides, clarithromycin and erythromycin, was found in 8.2% (9/110)
and 9.1% (10/110) of the H. pylori strains, respectively (Figure 3.4). All clarithromycin-
resistant isolates also conferred erythromycin resistance with MIC of >256 mg/L. One
strain was erythromycin resistant (MIC >256mg/L) but clarithromycin-sensitive (MIC =
0.125mg/L). Resistance to metronidazole was found in 8 isolates (7.3%). Two of them
were also resistant to clarithromycin and erythromycin. Ciprofloxacin resistance was
found in 2 isolates (1.8%). One isolate (0.9%) was resistant to tetracycline
(intermediate, MIC 1 mg/L). Amoxycillin resistance was not detected. The results from
this study reveal that the prevalence of macrolide resistance in Scotland is greater than
to any other antibiotics. Clarithromycin is a potent antibiotic widely used in the
treatment regimen. Resistance to clarithromycin will, therefore, affect the cure rate and
account for treatment failure. Although metronidazole resistance (7.3%) is relatively
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4.1 Introduction
Metronidazole is one of the antibiotics frequently employed in the treatment of
Helicobacter pylori infection; however, the prevalence rate of metronidazole resistance
is variable, ranging from 11 to 70% in developed countries and even more prevalent in
developing countries. It is possible that some of the variation in reported resistance
levels derives from difficulties in the method of sensitivity testing. Smith and Edwards
(1995) indicated that H. pylori NCTC 11637 is a metronidazole-resistant strain because
it is resistant in microaerophilic conditions and that anaerobic conditions render this
strain sensitive. This does raise an important point, as to whether the strains which are
metronidazole-resistant in vitro in microaerophilic conditions are really true resistant
strains in vivo. Consequently, the methodology for the determination of susceptibility of
H. pylori to metronidazole is crucial in the prediction of the success for eradication this
bacterium. An evaluation of the variation in methodology on the outcome of
susceptibility testing was consequently performed.
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4.2 The Effect of Pre-incubation under Anaerobic Conditions
To verify the effect of 24 hour pre-incubation in an anaerobic atmosphere, the
metronidazole MICs of 21 H. pylori strains were determined by E-test. The plates were
incubated for 72 hours under microaerophilic conditions, with or without a 24-hour
period of anaerobic pre-incubation. H. pylori NCTC 11637 was included as a control.
The MICs of individual strains are shown in Table 4.1. The comparison of the
metronidazole MIC of individual strains determined with and without a 24-hour
anaerobic pre-incubation is shown in Figure 4.1.
The E-test had shown that H. pylori NCTC 11637 was highly metronidazole-resistant
(MIC >256 mg/L) when incubated under microaerophilic conditions. Interestingly, H.
pylori NCTC 11637 became sensitive to metronidazole with an MIC of 0.016 mg/L
when pre-incubated under anaerobic conditions for 24 hours. This suggests that
microaerophilic conditions cannot activate metronidazole to its active form. In anaerobic
conditions, metronidazole is activated by the reduction of a nitro group to a radical anion
which damages the DNA. The requirement for an anaerobic environment for the
effective activation of metronidazole may explain why some centres have reported high
levels of metronidazole resistance.
A similar finding was observed in 21 H. pylori strains. The MIC50 and MIC90 were 0.5
and >256mg/L, respectively when tested under microaerophilic conditions (Table 4.2
and Figure 4.2). When pre-incubated in anaerobic environment the MIC50 and MIC90 of
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metronidazole decreased to 0.016 and 0.19mg/L for, respectively. The ratio between
metronidazole MIC determined with and without pre-incubation under anaerobic
conditions is shown in Figure 4.2. All strains, except HP-91, had 2.6 to 16,000-fold
decrease in the MIC when pre-incubated under anaerobic conditions. Five strains
including the control strain NCTC 11637 had a 16,000-fold decrease in the MIC. A 750-
fold decrease in the MIC was observed in one isolate. MIC decrease of 11.8 to 93.7-fold
was observed in 9 strains when pre-incubated in anaerobic atmosphere. Only six strains
showed less than 10-fold decrease in the MIC.
MICs of most of H. pylori strains were decreased significantly when pre-incubated
under anaerobic atmosphere. Anaerobic pre-incubation had great effect in the MIC
value. Of the 21 H. pylori strains, 6 strains were reported as sensitive strains when the
MIC was tested under microaerophilic condition, whereas only one resistant strain (HP-
91, MIC >256mg/L) had no change in the MIC and might be considered truly resistant.
These results explain the variation in the resistance levels reported and suggest that
anaerobic pre-incubation should be used to perform the susceptibility testing as
metronidazole is still effective in the eradication treatment which is in contrast to a very
high prevalence of metronidazole resistance reported.
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Figure 4.1 Comparison of the metronidazole MIC of individual strains determined
with and without pre-incubation under anaerobic conditions
Table 4.2 MIC50 and MIC90 of //. pylori strains determined with and without a 24-
hour anaerobic pre-incubation
Incubation conditions MIC50 (mg/L) MIC90 (mg/L)
Anaerobic pre-incubation 0.016 0.19
No anerobic pre-incubation 0.5 >256
98
Chapter 4 Results: Susceptibility Testing for Metronidazole
Figure 4.2 Comparison of MIC50 and MIC90 of H. pylori strains determined with
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Figure 4.3 Ratio between MIC determined with and without pre-incubation under
anaerobic conditions.
4.3 The Effects of Anaerobic Pre-incubation, Inoculum Size,
Medium and Incubation Time
The effect of varying the conditions of susceptibility testing was evaluated with the H.
pylori NCTC 11637 and NCTC 11916. Table 4.3 shows a comparison of incubation of
the MIC plates in an anaerobic jar and an anaerobic chamber (10% C02, 10% H2 and
80%N2) before transferring to microaerophilic conditions. Inconsistency in H. pylori
growth was observed when the MIC plates were pre-incubated in an anaerobic chamber.
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H. pylori grew very well when an anaerobic jar was used to achieve anaerobic
conditions. This indicates that H. pylori growth depends on a high level of humidity
which is not provided in an aerobic chamber. The effects of medium, inoculum size and
incubation period were shown in Table 4.4. Columbia and Mueller-Hinton agar were
investigated. H. pylori growth was poor on Mueller-Hinton agar with 7% horse blood;
however, on Columbia agar with 7% horse blood there was significant growth. It was
difficult to read the MICs when the inoculum size was 0.5 McFarland because of the
poor growth; however, the turbidity of McFarland No.3 provided good growth and
reproducibility. After 48-hour incubation under microaerophilic conditions, it was not
possible to read the MICs because the growth was too weak. When the plates were
incubated for 72 hours, the MICs were easier to read and the results were unequivocal.
The optimal conditions for susceptibility to metronidazole obtained from this study were
pre-incubation under anaerobic conditions for 24 hours prior to a 72-hour
microaerophilic condition incubation in anaerobic jar on Columbia agar with inoculum
size of No.3 McFarland standard. Anaerobic pre-incubation is important to achieve the
accurate results.
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Table 4.3 Comparison of anaerobic pre-incubation conditions. ± indicates poor
growth and ++ indicates good growth.




H. pylori NCTC 11916 ++ ±
H. pylori NCTC 11637 ++ ±
Table 4.4 Effects of medium (a), inoculum size (b) and incubation time (c).








H. pylori NCTC 11916 ± ++
H. pylori NCTC 11637 ± ++
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0.5 McFarland No.3 McFarland
Columbia agar
H. pylori NCTC 11916 ± ++




48 hours 72 hours
H. pylori NCTC 11916 ± ++
H. pylori NCTC 11637 ± ++
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5.1 Introduction
Clarithromycin is a potent macrolide that has frequently been used in eradication
regimens for H. pylori infection. Resistance to clarithromycin varies with geographic
location, but it is generally less than 10%. This study shows that the prevalence of
clarithromycin resistance in Scotland is 8.2% (See Chapter 3). The development of
clarithromycin resistance is a major cause of treatment failure. Macrolide resistance in
H. pylori is associated with single nucleotide mutation in the peptidyl transferase region
of the 23S rRNA. The A to G mutations at either position 2142 or 2143, equivalent to
position 2058 or position 2059 in E. coli, were found in most isolates associated with
clarithromycin resistance.
In this study, the 23S rRNA of clinical strains isolated in Scotland was analysed to
determine the presense of mutation conferring macrolide resistance.
5.2 PCR Amplification of 23S rRNA
Ten macrolide-resistant strains isolated in Scotland, TC-18, TC-19, TC-24, TC-40, TC-
78, TC-140, TC-175, TC-185, TC-215 and TC-284, were used in this study. Macrolide
resistance conferring mutations in the peptidyl transferase region of the 23S rRNA gene
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were determined by PCR amplification and DNA sequencing. A 425bp fragment was
amplified by PCR and then sequenced. The results are shown in Figure 7.1. Bands of
expected size, 425bp, were observed in all isolates.
Figure 7.1 PCR amplification of a 425bp fragment of the peptidyl tranferase region
of the 23S rRNA
m
500bp 425bp
Lane 1: 100-bp ladder
Lane 2-6: 23S rRNA gene PCR products from TC-18, TC-19, TC-24, TC-40,
TC-78
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5.3 Mutations in the 23S rRNA
Mutations in the peptidyl transferase region of the 23S rRNA gene were analysed by
DNA sequencing. Of the 10 macrolide-resistant isolates, nine isolates were resistant to
clarithromycin and cross-resistant to erythromycin. The MICs of erythromycin and
clarithromycin are shown Table 5.1. Only one isolate was resistant to erythromycin
alone (TC-175, MIC >256mg/L). Nine clarithromycin-resistant strains, including one
strain with intermediate resistant (TC-19), had the MIC range of 1.5->256mg/L). All
isolates had very high erythromycin MIC of >256mg/L.
Table 5.1 Mutations in the 23S rRNA gene of 10 macrolide-resistant H. pylori
Strain
MIC (mg/L) 23S rRNA mutations
Clarithromycin Erythromycin
TC-18 >256 >256 -
TC-24 >256 >256 A2143G, T2182C
TC-40 32 >256 A2143G, T1934C
TC-78 6 >256 A2143G
TC-19 1.5 >256 A2143G
TC-140 3 >256 A2143G
TC-175 0.125 >256 T2182C
TC-185 24 >256 A2143G
TC-215 3 >256 A2143G
TC-284 8 >256 C2195T
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Table 5.1 summarises the mutations that occurred in the 23S rRNA of 10 macrolide-
resistant isolates. The alignment of 23S rRNA sequence is shown in Figure 5.2.
Sequences of macrolide-resistant isolates were also compared against the sequence of H.
pylori 26695 from the GenBank database. Sequence analysis revealed four different
point mutations in the 23S rRNA (position 2143, 2182, 1934 and 2195) (Table 5.1). The
majority of macrolide-resistant isolates contained A to G mutation at position 2143.
Seven of the ten macrolide-resistant isolates had mutations at position 2143 (A to G).
Two of the seven isolates carried an additional T to C mutation at either position 2182 or
1934. Of the 10 macrolide-resistant isolates, two had a single mutation at either position
2182 (TC-175, erythromycin MIC >256mg/L and clarithromycin MIC= 0.125mg/L) or
2195 (TC-284, erythromycin MIC >256mg/L and clarithromycin MIC =8mg/L).
Mutation at position 2182, however, has previously been determined not to be associated
with macrolide resistance, indicating that other mechanisms of resistance play a role in
TC-175. Mutation at position 2195 may be involved in the mechanism of macrolide
resistance, but further investigation is needed to confirm as the results for H. pylori
strains TC-18 and TC-175 suggest that other additional mechanisms of macrolide
resistance exist in H. pylori. The mutations at position at 1934 (T to C) and position
2195 (C to T) have not previously been reported. Since T1934C mutation (TC-40) was
found together with an A2143G mutation, which is known to confer macrolide
resistance in H. pylori, the contribution of the T1934C is still unclear. One of the 10
isolates (TC-18, erythromycin and clarithromycin MICs >256 mg/L) had no alteration
in the 23S rRNA, suggesting that other mechanisms are involved in macrolide resistance
in this strain.
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Figure 5.2 Multiple suquence alignment of the 23S rRNA gene, (a) mutation at
position 1934; (b) mutations at position 2143, 2182 and 2195. Point mutations are
indicated in purple, red, blue and pink.
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6.1 Introduction
Fluoroquinolones are known to target DNA gyrase. In gram-negative bacteria, DNA
gyrase is the primary target of fluoroquinolones. Mutations in the QRDR of the gyrA are
associated with an increase in MIC of quinolone drugs. In E. coli, mutations in serine-83
and aspartate-87 confer high-level of resistance. In II. pylori, resistance to
fluoroquinolone was found in a clinical trial that examined the efficacy of ciprofloxacin
in the treatment of H. pylori infection (Moore et al. 1995). Sequencing analysis showed
that mutations in the gyrA gene, encoding DNA gyrase subunit A, at amino acid 87, 88,
91 and double amino acid substitution at positions 91 and 97 were associated with an
increase in resistance (MIC). However, gyrA mutations yielded ciprofloxacin resistance
of 4-8mg/L, which is not very high.
To investigate the development of resistance and identify the target of ciprofloxacin in
H. pylori, the sequential progression to high-level fluoroquinolone resistance in vitro
was determined by a stepwise mutation experiment. Mutants of H. pylori strains were
selected in 3 steps on plates with increasing ciprofloxacin concentrations. To
characterise the genetic mutation associated with resistance, the QRDR of the gyrA gene
of the laboratory mutants was amplified and sequenced. In order to correlate gyrA
mutations in laboratory mutants and clinical isolates, the gyrA gene of H. pylori clinical
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isolates that exhibited decreased susceptibility to ciprofloxacin were characterised by
PCR amplification and DNA sequencing.
6.2 In-vitro Fluoroquinolone Selection
To investigate the development of fluoroquinolone resistance in H. pylori in vitro,
sequential mutations in the QRDR of the gyrA gene of five different laboratory
ciprofloxacin-resistant mutants were characterised. The mutants were generated from
five ciprofloxacin-sensitive strains: HP-1, HP-4, HP-7, HP-17, H. pylori NCTC11916.
6.2.1 Ciprofloxacin Selection of HP-1 and HP-4
Ciprofloxacin-resistant mutants were selected from H. pylori HP-1 and HP-4 in stepwise
manner on increasing concentrations of ciprofloxacin. To characterise the order of
mutations in the development of ciprofloxacin resistance, the QRDR of the gyrA gene
(238bp) of all the laboratory mutants and parent strains was amplified by PCR and the
fragment was analysed by automated DNA sequencing. The MICs and sequential
mutations in gyrA are shown in Table 6.1, 6.2 and 6.3. The MICs of the mutants showed
decreased sensitivity to ciprofloxacin, with the MIC between 125 and 2000-fold higher
than the parent strain HP-1 and 1000 to 16000 fold higher than the parent strain HP-4.
The first-step mutants HP-1.1 had the MIC of 8 mg/L, which was a 125-fold increase in
ciprofloxacin MIC in comparison to the parent strain (HP-1, MIC = 0.064mg/L). HP-1
showed an amino-acid change in gyrA from Aspartic acid-91 to Asparagine. The first-
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step mutant from HP-4 (HP-4.1, MIC 16mg/L) also had gyrA mutation at position 91
but with amino acid change from Aspartic acid to Tyrosine. The MIC of the first-step
mutant increased by 1000-fold compared to the parent strain HP-1 (MIC = 0.016mg/L).
The second step mutants HP-1.2 and HP-4.2 (MIC = 64 mg/L) with 8-fold and 4-fold
increase in the MIC, respectively, had no change in the sequences. No alterations in the
QRDR of the gyrA gene were observed in the third-step mutants (MIC = 128mg/L for
HP-1.3 and MIC = 256mg/L for HP-4.3) with 2-fold and 4-fold increase in the MIC.
Mutations at Aspartic acid-91 to either Asparagine or Tyrosine are associated with high-
level fluoroquinolone resistance in H. pylori. No additional mutation was found in the
second-step and third-step mutations of HP-1 and HP^4, suggesting that other
mechanisms of resistance may play a role in the mechanism of ciprofloxacin resistance
in H. pylori.
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HP-1.1 8 Asp-91 -A Asn
HP-4.1 16 Asp-91 -> Tyr
2nd Step
HP-1.2 64 Asp-91 -> Asn
HP-4.2 64 Asp-91 -> Tyr
3rd Step
HP-1.3 128 Asp-91 -> Asn
HP-4.3 256 Asp-91 Tyr
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Table 6.2 Comparison of partial DNA sequences of ciprofloxacin-resistant mutants
of HP-1. The deduced amino acid sequences are given below the nucleotide sequences.
Letters in red indicate point mutations, leading to amino-acid substitutions.
Mutations in the QRDR ofgyrA
Strain
Codon 80 81 82 83 84 85 86 87 88 89 90 91 92 93
HP-l
aaa tac cac ccc cat ggc gat aat gcg gtt tat gat gcg eta
K Y H p H G D N A V Y D A L
HP-1.1 aaa tac cac ccc cat ggc gat aat gcg gtt tat aat gcg eta
K Y H p H G D N A V Y N A L
HP-1.2 aaa tac cac ccc cat ggc gat aat gcg gtt tat aat gcg eta
K Y H p H G D N A V Y N A L
HP-1.3
aaa tac cac ccc cat ggc gat aat gcg gtt tat aat gcg eta
K Y H p H G D N A V Y N A L
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Table 6.3 Comparison of partial DNA sequences of ciprofloxacin-resistant mutants
of HP-4. The deduced amino acid sequences are given below the nucleotide sequences.
Letters in red indicate point mutations, leading to amino acid substitutions.
Strain
Mutations in the QRDR ofgyrA
Codon 8 0 81 82 83 84 85 86 87 88 89 90 91 92 93
HP-4
aaa tac cac ccc cat ggc gat aac gcg gtt tat gat gcg eta
K Y H p H G D N A V Y D A L
HP-4.1
aaa tac cac ccc cat ggc gat aac gcg gtt tat tat gcg eta
K Y H p H G D N A V Y Y A L
HP-4.2 aaa tac cac ccc cat ggc gat aac gcg gtt tat tat gcg eta
K Y H p H G D N A V Y Y A L
HP-4.3
aaa tac cac ccc cat ggc gat aac gcg gtt tat tat gcg eta
K Y H p H G D N A V Y Y A L
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6.2.2 Ciprofloxacin Selection of HP-7 and H. pylori NCTC11916
The MICs and sequential mutations in gyrA of laboratory mutants of HP-7 and H. pylori
NCTC11916 are shown in Table 6.4, 6.5 and 6.6. The mutants showed decreased
sensitivity to ciprofloxacin, with the MICs between 500- and 16000-fold higher than the
parent strain HP-7 and 250- to 2000-fold higher than the parent strain H. pylori NCTC
11916. The two first-step mutants, with the MIC of 16mg/L (HP7.1 and NCTC
11916A), had the same gyrA mutation at Aspartic acid 91 to Asparagine and there was
500-fold and 250-fold increase in ciprofloxacin MIC in comparison to the parent strain
(HP-7, MIC = 0.032mg/L, NCTC11916, MIC = 0.064mg/L). The second-step mutant
HP-7.2 had the MIC of 128 mg/L with a 8-fold increase in the MIC and carried an
additional mutation at Asparagine-87 to Lysine. The second-step mutation of NCTC
11916 (NCTC11916B) raised the MIC to 64 mg/L, with MIC increasing by 4 fold, but
no change was found in the sequence. On the other hand, the third step mutation of
NCTC 11916 (NCTC11916C, MIC 128 mg/L) had the additional mutation at
Asparagine-87 to Lysine, with a two-fold increase in the MIC. The third-step mutation
of HP-7 (HP-7.3, MIC 512 mg/L) had no amino-acid changes in sequence and the MIC
increased by 4-fold. Silent nucleotide substitutions, which did not confer amino-acid
changes, were found at positions 87 and 93 in the first-step mutant HP-7.1 and at
positions 73, 78, 82 and 88 in the second- and third-step mutant of HP-7. The third-step
mutant of H. pylori NCTC11916 had silent mutations at positions 73, 78, 82 and 88.
A single amino-acid substitution at Aspartic acid-91 to Asparagine or a double amino
substitutions at Aspartic acid-91 to Asparagine or Asparagine-87 to Lysine are
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associated with fluoroquinolone resistance in H. pylori. High-level resistance to
ciprofloxacin was associated with two mutation sites in the gyrA gene in laboratory
mutants. Other mechanisms of resistance, besides target site mutations, may play a role
in the mechanisms of ciprofloxacin resistance in H. pylori, as no additional mutation was
identified in the second-step mutation of NCTC11916 and the third-step mutation of
HP-7.
Table 6.4 Mutation in the QRDR of ciprofloxacin-resistant mutants from HP-7









HP-7.1 16 Asp-91 -> Asn
NCTC11916A 16 Asp-91 -> Asn
2nd Step
HP-7.2 128 Asp-91 -> Asn, Asn-87 -> Lys
NCTC11916B 64 Asp-91 -> Asn
3rd Step
HP-7.3 512 Asp-91 -4 Asn, Asn-87 -> Lys
NCTC11916C 128 Asp-91 -> Asn, Asn-87 -> Lys
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Table 6.5 Comparison of partial DNA sequences of ciprofloxacin-resistant mutants
of HP-7. The deduced amino-acid sequences are given below the nucleotide sequences.
Letters in red indicate point mutations, leading to amino-acid substitutions. Letters in
green indicate silent nucleotide mutations.
Strain
Mutations in the QRDR ofgyrA
Codon 80 81 82 83 84 85 86 87 88 89 90 91 92 93
aaa tac cac ccc cat ggc gat aat gcg gtt tat gat gcg tta
HP-7































aaa tac cat ccc cat ggc gat aaa gca gtt tat aat gcg eta
K Y H p H G D K A V Y N A L
HP-7.3 aaa tac cat ccc cat ggc gat aaa gca gtt tat aat gcg eta
K Y H p H G D K A V Y N A L
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Table 6.6 Comparison of partial DNA sequences of ciprofloxacin-resistant mutants
of H. pylori NCTC11916. The deduced amino-acid sequences are given below the
nucleotide sequences. Letters in red indicate point mutations, leading to amino-acid
substitutions. Letters in green indicate silent nucleotide mutations.
Strain
Mutations in the QRDR ofgyrA
Codon 80 81 82 83 84 85 86 87 88 89 90 91 92 93
NCTC11916 aaa tac cac ccc cat ggc gat aat gcg gtt tat gat gcg eta
K Y H p H G D N A V Y D A L
NCTC11916A aaa tac cac ccc cat ggc gat aat gcg gtt tat aat gcg eta
K Y H p H G D N A V Y N A L
NCTC11916B aaa tac cac ccc cat ggc gat aat gcg gtt tat aat gcg eta
K Y H p H G D N A V Y N A L
NCTC11916C aaa tac cat ccc cat ggc gat aaa gca gtt tat aat gcg eta
K Y H p H G D K A V Y N A L
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6.2.3 Ciprofloxacin Selection of HP-17
The MICs and sequential mutations in gyrA of the laboratory mutants of HP-17 are
shown in Table 6.7 and 6.8. The mutants showed decreased sensitivity to ciprofloxacin,
with the MIC between 250- and 4000-fold higher than the parent strain HP-17. The first-
step mutant had an MIC of 8mg/L with a 250-fold increase in the MIC compared to the
parent strain HP-17 (MIC = 0.032mg/L). Sequence analysis showed a mutation in the
gyrA gene at Aspartic acid-91 to Asparagine. The second-step mutant (MIC 64mg/L)
carried an additional mutation at Glycine-85 to Cysteine with ciprofloxacin MIC
increasing by 8 fold. Interestingly, the third-step mutant had a gyrA change at amino
acid 91 again, changing from Asparagine to Tyrosine and associated with ciprofloxacin
MIC of 128mg/L, which is a 2-fold increase in the MIC.
A single amino-acid substitution at Aspartic acid-91 to Asparagine or a double amino
substitution at Aspartic acid-91 to either Asparagine or Tyrosine, and Glycine-85 to
Cysteine confer fluoroquinolone resistance in H. pylori. It was demonstrated that
high-level ciprofloxacin was associated with a double amino-acid change in the gyrA
gene the laboratory mutants.
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HP-17.1 8 Asp-91 -> Asn
2nd Step
HP-17.2 64 Asp-91 -> Asn, Gly-85 -> Cys
3rd Step
HP-17.3 128 Asp-91 -> Tyr, Gly-85 Cys
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Table 6.8 Comparison of partial DNA sequences of ciprofloxacin-resistant mutants
of HP-17. The deduced amino acid sequences are given below the nucleotide sequences.
Letters in red indicate point mutations, leading to amino acid substitutions.
Strain
Mutations in the QRDR ofgyrA






























HP-17.1 aaa tac cac ccc cat ggc gat aat gcg gtt tat aat gcg tta
K Y H p H G D N A V Y N A L
HP-17.2 aaa tac cac ccc cat tgc gat aat gcg gtt tat aat gcg tta
K Y H p H c D N A V Y N A L
HP-17.3
aaa tac cac ccc cat tgc gat aat gcg gtt tat tat gcg tta
K Y H p H C D N A V Y Y A L
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6.3 Clinical Fluoroquinolone Resistance
In the previous section (Section 6.2), I have identified the mechanism of fluoroquinolone
resistance by target site mutations in that occurred in vitro. This study further examined
the contribution of the gyrA gene to the development of resistance to fluoroquinolone in
H. pylori in vivo. Mutations in the gyrA gene that confer fluoroquinolone resistance in
three ciprofloxacin-resistant H. pylori clinical isolates were characterised. These
isolates were isolated in Scotland. TC-246 (MIC = 16mg/L) and TC-413 (MIC =
>32mg/L) were the isolates obtained from this project (Chapter 3). TC-24 (MIC
=32mg/L) was obtained from the Infection and Immunity laboratory, University of
Edinburgh.
The QRDR of the gyrA gene from each isolate was amplified by PCR. A 238bp
fragment was analysed by automated DNA sequencing and compared with the
ciprofloxacin-sensitive H. pylori NCTC 11916. Analysis of the QRDR of the gyrA gene
showed that all three ciprofloxacin-resistant isolates harboured a gyrA mutation (Table
6.9).
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Table 6.9 Amino acid substitutions in the QRDR ofgyrA in clinical isolates
Strain MIC (mg/L) gyrA mutation
TC-246 16 Asp-91-> Asn
HP-24 32 Asn-87 -> Lys
TC-413 >32 Asp-91-> Asn
Sequence analysis revealed that TC-246 and TC-413 had a GAT-to-AAT mutation, in
codon 91, changing from Aspartic acid to Asparagine. HP-24 carried a single amino acid
substitution at Asparagine-87 to Lysine (AAT to AAA) and silent nucleotide
substitutions, which did not confer amino-acid changes at positions 82 and 88. Table
6.10 shows the sequence alignment and corresponding amino-acid substitution of gyrA.
Nucleotide sequence of the gyrA fragment obtained from the wild-type ciprofloxacin-
sensitive H. pylori NCTC 11916 was used as a control.
Mutations conferring ciprofloxacin resistance in clinical isolates from this study
demonstrated that a single amino-acid substitution in the QRDR of the gyrA gene is
responsible for fluoroquinolone resistance in H. pylori in vivo. Amino-acid substitutions
at position 91 (Aspartic acid to Asparagine) and position 87 (Asparagine to Lysine) were
found in the mutation studies in the laboratory mutants in this study and were also
identified in the clinical isolates from the study by Moore et al. (1995).
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Table 6.10 Comparison of partial DNA sequences of ciprofloxacin-resistant clinical
isolates. The deduced amino acid sequences are given below the nucleotide sequences.
Letters in red indicate point mutations, leading to amino acid substitutions. Letters in
green indicate silent nucleotide mutations.
Strain
Mutations in the QRDR ofgyrA
Codon 80 81 82 83 84 85 86 87 88 89 90 91 92 93
Aaa tac cac ccc cat ggc gat aat gcg gtt tat gat gcg eta
NCTC 11916
K y H p H G D N A V Y D A L
aaa tac cat ccc cat ggc gat aaa gca gtt tat gat gcg eta
HP-24
K Y H p H G D K A V Y D A L
TC-246
aaa tac cac ccc cat ggc gat aac gcg gtt tat aat gcg eta
K Y H p H G D N A V Y N A L
TC-413
aaa tac cac ccc cat ggc gat aac gcg gtt tat aat gcg eta
K Y H p H G D N A V Y N A L
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7.1 Introduction
Metronidazole is an important component of many currently used H. pylori treatment
regimens and resistance to metronidazole is one of the major causes of treatment failure.
Metronidazole resistance was 16-42% in Europe (Megraud et al., 1999) and 37% in the
US (Osato et al., 1999). The prevalence of metronidazole resistance is far higher in
developing countries, where metronidazole is used to treat anaerobic and parasitic
infections. Metronidazole resistance rate was 90% in India (Mukhopadhyay et al., 2000)
and 78% in China (Wu et al., 2000). Several mechanisms have been proposed for the
metronidazole resistance, such as enhanced scavenging of toxic oxygen radicals by an
altered catalase or superoxide dismutase and an efficient DNA damage repair
mechanism. Goodwin et al. (1998) recently reported that the loss of oxygen-insensitive
NADPH nitroreductase activity resulted in the development of metronidazole resistance
in H. pylori. The rdxA gene encodes an oxygen-insensitive NADPH nitroreductase that
reduces metronidazole to its active metabolite that is toxic for H. pylori. It has been
proposed that mutational inactivation of rdxA confers metronidazole resistance
(Goodwin et al., 1998). However, an intact rdxA gene has also been reported in
metronidazole-resistant H. pylori (Jenks et al., 1999). To investigate the contribution of
metronidazole to the development of metronidazole resistance, the rdxA gene of
metronidazole-resistant H. pylori isolated from Scotland was amplified and then
sequenced. This study also examined the rdxA gene of H. pylori NCTC 11637 that has
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been reported as a metronidazole-resistant strain but when tested for metronidazole
resistance by our susceptibility method (a 24-hour anaerobic pre-incubation), it behaves
to be a sensitive strain.
7.2 PCR Amplification of rdxA
The rdxA gene encoding oxygen-insensitive NADPH nitroreductase was amplified by
PCR from six metronidazole-resistant strains isolated in Scotland, TC-18, TC-165, TC-
232, TC-243, TC-296 and TC-376 (MIC range, 4 - >256mg/L) and two sensitive strains,
H. pylori NCTC11637 and NCTC11916 (MIC = 0.016mg/L), producing a 947bp
fragment. The results are shown in Figure 7.1.
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Figure 7.1 Confirmation rdxA fragment sizes
Lane 1: 100-bp ladder
Lane 2-9: rdxA PCR products from H. pylon NCTC11637, NCTC11916, TC-18,
TC-165, TC-232, TC-243, TC-296 and TC-376.
Bands of expected size, 947bp, were observed in all resistant strains but not for the two
sensitive strains, NCTC11637 and NCTC11916. PCR products from NCTC11637 and
NCTC11916 yielded a product of approximately 200bp smaller than the expected size
and those of other resistant strains, suggesting that deletions have occurred in the
sequences. All PCR products were then further characterised by DNA sequencing.
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7.3 Mutations in rdxA
Mutations in each of the rdxA gene were analysed by DNA sequencing. The PCR
products were purified by Qiaquick PCR purification kit and sequenced using the PCR
primers. The rdxA sequences were compared to H. pylori 26695 rdxA in GenBank, with
accession number AE000604. Amino-acid substitutions and alignment of RdxA of 6
metronidazole-resistant strains is shown in Table 7.1 and Figure 7.2.
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Figure 7.2 Alignment of RdxA proteins of 6 metronidazole-resistant isolates. The
RdxA sequences of metronidazole-resistant strains were compared to that of H. pylori
26695. Letters in red show amino acids in the conserved region of the RdxA protein
(amino acids positions 43 to 57). Letters in red indicate amino-acid substitutions. Stop
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There were 20 different amino-acid changes (positions 6, 16, 24, 31, 51, 52, 55, 59, 62,
71, 75, 83, 85, 90, 97, 103, 114, 118 and 172) in rdxA of metronidazole-resistant strains,
comparing with the rdxA gene of H. pylori 26695. The rdxA gene of all six
metronidazole-resistant strains contained missense mutations that resulted in amino-acid
substitutions. One isolate, TC-232, had an additional nonsense mutation at position 52,
resulting in a stop codon. All strains had two to seven amino-acid changes in the
sequences. Five strains contained the same amino-acid substitution at position 59,
changing from Aspartic acid (D) to Asparagine (N). Two of the substitutions, Proline (P)
to Leucine (L) at position 51 in TC-376 and a Valine (V) to Leucine (L) at position 55 in
TC-165, were at position within a region that is highly conserved in classical oxygen-
insensitive NADPH nitroreductase (position 43-57). Three isolates had mutations at the
same position (position 118) but different in amino-acid substitutions. Two of these
three isolates had Alanine (A) to Serine (S) substitutions (TC-296 and TC-376) and one
isolate (TC-18) had an Alanine (A) to Threonine (T) substitution. Amino-acid changes
from Threonine (T) to Glutamic acid (E) were found in two isolates (TC-232 and TC-
376) at position 31. Amino acid changes from Arginine (R) to Lysine (K) at position 90
were found in TC-18 and TC-165. Two isolates had a Valine (L) to Isoleucine (I)
substitution at position 172 (TC-18 and TC-376). The other amino-acid changes were
Glutamine (Q) to Histidine (H) (position 6), Arginine (R) to Cysteine (C) (position 16),
Serine (S) to Tyrosine (Y) (Position 24), Leucine (L) to Valine (V) (position 62),
Tyrosine (Y) to Phenylalanine (F) (position 71), Glutamic acid (E) to Lysine (K)
(position 75), Leucine (L) to Valine (V) (position 83), Valine (V) to Leucine (L)
(Position 85), Histidine (H) to Threonine (T) (position 97), Asparagine (N) to Threonine
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(T) (position 103), Isoleucine (I) to Leucine (L) (position 114). There is no correlation
between MIC for metronidazole-resistant isolates and either the type or position of
mutation in the rdxA gene.
The alignment of RdxA protein of metronidazole-sensitve strains, H. pylori NCTC
11637 and NCTC11916, comparing them with H. pylori 26695, are shown in Figure 7.3.
Both H. pylori NCTC 11637 and NCTC 11916 had the same amino-acid changes. Four
different amino-acid substitutions were found at amino acid position 14 (Asparagine to
Lysine), position 31 (Threonine to Glutamic acid), position 36 (Isoleucine to Valine) and
position 56 (Methionine to Isoleucine). Amino-acid substitution at position 56 is in the
conserved region. Both strains had nonsense mutations at position 73, leading to a stop
codon. My result is different from the study of the rdxA sequence of H. pylori NCTC
11637 by Debets-Ossenkopp et al (1999), who found nonsense mutation at position 83.
133
Chapter 7 Results: Metronidazole Resistance
Figure 7.3 Alignment of RdxA protein of metronidazole-sensitive strains. The
sequences were compared to the amino acids of H. pylori 26695. Letters in green show
amino acids in the conserved region of the RdxA protein (amino acids positions 43 to
57). Letters in red indicate amino-acid substitutions. Letters in blue show amino acid in






















HP26695 PWHFVMVTDK DLKKQIAAHS YFNEEMIKSA SALMWCSLR PSELLPHGHY
NCTC 11916 PWHFVIVTNK DLNHPSRNPK HL-
NCTC 11637 PWHFVIVTNK DLNHPSRNPK HL-
Sequence analysis showed that these two metronidazole-sensitive strains had insertions
of a 267-bp fragment and deletions of a 469-bp segment starting at nucleotide position
189. This can explain the smaller size of PCR products of these strains, which are 202bp
smaller than the expected size (947bp). The sequence of the 267-bp insertion is shown
in Figure 7.4. A BLAST search revealed that the 267-bp insertion fragment is closely
matched to the H. pylori vacuolating cytotoxic gene and cag I pathogenicity island. The
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41 and 33bp at the left and right ends of the insertion (Figure 7.4) are closely matched to
the left and right ends of IS605, a 2-kb insertion sequence. Censini et al (1996) found
the is605, a variant of IS605, at the right end of cag pathogenicity island in H. pylori
strain CCUG 17874. The is6"05 is composed of two arms of IS605 with no association in
the ORFs.
Figure 7.4 Alignment of the mini-IS605 sequence present in the rdxA of H. pylori
NCTC11637 and NCTC11916. Letters in blue indicate a 267bp insertion. Letters in
bold indicate the left and right ends of the insertion which correspond to the mini-IS605
found at the right end of the cag pathogenic island.
189
t
NCTC11916 CCACCCAAGC AGAAATCCCA AACATCTTTA GTGTTTGGGA TGAATGCTGC
NCTC11637 CCACCCAAGC AGAAATCCCA AACATCTTTA GTGTTTGGGA TGAATGCTGC
NCTC11916 TAATTTGTAG TATAATATCT CCATACATTT GTATCTAGCG TAGGAAGTAC
NCTC11637 TAATTTGTAG TATAATATCT CCATACATTT GTATCTAGCG TAGGAAGTAC
NCTC11916 GCAAAGTTAC GCCTTTGGAG ATATGATGTG TGAGACCTGT AGGGAATGCG
NCTC11637 GCAAAGTTAC GCCTTTGGAG ATATGATGTG TGAGACCTGT AGGGAATGCG
NCTC11916 TTGGAGATCA AACTCTGTAA AATCCCTATG ATTAGGGACA CAAAGTGAGA
NCTC11637 TTGGAGATCA AACTCTGTAA AATCCCTATG ATTAGGGACA CAAAGTGAGA
NCTC11916 ACCAAACTTT CCCTATGGGC AACATCAGCC GAGGAAGCCC AATCGCTTTA
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Table 7.2 summarises mutations in the RdxA protein. The mutations were compared to
metronidazole-sensitive H. pylori 26695. The majority of changes in the rdxA gene were
the results of missense mutations, leading to amino-acid substitution. Alterations in rdxA
were found in both sensitive and resistant strains. Only three strains had mutations
causing a premature stop codon, two of which were metronidazole-sensitive strains.
Therefore, only one metronidazole-resistant isolate had a truncated Rdx protein. The
majority of amino-acid substitutions found in this study were reported in sensitive
strains by other published papers. Only two of them (position 24 and 103) have not been
yet been identified. The rdxA gene of H. pylori has been reported to have about 95%
similarlity among H. pylori strains. The amino-acid substitutions found in resistant
strains may not be responsible for the mechanism of resistance. The alterations in the
rdxA gene of the two sensitive strains from this study generated a truncated protein,
suggesting that other mechanisms of metronidazole resistance exist. The results also
indicate that mutations in the rdxA gene do not always contribute to the mechanism of
metronidazole resistance. An alternative mechanism must be involved in the resistance
mechanism.
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Table 7.2 Mutations in the rdxA gene of 8 H. pylori strains
Strain MIC (mg/L) RdxA mutations
H. pylori NCTC11637 0.016 Insertion of a 267bp fragment and
deletion of a 469bp segment, amino
aqcid substitutions at positions 14, 31,
36 and 56
H. pylori NCTC11916 0.016 Insertion of a 267bp fragment and
deletion of a 469bp segment, amino
aqcid substitutions at positions 14, 31,
36 and 56
TC-18 12 Amino acid substitutions at positions
6, 16, 59, 90, 97, 118, 172
TC-165 16 Amino acid substitutions at positions
55, 59, 83, 90, 103.
TC-232 64 Amino acid substitutions at positions
24, 31 and a nonsense mutation at
position 52 (Stop codon)
TC-243 16 Amino acid substitutions at 59, 62, 75,
85 and 114
TC-296 4 Amino acid substitution at positions
59,71 and 118
TC-376 >256 Amino acid substitution at positions
31, 51, 59,118 and 172
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Chapter 8 Results: Cloning, Expression and
Purification of H. pylori DNA Gyrase
8.1 Introduction
Bacterial DNA topoisomerases play an important role in cellular processes by
controlling the topology states of DNA in DNA replication and transcription. DNA
gyrase and topoisomerase IV are classified as type n topoisomerases. DNA gyrase, a
heterotetramer protein, consist of two subunits, GyrA and GyrB, encoded by gyrA and
gyrB (Swanberg and Wang, 1987). GyrA is responsible for the transient breakage and
rejoining, whereas GyrB is responsible for ATPase activity, providing energy required
for the supercoiling reaction. Topoisomerase IV, encoded by parC and parE, is a
decatenating enzyme that acts during DNA replication (Kato et al., 1990). DNA gyrase
is a primary target of quinolones in gram-negative bacteria while topoisomerase IV is a
primary target of quinolones in gram-positive bacteria (Chen et al., 1996; Khodursky et
al., 1995; Ng et al., 1996). In H. pylori, alterations in the QRDR of the gyrA gene have
been reported to be associated with fluoroquinolone resistance by Moore et al. (1995).
My study has also confirmed this finding (See Chapter 6). Since parC gene has not yet
been identified in H. pylori genomic DNA (GenBank accession number NC_000915 and
NC_000921), any contributions to the mechanism of quinolone resistance from
topoisomerase IV cannot be quantified. This raised the question if DNA gyrase in H.
pylori has topoisomerase IV activity to compensate for the absence of topoisomerase IV.
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To characterise the DNA gyrase activity, cloning, expression and purification of DNA
gyrase were determined. The gyrA and gyrB genes from a fluoroquinolone-sensitive H.
pylori NCTC11637 were separately cloned and overexpressed in E. coli BL21
(DE3)pLysS. The individual subunits were purified and tested for DNA gyrase activity.
8.2 Cloning of PCR Fragments
The gyrA and gyrB genes of H. pylori NCTC11637 were amplified by PCR. A 2590-bp
fragment was obtained from gyrA amplification and a 2380-bp fragment yielded from
gyrB amplification (Figure 8.1). The PCR products of gyrA and gyrB were cloned
separately into the expression vector pCR-T7/NT and then transformed to TOP 10F'
competent cells. The positive clones were further identified by restriction analysis and
DNA sequencing.
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Lane 1: gyrA PCR product
Lane 2: gyrB PCR product
Lane 3: Lambda////ndIII marker
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8.3 Analysis of Positive Clones
8.3.1 Restriction Analysis
Plasmids of the positive clones were analysed by restriction analysis and DNA
sequencing to detect the orientation of the inserts. HindHl was used to cleave the
plasmid pCR T7/NT harbouring a gyrA insert and a gyrB insert. The expected sizes of
the restricted plasmid containing gyrA were 4462, 537, and 463 bp. The expected sizes
of the restricted plasmid containing gyrB were 3660, 1023, 479 and 90bp. The restriction
maps are shown in Figure 8.2. Restriction patterns of plasmids from clone 2A (gyrA
clone) and clone 17B (gyrB clone) are shown in Figure 8.3 and 8.4. The results
demonstrated expected HindUI fragments from both plasmids, suggesting that the
plasmids pTC2A from clone 2A and pTC17B from clone 17B harboured gyrA and gyrB
with the correct orientation, respectively.
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Figure 8.2. Restriction maps of plasmid pCR T7/NT TOPO containing gyrA and
gyrB. The gyrA and gyrB genes are indicated in pink and green boxes, respectively.
(a) The map of pCR T7/NT TOPO containing a gyrA insert with Hindlll
restriction sites
gyrA S £
Ilindlll restriction site: Insert: position 1603 and 2140
: Vector: position 218
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(b) The map of pCR T7/NT TOPO containing a gyrB insert with Hindlll
restriction sites
gyrB £ £
Hindlll restriction site: Insert: position 801,1824 and 1914
Vector: position 218
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Figure 8.3 Restriction patterns of plasmid pTC2A containing a gyrA insert.
Agarose gel shows restriction analysis of plasmid pTC2A from clone 2A. The HindBl
fragments of 4459, 537 and 450bp indicated the correct orientation of the insert.
Lane 1: HindUl fragments of plasmid pTC2A containing a gyrA insert
Lane 2: lkb DNA ladder
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Figure 8.4. Restriction pattern of plasmid pTC17B containing a gyrB insert.
Agarose gel shows restriction analysis of plasmid pTC17B from clone 17B. The HindTIl
fragments of 3660, 1023, 479 and 90bp indicate the correct orientation of the insert.
Lane 1: Hindlll fragments of plasmid pTC17B
Lane 2: lkb DNA ladder
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8.3.2 Sequence Analysis
The plasmids pTC2A and pTC17B were sent to the Department of Haematology, Royal
Infirmary, Edinburgh, Scotland for automated sequencing. The T7 sequencing primer (a
vector-specific forward primer) was used to determine the orientation of the inserts and
identify whether the inserts were in frame with the N-terminal tag. The sequence of
pTC2A and pTC17B were compared the vector pCR T7/NT and shown in Figure 8.5
and 8.6. Sequence analysis demonstrated that both gyrA and gyrB inserts were in frame
with the N-terminal tag and placed in the correct orientation.
The complete nucleotide sequences of gyrA and gyrB inserts were determined by
automated DNA sequencing on the plasmid DNA templates, pTC2A and pTC17B. The
sequence analysis showed that an open reading frame of 2322 and 2487 nucleotides
coded for a polypeptide of 828 and 773 amino acids for gyrA and gyrB, respectively,
with a calculated molecular mass of 92 kDa for GyrA and 86 kDa for GyrB. The
complete sequences of gyrA and gyrB genes are show in Appendix II.
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Figure 8.5. Sequence analysis of pTC2A containing a gyrA insert. The nucleotide
sequence of pTC2A was compared with the vector pCR T7/NT. The partial nucleotide sequence
of the gyrA insert in plasmid pTC2A is shown in bold and red. The yellow box indicates amino
acid of the N-terminal tag. Polyhistidine region (6xHis) is indicated in bold. The grey box
indicates the amino acid of the gyrA gene. Ribosome binding site is shown in green. Gaps in the
sequence are indicated with dashes.
Ribosome binding site
pCR T7/NT AGAAATAATTT TGTTTAACTTTA AGAAGGA GATATACAT ATG CGG GGT TCT
pTC2A AGATTCAATTT TGTTTAACTTTA AGAAGGA GATATACAT ATG CGG GGT TCT
M R G S
pCR T7/NT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT GGT GGA CAG
pTC2A CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT GGT GGA CAG
HHHHHHGMASMTGGQ
Polyhistidine (6xHis) region
pCR T7/NT CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT CCA ACC
pTC2A CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT CCA ACC
QMGRDLYDDDDKDPT
Start codon of gyrA
pCR T7/NT CTT-
pTC2A CTT ATG CAA GAT AAT TCA GTC AAT GAA ACA AAA AAT ATT GTA GAA
LMQDNSVNETKNIVE
_ gyrA insert —
pCR T7/NT
pTC2A GTG GGG ATT GAT TCT TCT ATT GAA GAG AGC TAT TTA GCT TAT TCA
VGIDSSIEESYLAYS
pCR T7/NT
pTC2A ATG AGC GTG ATC ATA GGG CGC GCC TTA CCG GAC GCT AGA GAT GGC
MSV I IG RALPDARDG
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Figure 8.6. Sequence analysis of pTC17B containing a gyrB insert. The nucleotide
sequence of pTC17B was compared with the vector pCR T7/NT. The partial nucleotide
sequence of the gyrB insert in plasmid pTC17B is shown in bold and red. The yellow box
indicates amino acid of the N-terminal tag. Polyhistidine region (6xHis) is indicated in bold. The
grey box indicates the amino acid of the gyrB gene. Ribosome binding site is shown in green.
Gaps in the sequence are indicated with dashes.
Ribosome binding site
pCR T7/NT AGAAATAATTT TGTTTAACTTTA AGAAGGA GATATACAT ATG CGG GGT TCT
PTC17B AGATTCAATTT TGTTTAACTTTA AGAAGGA GATATACAT ATG CGG GGT TCT
M R G S
pCR T7/NT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT GGT GGA CAG
PTC17B CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT GGT GGA CAG
HHHHHHGMASM TGGQ
Polyhistidine (6xHis) region
pCR T7/NT CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT CCA ACC
pTC17B CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT CCA ACC
QMGRDLYDDDDKDPT
Start codon of gyrB
pCR T7/NT CTT-^




PTC17B TTA GAG GGG GTT AGG AAA CGC CCT GGA ATG TAT ATT GGC GAT ACC
LEGVRKRPGMYIGDT
pCR T7/NT
PTC17B AAT GTG GGT GGG TTG CAC CAC ATG GTG TAT GAA GTC GTG GAT AAC
NVGGLHHMVYEVVD
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8.4 Expression of gyrA and gyrB of H. pylori
The plasmids pTCA2 and pTCB17 were overexpressed in E. coli BL21 (DE3)pLysS .
After IPTG induction, the His-tagged proteins were detected by SDS-PAGE. The
diagram of the His-tagged GyrA and GyrB are shown in Figure 8.7 and the SDS-PAGE
analysis are shown in Figure 8.8. The expected sizes of the His-tagged GyrA and GyrB
are 96kDa and 90kDa, respectively. SDS-PAGE analysis showed low-level expression
of GyrA and GyrB. Although the expression conditions, including time, temperature and
IPTG concentration, were optimised, the expression was still low. The proteins were
expressed at 37°C with ImM IPTG for 4 hours. As the bands of expected size of the His-
tagged GyrA and GyrB were observed, the western blot analysis was further determined
to confirm that these bands were the His-tagged proteins.
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Figure 8.7. Diagram of the His-tagged GyrA and GyrB. GyrA and GyrB are
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Figure 8.8. SDS-PAGE analysis of GyrA (a) and GyrB (b) expressions.
(a) GyrA expression.
1 2 3 4 5 6 7
lOOkD —►
50kDa —►
Lane 1,7: MW marker
Lane 2-5: IPTG-induced cell lysate after 4, 3, 2 and 1 hours, respectively
Lane 6: Uninduced cell lysate
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Lane 1-4: IPTG-induced cell lysate after 4, 3, 2 and 1 hours, respectively.
Lane 5: Uninduced cell lysate
Lane 6: MW marker
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8.5 Western Blot Analysis
To detect the expression of GyrA and GyrB fusion proteins, western blot analysis were
determined. The antibody to 6xHis was used to detect the presence of the fusion
proteins. The His tail is located at the N-terminal of the fusion protein. The results
showed a single band for GyrA purification but two bands for GyrB purification (Figure
8.9). The molecular weights were estimated to be 96 kDa for GyrA and 90 kDa for
GyrB, which correspond to the predicted amino acid plus 4kDa increased in the size of
both proteins, derived from the N-terminal tag (See Figure 8.7). The unexpected band of
GyrB was approximately 67kDa. This protein should be a truncated protein of GyrB as
this protein was hybridised with the anti-6xHis-tagged antibody. Western blot analysis
also showed that His-tagged GyrA and GyrB proteins were observed before the IPTG
induction. This can explain why no distinct bands of the expected recombinant proteins
were found on the SDS-PAGE gels after IPTG induction.
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Lane 1: Uninduced cell lysate
Lane 2: IPTG-induced cell lysate after 4 hours
Lane 3: IPTG-induced cell lysate after 2 hours
Lane 4: MW marker.
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(b) GyrB
Lane 1: IPTG-induced cell lysate after 4 hours
Lane 2: IPTG-induced cell lysate after 2 hours
Lane 3: Uninduced cell lysate
Lane 4: MW marker
155
Chapter 8. Results: Cloning, Expression and Purification of H. pylori DNA Gyrase
8.6 Protein Purification
GyrA and GyrB proteins were separately purified by affinity chromatography with
ProBond resin (Nickel-charged Sepharose resin). The His-tagged proteins bound to the
resin and were eluted with imidazole. SDS-PAGE analysis of the fractions eluted from
the column was determined. The proteins with approximately expected size for GyrA
and GyrB were found in the fractions. However, the results revealed that both
recombinant GyrA and GyrB had low affinity for resin as they came off with
contaminant proteins as shown in Figure 8.10 and 8.11. These partially purified GyrA
and GyrB were used to further determine the activity of DNA gyrase as the time is
limited for this study.
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Figure 8.10. GyrA purification
Lane 1: Purified GyrA
Lane 2: MWmarker
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Figure 8.11. GyrB purification
Lane 1: Purified GyrB
Lane 2: MW marker
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8.7 DNA Supercoiling Assay
The partially purified GyrA and GyrB (Section 8.5) were assayed for the DNA
supercoiling activity. The results are presented in Figure 8.12. No DNA supercoiling
activity was detected from the protein preparations. The positive control derived from
DNA gyrase of E.coli had the supercoiling activity. As the time is limited, the optimum
condition for this assay could not be further determined.
These results show that the conditions were not optimal for supercoiling activity,
although the positive control worked. Alteration of the relative protein concentrations
did not improve the situation so it would be necessary to re-evaluate the individual
polypeptides. This would have to be performed probably by N-terminal sequencing.
Unfortunately, time and resources did not allow this to happen.
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Figure 8.12 Comparison of supercoiling activities ofH. pylori DNA gyrase purified
from NCTC11637 and E.coli DNA gyrase. Relaxed pBR322 was incubated with
either 1, 2 or 4 units of E.coli gyrase (Lane 1, 2 and 3) or no enzyme (Lane 4 and 6) or
H.pylori gyrase partially purified from NCTC11637 (Lane 7 and 8). Lane 5: pBR322 (a








Antimicrobial therapy has been widely used for H. pylori infection. As a single
antibiotic fails to eradicate H. pylori, combinations of a proton pump inhibitor and
antibiotics such as amoxycillin, clarithromycin, metronidazole and tetracycline are
commonly used to eradicate H. pylori. Resistance to antibiotics is an important factor for
treatment failure and primary resistance reduces the success of H. pylori eradication
(Houben et al., 1999). Susceptibility testing of H. pylori is, therefore, increasingly
important. In this study, the prevalence and antibiotic susceptibility patterns of H. pylori
against amoxycillin, ciprofloxacin, clarithromycin, erythromycin, tetracycline and
metronidazole were investigated to identify the potential resistance problems in
Scotland. The susceptibility testing of metronidazole was also evaluated examining
variations in methodology on the outcome of susceptibility testing.
This study shows results on mutations in target proteins of fluoroquinolones, macrolides
and metronidazole, which target DNA gyrase, 23S rRNA and oxygen-insensitive
nitroreductase, respectively. The study of target protein alterations associated with
antibiotic resistance provides a better understanding of resistance mechanisms. In
addition, this thesis demonstrates cloning of DNA gyrase and attempted to express H.
pylori DNA gyrase.
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Chapter 9 Discussion
This work is the first prospective study in Scotland, investigating the susceptibility
patterns and prevalence of antibiotic resistance in H. pylori. As H. pylori is the major
cause of peptic ulcers disease and a risk factor in gastric cancer, eradication with
antimicrobial therapy has been recommended. Antibiotic resistance in H. pylori is of
particular concern as it is the major factor in the failure of eradication regimens (Peitz et
al., 1999) and the prevalence of resistance varies between countries. Therefore,
antibiotic susceptibility profiles in individual areas would allow the selection of
adequate antibiotic treatment for successful H. pylori eradication.
Clarithromycin, metronidazole, amoxycillin and tetracycline are the antibiotics
frequently used in the treatment regimens. Although H. pylori is susceptible to many
antibiotics in vitro, resistance has been reported to most antimicrobials used.
Tetracycline and clarithromycin resistance can be found in 5%-10%. Metronidazole
resistance is more common and variable, ranging from 10% to >90% (Dunn et al.,
1997).
In this study MIC5o, MIC90 of amoxycillin, ciprofloxacin, clarithromycin, erythromycin,
tetracycline and metronidazole showed that amoxycillin was the most potent antibiotic
against H. pylori as the MIC90 was <0.016 mg/L and no resistance was found in all of
the strains. For macrolides, clarithromycin showed high activity against H. pylori with
the MIC90 of 0.023mg/L, compared with the MIC90 of 0.125mg/L for erythromycin.
162
Chapter 9 Discussion
Clarithromycin is the second potent antibiotic, followed by tetracycline and
ciprofloxacin with the MIC90 of 0.064mg/L, erythromycin (MIC90 = 0.125mg/L) and
metronidazole (MIC90 = 0.75mg/L). The MIC50 and MIC90 values of all antibiotics are
below the breakpoints, suggesting that these antibiotics have high activities against H.
pylori. Metronidazole is the least active compared to other antibiotics tested. This result
is similar to previous studies except that the MIC90 of metronidazole (MIC90 =0.75mg/L)
obtained from this study is much lower than that of other reports (MIC90 range of 16-
128mg/L) (Lopez-Brea et al., 1997; Megraud et al., 1999; Piccolomini et al., 1997;
Wolle et al., 2002). It is likely that the difference in the method determining
metronidazole susceptibility is involved in the variations in the MICs. Pre-incubation
under anaerobic conditions (See Chapter 4) was performed in this study.
In the present study, the prevalence of macrolide resistance is greater than other
antibiotics, 9.1% (10/110) for erythromycin and 8.2% (9/110) for clarithromycin. This
rate was higher than those in Sheffield, the UK (4.4%), the Netherlands (1.7%),
Germany (2.2%), Ireland (4.5%) but lower than those in Spain (21%), Poland (23.5%)
(Debets-Ossenkopp et al., 1999; Dzierzanowska-Fangrat et al., 2001; Lopez-Brea et al.,
2001; Parsons et al., 2001; Wolle et al., 2002; Xia et al., 1996).
Cross-resistance among macrolides has been reported (Glupczynski and Burette, 1990;
Xia et al., 1996). In this study, all clarithromycin-resistant strains were resistant to
erythromycin (MIC > 256mg/L). This suggests that the history of previous use of any
macrolides should be taken into account when clarithromycin is prescribed for H. pylori
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eradication. The increasing use of macrolide in clinical practice is also associated with
the rise of clarthromycin resistance in H. pylori.
Clarithromycin, a newer macrolide with greater acid stability and higher blood and
tissue level than erythromycin (Goldman et al., 1994; Hardy et al., 1988), is a potent
component of most widely used regimens for H. pylori eradication. Resistance to
clarithromycin will affect the cure rates of H. pylori and account for treatment failure.
The increased consumption of macrolides is likely to influence the prevalence of
clarithromycin resistance in H. pylori.
The prevalence of metronidazole resistance is highly variable. In developed countries, a
European multicenter study reported that the overall metronidazole resistance rate was
27%, ranging from 16% in France to 42% in Norway (Megraud et al., 1999). Parsons et
al. al reported overall metronidazole resistance was 40% in Sheffield, UK (Parsons et
al., 2001). Resistance rates reported from the US was 37% (Osato et al., 1999), the
Netherlands was 21% (Debets-Ossenkopp et al., 1999). Resistance rates are higher in
developing countries; resistance rate in China is 78% (Wu et al., 2000) and it can be as
high as 90% in India (Mukhopadhyay et al., 2000).
Resistance to metronidazole in this study is relative low (7.3%), comparing with other
reports. The difference in methodology for the susceptibility testing of metronidazole
(See Chapter 4) could explain the lower in the prevalence of metronidazole resistance in
Scotland. Lack of standardisation of susceptibility tests makes it more difficult to
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categorise a strain as susceptible or resistant. The consumption of metronidazole for the
gynaecological or dental treatment may contribute to the increase in metronidazole
resistance in developed countries. As metronidazole resistance is higher in developing
countries, this may be caused by the common use of metronidazole in protozoa diseases
and genital infection.
In this thesis, resistance to both metronidazole and clarithromycin was identified. Two
of the 8 metronidazole-resistant isolates (25%) were resistant to clarithromycin. Double
resistance to metronidazole and clarithromycin has been reported in other studies
(Debets-Ossenkopp et al., 1999; Osato et al., 1999; Parsons et al., 2001). In the UK,
Parsons also found that 21 of the 36 macrolide-resistant isolates (58.3%) had
metronidazole resistance (Parsons et al., 2001). However, they may have shown a
greater level of metronidazole because of the method that they used to test it. Dual
resistance may be the consequence of the combination of therapy of clarithromycin and
metronidazole.
Amoxycillin resistance is infrequent. No amoxycillin resistance was identified in this
study. Similar results are reported by the studies in the Netherlands, Germany, Spain, the
UK (Debets-Ossenkopp et al., 1999; Parsons et al., 2001; Wolle et al., 2002) although
31% of amoxycillin-resistant strains isolated in Italy (Dore et al., 1998) and 71.9% of
isolates from China (Wu et al., 2000) were reported. The reason for the high rate of
amoxycillin resistance in Italy is unclear but in China, amoxycillin has been commonly
used in the community in recent years.
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Tetracycline resistance has been recently reported in one H. pylori strain in Australia
(Midolo et ah, 1996). Piccolomini et al. showed that 6% of H. pylori strains isolated in
Italy had tetracycline resistance (Piccolomini et al., 1997). No resistance to tetracycline
was observed in the studies in Germany, the Netherlands (Debets-Ossenkopp et al.,
1999; Wolle et al., 2002). In the U.K, tetracycline resistance has been reported to be
0.5% (Parsons et al., 2001). A similar result is obtained from this study, with the
resistance rate of 0.9%. A report from China, where tetracycline resistance is used
extensively as therapy for other infections, such as non-gonococcal urethritis, showed
high rates of tetracycline resistance of 58.8% (Wu et al., 2000).
Ciprofloxacin resistance is usually reported less than 1%. In this study, ciprofloxacin
resistance is 1.8%. As ciprofloxacin is not currently used in the treatment regimens, the
result suggests that ciproflaoxacin resistance in these strains may result from the use of
fluoroquinolone for the treatment of other diseases. Unlike macrolides, the greatest
concentration of fluoroquinolone use is to treat severe infections in the hospital, not in
the community and so the exposure to fluoroquinolone has probably been limited
(Megraud, 1997). Recently, fluoroquinolone resistance has been reported in the
Netherlands with increasing resistance rate. Trovafloxacin resistance was 4.7%,
suggesting that the resistance may be caused by the induction by other quinolones as
trovafloxacin has not yet been introduced in the market in the country (Debets-
Ossenkopp et al., 1999).
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The results from this study shows the importance of sensitivity testing before starting
therapy as macrolide and metronidazole resistance is emerging in H. pylori isolated in
Scotland. It would be beneficial for treatment outcome, especially when clarithromycin
and metronidazole are prescribed. Inter-laboratory standardisation is also required for
the accurate susceptibility profiles. This study does not demonstrate whether treatment
has caused resistance, as there are no data on whether patients had previously been
treated for H. pylori. However, they would provide a useful guide for appropriate
eradication regimens for the patients.
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9.2 Susceptibility Testing for Metronidazole
Treatment of H. pylori infection requires a combination of antimicrobial agents.
Metronidazole is frequently used in the treatment regimens. The prevalence of
metronidazole resistance varies between countries, ranging from 11-70% in developed
countries and up to 90% in developing countries (Dunn et al., 1997). Since H. pylori
susceptibility testing has not yet been standardised, the variation may be the differences
in the method determining susceptibility test.
Resistance to metronidazole has been reported to be associated with a significantly
lower H. pylori eradication rate (Bell et al., 1992; Buckley et al., 1997; Burette et al.,
1992; Noach et al., 1994; Rautelin et al., 1992). It was demonstrated that triple therapy
provided an eradication rate of 86-98% in patients with metronidazole-sensitive strains,
however, eradication rate in the patients infected with metronidazole-resistant strains
was still up to 68%, which is relatively high. These findings indicate that metronidazole
still has the activity against some metronidazole-resistant strains. Cederbrant et al.
(1992) demonstrated that significant decreases in metronidazole MIC were observed in
metronidazole-resistant strains when there were pre-incubated under anaerobic
conditions. Smith and Edwards showed that H. pylori NCTC11637 was resistant to
metronidazole when tested under microaerophilic conditions, but became susceptible




The question is raised whether the reported resistant strains under microaerophilic
conditions in vitro are true resistant strains in vivo. As metronidazole resistance affects
the H. pylori eradication rate of metronidazole-including therapy, this study evaluated
variations in methodology on the outcome of susceptibility testing, including anaerobic
pre-incubation, media, size of inoculum and incubation time.
Pre-incubation under anaerobic conditions was shown to significantly decrease the MIC
of metronidazole in most of the strains. The ratio between the MIC determined with and
without pre-incubation ranged from 2.6 to 16,000 fold, except one strain (HP-91) had no
change in the MIC (MIC >256mg/L). Only 6 strains showed less than 10-fold decreased
in the MIC. The MIC5o and MIC90 decreased from 0.5 and >256mg/L to 0.016 and
0.19mg/L. This finding is in agreement with that reported by Cederbrant et al (1992).
The result suggests that metronidazole is activated under anaerobic conditions by the
reduction of a nitro group to a radical anion that damages the DNA (Edwards, 1993).
The requirement of anaerobic pre-incubation may explain the high resistance rate of
metronidazole reported by some centres. In this study, resistance to metronidazole was
28.6% (6/21) when tested under microaerophilic conditions, whereas the resistance rate
was 4.7% (1/21) when tested under anaerobic conditions for 24 hours followed by
microaerophilic conditions for 72 hours. This result showed a significant decrease in
resistance levels when anaerobic pre-incubation was performed. It appears that
anaerobic conditions are essential for resistant strains to restore resistant phenotype.
This finding is in agreement with the findings by previous studies, which showed all
metronidazole-resistant isolates became susceptible when pre-incubated for 24 hours
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under anaerobic conditions (van Zwet et al., 1995; Weel et al., 1996). These findings
also supports the hypothesis of Cederbrant et al. that resistant strains have lost the ability
to reach a sufficient low redox potential to reduce a nitro group of metronidazole in
microaerophilic environments, which is essential for reduction of metronidazole
(Cederbrant et al., 1992). Chatsuwan and Amyes (1999) suggested that anaerobic pre¬
incubation should be used for the determination of metronidazole susceptibility testing
(Chatsuwan and Amyes, 1999).
In contrast, Abdi et al. showed that anaerobic pre-incubation had little effect on the
estimation of prevalence of metronidazole resistance and appeared to have little
advantage over microaerophilic incubation alone (Abdi et al., 1999). The difference may
be a large number of resistant strains were presented in the study. As the resistance rate
when tested under microaerophilic conditions by E-test was 60%, comparing with 56%
when tested with anaerobic pre-incubation.
A comparison was made contrasting the incubation of the MIC plates in an anaerobic jar
and an anaerobic chamber, before transferring to microaerophilic conditions.
Inconsistency in H. pylori growth was observed when the MIC plates were pre-
incubated in an anaerobic chamber. H. pylori grew very well when an anaerobic jar was




In this study, the effects of medium, inoculum size and incubation period were
evaluated. It was demonstrated that H. pylori grew very well on Columbia agar with 7%
horse blood, comparing with poor growth observed on Mueller-Hinton agar with 7%
horse blood. The MICs were difficult to interpret when the inoculum size was 0.5
McFarland because of the poor growth but was clear and reproducible with higher
inoculum (a No.3 McFarland standard). A similar observation has been reported by
Hartzen et al. that higher inoculum size gave better results than the lower one (Hartzen
et al., 1997). After a 24-hour anaerobic pre-incubation, the MICs were easier to read
when the plates were incubated under microaerophilic conditions for 72 hours.
In this study, the optimum conditions for metronidazole susceptibility testing of H.
pylori were identified. In particular, it is imperative that pre-incubation of H. pylori
under anaerobic conditions, in an anaerobic jar, is necessary to achieve accurate
susceptibility results. Our interpretation is that these H. pylori strains are inherently
sensitive to metronidazole. If the drug is pre-reduced, as it has to be for metronidazole
sensitivity tests with other bacteria, then most H. pylori are extremely sensitive. It has
been suggested that these bacteria are resistant under microaerophilic conditions. As
there is no definite means of verifying whether the conditions used in the sensitivity test
exactly match those at the site of infection, the conclusion is unwarranted. However, the
clinical success of metronidazole suggests that most bacteria truly are sensitive to this




Clarithromycin is active against H. pylori, even in the acidic environment of the
stomach. This is the reason why clarithromycin is often used as an eradication regimen
for H. pylori infection. However, development of resistance is predominantly a reason
for therapy failure. In E. coli and some other bacteria, the most common macrolide
resistance mechanism is methylation of the A2058 in 23S rRNA by methytransferases.
The A2058 is the target of ribosomal methyltransferase, encoded by the erm gene and is
also the macrolide-binding site (Vannuffel et al., 1992; Weisblum, 1995). However, in
H. pylori, point mutations in the 23S rRNA have been found to reduce drug binding to
ribosome (Occhialini et al., 1997) and consequently confers macrolide resistance
(Hulten et al., 1997; Occhialini et al., 1997; Versalovic et al., 1996). Similar findings
were observed in Mycobacterium spp., Mycoplasma pneumoniae or Propionibacterium
spp that mutations in the 23S rRNA conferred macrolide resistance (Ross et al., 1997)
(Lucier et al., 1995; Meier et al., 1994; Nash and Inderlied, 1995).
Initially, mutations conferring macrolide resistance in H. pylori were identified at
positions 2058 and 2059 (Hartzen et al., 1997) or positions 2143 and 2144 (Versalovic
et al., 1997) or positions 2514 and 2515 (Debets-Ossenkopp et al., 1996) by different
groups of investigators. After the study by Taylor et al., positions correspond to E. coli
bases 2058 and 2058 are considered as positions 2142 and 2143 in H. pylori, based on
the structure of the gene in H. pylori (Taylor et al., 1997). Five distinct point mutations
have been reported to confer macrolide resistance in H. pylori isolates, i.e., G2115A,
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G2141A, A2142G, A2142C and A2143G (Hulten et al., 1997; Occhialini et al., 1997;
Stone et al., 1997; Versalovic et al., 1996). The A2142G and A2143G mutations are the
most predominant among macrolide-resistant strains.
This study analysed the association between macrolide resistance and mutations in the
peptidyl transferase region of the 23S rRNA gene in 10 macrolide-resistant isolates, nine
of which were resistant to clarithromycin and cross-resistant to erythromycin (MIC of
>256mg/L), suggesting the common target between macrolides. Mutations in the 23S
rRNA were characterised by DNA sequencing. The MICs were correlated with the
presence of alterations in the 23S rRNA. Point mutations were detected in 9 of the 10
macrolide-resistant isolates (90%). The majority of isolates (70%, 7/10) contained the
A2143G mutation. The result is similar to the finding of Gracia-Arata et al., Alarcon et
al. and Domingo et al. (Alarcon et al., 2000; Domingo et al., 1998; Garcia-Arata et al.,
1999) but different from some other reports, which found mutation at A2142G in the
majority of resistant isolates (Versalovic et al., 1997; Wang and Taylor, 1998). Although
mutation at A2142G and A2143G usually found in macrolide-resistant H. pylori,
mutation at A2142G was not detected in this study. It has been demonstrated that high-
level clarithromycin resistance is associated with the presence of the A2142G mutation
in H. pylori (Alarcon et al., 2000; Versalovic et al., 1997). The absence of A2142G in
this study may be because a small number of resistant isolates being studied and the
MICs of most of the strains were not high. Only 3 clarithromycin-resistant isolates had
the MIC of > 32mg/L.
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One isolate had mutation at A2143G and T2182C with the MIC of >256mg/L for both
erythromycin and clarithromycin. These mutations were previously identified and
reported that a C2182T mutation was not associated with clarithromycin resistance by
site-directed mutagenesis (Wang et al., 1998). In this study, a single mutation at
T2182C was identified in one isolate with the clarithromycin MICs of 0.125mg/L and
erythromycin MIC of >256mg/L. Therefore, this result supports the study by Wang et
al and suggests that alternative resistance mechanisms play a role in this strain.
Mutations at C2195T and T1934C have not yet been reported. A C2195G was found in
one isolate with the MIC of 8 and >256m/L for clarithromycin and erythromycin,
respectively while a T1934C was presented with A2143G with the MIC of 32mg/L for
clarithromycin and of >256mg/L for erythromycin. Further study is needed to be
determined whether C2195T and T1934C mutations contribute to macrolide resistance.
One isolate had very high macrolide MICs, erythromycin and clarithromycin MICs of
>256mg/L but no mutation was found in this isolate. Other mechanisms must be
involved in macrolide resistance in this isolate.
As a single point mutation is able to confer resistance to clarithromycin. This can
explain why clarithromycin resistance develops at high frequency after eradication
therapy. A widespread consumption of macrolides for respiratory or gastrointestinal




Fluoroquinolones are potent antibiotics that have DNA gyrase and topoisomerase IV as
their intracellular targets (Drlica, 1999). DNA gyrase introduces negative supercoiling of
DNA and is required for DNA replication and RNA transcription (Maxwell, 1992). The
primary target for Gram-negative bacteria is GyrA and for Gram positive is ParC
(Gonzalez et al., 1998; Kanematsu et al., 1998; Mouneimne et al., 1999; Nakano et al.,
1997; Yoshida et al., 1990). Mutations conferring high-level quinolone resistance in
many bacteria occur in the QRDR of the gyrA gene, which consist of amino acids 67-
106 ((Maxwell, 1992; Yoshida et al., 1990). Amino-acid substitutions in the QRDR in
E. coli result in a reduction in quinolone binding to the gyrase-DNA complex (Maxwell,
1992). In E. coli, mutations at Serine-83 and Aspartic acid-87 give the greatest reduction
in the susceptibility. Mutation of Serine-83 to a hydrophobic amino acid generally
confers more resistance than mutation at Aspartic acid-87 (Khodursky et al., 1995;
Yoshida et al., 1990). Moore et al. (1995) reported ciprofloxacin resistance in H. pylori
isolated from the patients enrolled in a clinical trial evaluating the efficacy of
ciprofloxacin for H. pylori eradication and determined the mechanism of resistance. It
has been shown that resistance was associated with four classes of point mutations with
amino-acid substitution at Asparagine-87 to Lysine, Alanine-88 to Valine, Aspartic acid-
91 to Glycine or Asparagine, or Tyrosine and a double amino-acid substitutions at
Aspartic acid-91 to Asparagine and Alanine-97 to Valine in the gyrA gene, encoding the
A-subunit of DNA gyrase.
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This study characterised gyrA gene from H. pylori to determine the mechanism of
fluoroquinolone resistance in both in vitro and in vivo. The results demonstrate that
ciprofloxacin resistance in H. pylori is due to mutations in the QRDR of gyrA gene with
in agreement with the study by Moore et al (1995). This study also supports the existing
data, which shows a common region in bacterial gyrA conferring fluoroquinolone
resistance. Similar findings have also been found in other bacteria such as E. coli
(Yoshida et al., 1990) and C. jejuni (Wang et al., 1993). Mutation at Serine-83 is the
most common in E. coli and C. jejuni. In contrast to H. pylori, the most common amino-
acid substitution in H. pylori reported is Aspartic acid-91 (Aspartic acid-87 in E. coli)
(Moore et al., 1995). This study also demonstrates that mutations at position 91 have
been found in the majority of ciprofloxacin-resistant strains. All of the laboratory
mutants had mutations either a single mutation at Aspartic acid-91 or a double amino-
acid substitution at Aspartic acid-91 and either Glycine-85 or Asparagine-87. In
addition, two of the three ciprofloxacin-resistant clinical isolates showed a single amino-
acid substitution at Aspartic acid-91 and one had an amino-acid substitution at
Asparagine-87 (amino acid 83 in E. coli). These results confirm the study by Moore et
al. (1995).
As parC cannot be identified in the H. pylori genomic DNA (http;//www.ncbi.nlm.
nih.gov/entrez/query.fcgi), the contribution of this gene toward fluoroquinolone
resistance cannot be considered. This finding is similar to C. jejuni, which parC gene
cannot be found in the genomic DNA, although Gibreel et al. reported mutation in parC
at Arginine to Glutamine in C. jejuni (Gibreel et al., 1998). It is likely that the parC
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gene found in this study was not that of C. jejuni, as it was similar to E. coli parC, with
95% similarity.
The results obtained from this study reveal that gyrA mutation is primarily selected by
ciprofloxacin. The second- and third-step mutants of HP-1, HP-4 and HP-7 did not show
any additional mutations in their gyrA QRDR when the MICs were increased. Therefore,
alternative mechanisms, such as active efflux, may play a role in ciprofloxacin resistance
in H. pylori.
The ciprofloxacin-resistant mutants of HP-7 and NCTC 11916 had a double amino-acid
substitution at amino acid 91 and 87 in their second-and third-step mutations and the
mutant of HP-17 had a double amino-acid substitution at position 91 and 85 in its third-
step mutation. These two types of double amino-acid substitutions found in this study
have not been reported before in H. pylori. In the laboratory mutants, the MICs of
ciprofloxacin for stains with two gyrA mutations (Mutants of HP-7, HP-17 and NCTC
11916) are not different from those for strains with only a single amino-acid substitution
(Mutants of HP-1 and HP-4). Double amino-acid substitutions always found in the
second- and third-step mutants with high-level resistance, but not in the first-step
mutant, suggesting that two mutation sites in the gyrA gene confer high-level
ciprofloxacin resistance in the laboratory mutants.
The results also demonstrated that a single amino acid change at Aspartic acid-91 to
either Asparagine or Tyrosine (Mutants of HP-1 and HP-4, respectively) is responsible
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for high-level ciprofloxacin resistance in H. pylori. These findings suggest that the loss
of the acidic residual at position 91 is crucial for the emergence of fluoroquinolone
resistance.
High-level resistance to ciprofloxacin was associated with either a single or double
amino-acid mutations in the gyrA gene in laboratory mutants. A single mutation at either
Aspartic acid-91 or Asparagine-87 was associated with ciprofloxacin-resistant in clinical
isolates. Asparagine-87 in H. pylori is homologous to Serine-83 in E. coli. Mutations at





Metronidazole resistance is one of the major causes of treatment failure as it is widely
used in the eradication regimen. Mechanism of resistance is still unclear. Metronidazole
has to enter bacterial cell in order that the nitro group of imidazole ring is reduced and
form a hydroxylamine derivative, causing DNA damage and cell death (Edwards, 1993).
Recently, Goodwin et al. (1998) identified the rdxA gene, encoding oxygen-insensitive
NADPH nitroreductase, which can reduce metronidazole to its active form. It was
demonstrated that the loss of this enzyme activity confers metronidazole resistance and
showed that frameshift mutation, resulting in a truncated protein and missense mutations
contributed to metronidazole resistance (Goodwin et al., 1998). However, an intact rdxA
gene product can be found in some metronidazole-resistant strains (Jenks et al., 1999).
This study examined the role of rdxA in the development of metronidazole resistance in
H. pylori. The results showed that 5 of the 6 metronidazole-resistant isolates had
missense mutations and one isolate had a nonsense mutation, resulting in a stop codon
and leading to a truncated protein. The results are similar to the study by Goodwin et al.
that alterations in the rdxA gene were mostly due to missense mutations (Goodwin et al.,
1998). However, the mutations found in my study were not the same. In contrast to the
study in the mouse model, a majority of resistant strains carried frameshift mutations,
resulting in a stop codon (Jenks et al., 1999). Tankovic et al. and Jenks et al. found that
the majority of the frameshift mutations occurred within poly (A) tracts, suggesting that
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slipped-strand mispairing may be an important mechanism in the regulation of gene
expression (Jenks et al., 1999; Tankovic et al., 2000).
Solca et al. demonstrated amino acid substitutions were identified among both
susceptible and resistant isolates. Various missense mutations were identified and 15
mutations were shared by both resistant and susceptible strains and no particular
nucleotide mutation or amino acid substitution were associated to metronidazole
resistance and there was no specific cluster associated with the resistance phenotypes in
the phylogenic analysis (Solca et al., 2000). Similar to the work by Solca et al., the
present study showed 20 different amino-acid changes (positions 6, 16, 24, 31, 51, 52,
55, 59, 62, 71, 75, 83, 85, 90, 97, 103, 114, 118 and 172) in rdxA of metronidazole-
resistant strains, comparing with rdxA of H. pylori 26695. This study also demonstrated
that the majority of missense mutations were found in susceptible strains when
compared the result with other reports and there is no correlation between metronidazole
MIC and either type or position of mutation in the rdxA gene.
Both H. pylori NCTC11637 and NCTC11916, which are metronidazole-sensitive
strains, identified by our metronidazole-susceptibility testing, had three amino-acid
substitutions and nonsense mutations at position 73, leading to a stop codon which was
the result of deletions of a 469-bp segment and insertions of a 267-bp fragment. The
insert is closely matched to the vacuolating cytotoxic gene and cag I pathogenicity
island of H. pylori by BLAST search. The insert carried 41bp and 33bp at the left and
right ends, closely matched to the left and right ends of IS605. This variant of IS605 was
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found at the right end of cag pathogenicity island in H. pylori strain CCUG 17874
(Censini et al., 1996). My finding is different from the work by Debets-Ossenkopp et al
in that rdxA of the H. pylori NCTC11637 had a nonsense mutation at position 83 instead
of at position 73, identified by this study (Debets-Ossenkopp et al., 1999).
The present study demonstrated that inactivation of the rdxA gene is not the sole
contributor to the mechanism of metronidazole resistance. Only one of the six
metronidazole-resistant isolates had amino acid substitution, causing a premature stop
codon leading to a truncated RdxA and the finding that two metronidazole-sensitive
strains had truncated RdxA, due to deletion and insertion in the rdxA gene. In addition,
amino acid substitutions found in the resistant strains are also present in the sensitive
strains, identified by other studies, and the rdxA genes in metronidazole-sensitive H.
pylori strains differ by approximately 5% at the nucleotide level (Goodwin et al., 1998).
These findings suggest that mutations in the rdxA gene do not always confer
metronidazole resistance and alternative mechanisms of resistance exist in H. pylori.
Other mechanisms of resistance may be related to diminished uptake or active efflux;
more efficient DNA repair; enhanced scavenging of toxic oxygen radicals and the loss
of other enzyme involved in reduction of metronidazole to its active form.
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9.6 Cloning, Expression and Purification of H. pylori DNA
Gyrase
DNA gyrase introduces negative supercoils into covalent closed DNA by using the free
energy derived from ATP hydrolysis. It is a heterotetramer, composed of GyrA and
GyrB proteins, which are encoded by gyrA and gyrB, respectively. DNA gyrase activity
of H. pylori has not yet been reported (Reece and Maxwell, 1991). This study cloned,
overexpressed and purified GyrA and GyrB proteins to characterise the DNA gyrase
activity in H. pylori. As parC has not yet been identified, characterisation of the DNA
gyrase may explain the absence of topoisomerase IV in H. pylori.
In the present study, the complete nucleotide sequence of DNA gyrase of H. pylori
NCTC 11637 was determined. The gyrA and gyrB genes were compared to H. pylori and
other bacteria, confirming that the sequences are definitely gyrA and gyrB by BLAST
search. The sequencing analysis revealed that gyrA had an open reading frame of
2487bp, coding for 828 amino acids. The open reading frame of gyrB of 2322bp coded
for 773 amino acids. It was shown that GyrA and GyrB had a calculated molecular mass
of 92kDa and 86kDa, respectively. In E. coli, GyrA and GyrB protein consist of 875 and
804 amino acids, with the molecular mass of 97 and 90kDa, respectively (Reece and
Maxwell, 1991)
The gyrA and gyrB genes were compared to H. pylori and other bacteria, confirming that
the sequences are definitely gyrA and gyrB by BLAST search. There is approximately
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95-96% similarity in both gyrA and gyrB at the nucleotide levels. The DNA sequence of
gyrA is similar to that of H. pylori UC 763, accession No. L29481 (Moore et al., 1995)
and the sequences from complete genome of H. pylori 26695 and J99 from GenBank
(Accession No. AE000583 and AE001496, respectively). The results demonstrated that
the gyrA and gyrB genes are diverse among H. pylori strains, as there was 5-6%
difference between H. pylori strains.
In this study, the predicted GyrA for H. pylori NCTC11637 has one more amino-acid
residue than the sequence of H. pylori 26695 and two more residues for H. pylori UC
763. H. pylori NCTC11637 has the same number of amino acids (828 amino acids) as
that of H. pylori J99. Similarly, there is 5-6% difference in the GyrB, when compared
with the H. pylori sequences in the GenBank. The predicted GyrB for H. pylori for H.
pylori NCTC11637 has 773 amino acid residues, similar to both H. pylori 26695 and
J99.
Compared to other bacteria, amino-acid sequence of H. pylori GyrA showed 59%
identity with C. fetus and C. jejuni, 52% with B. subtilis, 45% with E. coli and V.
cholerae. The GyrB protein of H. pylori had 92-93% identity with H. pylori, 55-56%
with C. jejuni and 40-41% with E. coli, V. cholerae, H. influenzae and Salmonella spp.
Similar to other bacteria, the active site of GyrA, Tyrosine-122, which involves in the
DNA breakage and rejoining activities in E. coli (Horowitz and Wang, 1987), is found
to be conserved in H. pylori. In E. coli, it has been reported that amino acid residues
such as Tyrosine-5, Asparagine-46, Aspartic acid-73, Lysine-103, Tyrosine-109,
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Glutamine-335, and Lysine-337 involve in ATP binding (Wigley et al., 1991). All these
residues are also conserved in H. pylori and other bacteria.
The GyrA and GyrB proteins were overexpressed after confirmation that the gyrA and
gyrB inserts were in frame with the N-terminal tag and placed in the correct orientation
in the expression vectors. The proteins were separately purified with affinity
chromatography. The results of this study showed that no supercoiling activity could be
detected on relaxed DNA exposed to a combination of GyrA and GyrB proteins. The
degree of purity of the proteins could affect the supercoiling activity, as these proteins
were partially purified. In addition, GyrA and GyrB (His-Tagged proteins) contained the
N-terminal tag, which could certainly interfere with protein folding. Therefore, the
removal of the N-terminal tag may improve the enzyme activity and the re-evaluation of
A and B proteins need to be determined by N-terminal sequencing. As the time and
resources are limited, this investigation needs much further study. However, it is very
likely that the DNA gyrase of H. pylori must undertake the decatenation role normally




Antibiotic susceptibility patterns of H. pylori strains isolated in Scotland against
amoxycillin, ciprofloxacin, clarithromycin, erythromycin, tetracycline and
metronidazole revealed that the MIC50 and MIC90 values of all antibiotics are below the
breakpoints, indicating that these antibiotics have high activities against H. pylori.
Amoxycillin is the most active compound and metronidazole is the least active
compared to other antibiotics tested. Although, many antibiotics found to be active in
vitro, antibiotic resistance to H. pylori is emerging. In this study, the prevalence of
macrolide resistance is greater than other antibiotics, 9.1% (10/110) for erythromycin
and 8.2% (9/110) for clarithromycin. Resistance to metronidazole is relative low (7.1%,
8/110), compared with other reports but this largely reflects differences in methodology
for the susceptibility testing of metronidazole. Resistance to tetracycline with
intermediate resistance was found in one isolate (0.9%). Ciproflaxacin resistance was
found in 1.8% (2/110). No amoxycillin resistance was detected. The results from this
study suggest the importance of sensitivity testing before eradication therapy as
resistance to macrolide and metronidazole is emerging in H. pylori isolated in Scotland.
The method determining metronidazole susceptibility is involved in the variations in the
MICs. This present study showed that a 24-hour pre-incubation under anaerobic
conditions is necessary to achieve accurate susceptibility results. Activation of
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metronidazole requires anaerobic environment. Susceptibility testing of metronidazole
under microaerophilic conditions elevates the MICs.
This thesis demonstrated that mechanism of macrolide resistance was associated with
alterations in the peptidyl transferase region of the 23S rRNA. Point mutations were
detected in 9 of the 10 macrolide-resistant isolates (90%). The A2143G mutation was
found in the majority of isolates (70%, 7/10). Cross-resistance between erythromycin
and clarithromycin was demonstrated, suggesting the common target of macrolides.
High-level resistance to ciprofloxacin was found to be associated with two mutation
sites in the gyrA gene at Aspartic acid-91 and either Glycine-85 or Asparagine-87 in
laboratory mutants. The results also demonstrated that a single amino acid change at
Aspartic acid-91 to either Asparagine or Tyrosine is responsible for high-level
ciprofloxacin resistance in H. pylori, suggesting that the loss of the acidic residual at
position 91 is crucial for the emergence of fluoroquinolone resistance. Mutation at
Aspartic acid-91 to Asparagine was also found in ciprofloxacin resistant clinical isolates.
This study analysed the role of the rdxA gene conferring metronidazole resistance. The
results suggest that mutations in the rdxA gene do not always confer metronidazole
resistance and alternative mechanisms, such as reduced drug uptake, active efflux, more
efficient DNA repair; enhanced scavenging of toxic oxygen radicals and the loss of
other enzymes involved in reduction of metronidazole to its active form.
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The complete gyrA and gyrB genes were separately cloned into pCR T7/NT vector. The
sequencing analysis revealed that gyrA had an open reading frame of 2484bp, coding for
828 amino acids and the open reading frame of gyrB of 2322bp coded for 773 amino
acids. GyrA and GyrB had a calculated molecular mass of 92kDa and 86kDa,
respectively. It was found that the gyrA and gyrB genes are diverse among H. pylori
strains as there was 5-6% difference between H. pylori strains. Unfortunately, the
attempt to demonstrate DNA gyrase activity from the DNA gyrase subunit preparations
was not successful after overexpression and purification of GyrA and GyrB. The results
showed that supercoiling activity could not be detected on relaxed DNA exposed to a
combination of GyrA and GyrB proteins. As they are partially purified, the effect of the
impurity of the proteins could hinder the supercoiling activity. In addition, the N-
terminal tag could interfere protein folding. As the time and resource are limited, this
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Sir,
In a recent issue of the Journal, Conti et al. concluded that
so-called personalized antifungal susceptibility testing
might be superior to the standardized reference method in
terms of predicting the outcome of antifungal therapy.1
They rightly point out that a wide range of factors can
significantly affect the reproducibility of the test method.
In this sense, antifungal agents are no different to anti-
bacterials.
The findings of Conti et al. that the in-vitro activities of
antifungal agents when determined in plasma are markedly
different from those determined with a synthetic medium
(RPMI 1640) come as no surprise, similar observations
having been reported by several investigators in respect of
antibacterials.2 7 With regard to the latter, it was shown,
albeit in only a few instances, that the reduced activities
of these drugs in body fluids influence their clinical effi¬
cacy.2,4 We have evaluated the activities of amphotericin B
and fluconazole, alone and in combination, both in a
synthetic medium (broth) and in human blood and showed
that fluconazole, at certain concentrations, was fungistatic
when susceptibility testing was carried out in broth, but
fungicidal, at the same concentrations, when tested in
blood.8 This might explain why the results of in-vitro
testing failed to predict the efficacy of fluconazole in vivo.
For amphotericin B, we observed a marked decrease in its
activity in blood which could be accounted for by the
binding of the drug to the outer membranes of the cellular
components of blood and the consequent reduction in the
concentrations of free drug.9,10
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Metronidazole is frequently included in regimens used to
eradicate Helicobacter pylori. However, the rates of
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metronidazole resistance amongst H. pylori isolates are
highly variable—from 11% to 70% in developed countries
and even higher in developing countries.1 As susceptibility
testing of H. pylori has not been standardized, it may be
that variations in the rates of resistance can be accounted
for by differences in the methods of determining suscepti¬
bility. For example, Smith & Edwards2 demonstrated that
H. pylori NCTC 11637 is resistant to metronidazole when
tested under microaerophilic growth conditions, but sus¬
ceptible when tested under anaerobic conditions. This
raises an important question: are strains which are resistant
to metronidazole when in-vitro susceptibility testing is
carried out under microaerophilic conditions also resistant
in vivo? The methodology of determining the susceptibility
of this bacterium tometronidazole is crucial to the ability to
predict the efficacy of eradication therapy. The present
study was therefore undertaken to evaluate variations in
methodology on the outcome of susceptibility testing.
The MICs of metronidazole for 21 clinical isolates of
H. pylori were determined by the Etest method (AB
Biodisk, Solna, Sweden)3 according to the manufacturer's
instructions; the medium used was Columbia agar (Oxoid,
Basingstoke, UK) supplemented with 7% horse blood and
H. pylori NCTC 11637 was included as a control. The
inocula were prepared by suspending colonies from 48 h
growth on Columbia blood agar in Brain Heart Infusion
(BHI) broth (Oxoid) and adjusting the suspensions to
give turbidities equivalent to that of a No. 3 McFarland
standard. The plates were incubated at 37°C in a micro¬
aerophilic atmosphere (Campylobacter System Gas
Generating Kit, Oxoid) and MICs were recorded after 72 h.
The majority (12) of the 21 strains, as well as the control,
were resistant tometronidazole on the basis of a lower MIC
breakpoint of 3=0.5 mg/L recommended by AB Biodisk;
the MICs for five strains were 3=256 mg/L.
The effects of varying the conditions of susceptibility
testing were evaluated with the control strain which was
shown by us to be highly resistant to metronidazole (MIC
3=256 mg/L), although other investigators have reported it
to be susceptible.4,5 Firstly, the inoculated Etest plates were
incubated under anaerobic conditions for 24 h before being
incubated under microaerophilic conditions for a further
72 h. With the introduction of a pre-incubation phase, the
MIC for H. pylori NCTC 11637 fell to 0.016 mg/L which is
below the breakpoint defining susceptibility. This suggests
that metronidazole is activated, i.e. a nitro group is reduced
to a radical anion which damages DNA,6 only under strictly
anaerobic conditions. The requirement for an anaerobic
atmosphere of incubation for the activation of metron¬
idazole may explain why some centres have reported high
rates of resistance to this drug amongst H. pylori isolates.
The next step was to compare the outcome of incubating
H. pylori NCTC 11637 in an anaerobic jar with that in an
anaerobic chamber before the plates were incubated in a
microaerophilic atmosphere. Either no growth or only
poor growth was observed following pre-incubation in an
anaerobic chamber (Don Whitley Scientific Ltd, Shipley,
UK), whereas the strain grew well when an anaerobic jar
was used, suggesting that growth of H. pylori depends on a
high level of humiditywhich is not provided in an anaerobic
chamber.
Finally, we also investigated the effects of varying
the medium, inoculum size and duration of incubation on
the MICs of metronidazole for the control strain. The
media evaluated were Columbia and Mueller-Hinton
agar (Oxoid), both supplemented with 7% horse blood.
Colonies from a 48 h culture were suspended in BHI broth
and the turbidities of the suspensions were adjusted so that
they were equivalent to that of either a 0.5 or a No. 3
McFarland standard. The inoculated plates were then incu¬
bated in an anaerobic atmosphere for 24 h, followed by
incubation for either 48 h or 72 h in a microaerophilic
atmosphere. Growth on Mueller-Hinton agar was poor,
while that on Columbia agar was profuse. The MICs were
difficult to interpret when the lower inoculum was used, but
were clear and reproducible with the higher inoculum.
After 48 h of incubation, it was not possible to record the
MICs accurately because growth was too poor. On the
other hand, following incubation for 72 h, the MICs were
easy to read and unequivocal.
Susceptibility testing of all 21 H. pylori isolates to
metronidazole was then repeated under optimal con¬
ditions, i.e. pre-incubation of Columbia agar plates inocu¬
lated with the higher inoculum for 24 h in an anaerobic
jar, followed by incubation for 72 h in a microaerophilic
atmosphere. Under these conditions, the MIC50 and MIC90
were 0.016 mg/L and 0.19 mg/L respectively; only one
strain was truly resistant to metronidazole (MIC
>256mg/L).
We have identified the optimal conditions for deter¬
mining the susceptibility of H. pylori to metronidazole. In
particular, pre-incubation under anaerobic conditions,
ideally in an anaerobic jar, is regarded by us as being essen¬
tial if accurate results are to be obtained. Our interpreta¬
tion of the findings of this study is that H. pylori strains are
inherently susceptible to metronidazole—a view that is in
contrast with that of earlier investigators.2 If the drug is
pre-reduced, as it must be when undertaking susceptibility
testing with other bacteria, then most H. pylori isolates will
appear susceptible to it. It has been suggested previously
that H. pylori is resistant to metronidazole when suscep¬
tibility is determined under microaerophilic conditions.
We believe that, on the basis of current evidence, this con¬
clusion is unwarranted as there is no means of confirming
that the conditions that prevail during susceptibility testing
are the same as those at the site of infection. None the less,
the success achieved with metronidazole when it is used as
treatment of patients with H. pylori infection suggests that
most strains are susceptible to this drug, as our suscepti¬
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Sir,
The Vitek system (bioMerieux, Hazelwood, MO, USA) was
recently introduced into our laboratory as the principal
means of identifying clinical isolates and performing suscep¬
tibility testing. However, concerns about the system's ability
to accurately detect susceptibility to trimethoprim arose
when the number of strains ofmethicillin-resistant Staphylo¬
coccus aureus (TvfRSA) resistant to this agent increased.
Although trimethoprim is not normally regarded as first-line
treatment of patients with infections caused by MRSA, it has
been used successfully in combination with various other
agents as oral therapy1'2 and may also have some value as
monotherapy, owing to its in-vitro activity against most
staphylococci, including MRSA.3 Trimethoprim has the
added advantages of being inexpensive, being available as an
oral formulation, being well absorbed and having an excel¬
lent safety profile. In common with antibiotics in general,
any apparent increase in the incidence of resistance to
trimethoprim will limit its potential as treatment and the
investigations described here were undertaken in an attempt
to identify an explanation for this phenomenon.
The susceptibilities of 100 non-replicate clinical isolates
of MRSA to trimethoprim were determined in duplicate by
three different methods. Vitek GPS-AK cards were inocu¬
lated, susceptibilities read according to the manufacturer's
instructions and susceptibility categories assigned on the
basis of MIC breakpoints recommended by the National
Committee for Clinical Laboratory Standards (NCCLS),
i.e. susceptible, MIC =£2 mg/L and resistant, MIC >4
mg/L.4 The Stokes' disc diffusion method was performed
according to amethod described previously5 with DST agar
(Oxoid, Basingstoke, UK) supplemented with 2% lysed
horse blood, discs (Oxoid) containing 2.5 |xg of trimetho¬
prim and inocula with turbidities equivalent to that of a 0.5
McFarland standard. The Oxford strain of S. aureus was
used as the control and the zones of inhibition were read
after overnight incubation at 37°C. Susceptibility was
defined as a zone of inhibition greater than or equal to that
of the control or not >3 mm smaller and resistance as a
zone of inhibition >3 mm smaller than that of the control.
Finally, MICs were determined by an agar dilution method
recommended by the NCCLS;4 an MIC breakpoint of
=£2 mg/L was used to define susceptibility.6
Eighty-seven of the 100 isolates were identified as
susceptible to trimethoprim by both the disc diffusion and
agar dilution methods; MICs ranged from 0.25 to 1 mg/L.
Of these 87, 36 (41%) were classified as susceptible and 32
(37%) as resistant with the Vitek card. Susceptibility
testing of the remaining 19 strains by this method was
inconclusive, the isolates being susceptible on one of the
duplicate testings and resistant on the other, i.e. either
1 mg/L or 2 mg/L and 3=4 mg/L respectively. Thirteen
isolates were found to be resistant by all three methods.
Preliminary investigations with coagulase-negative staphylo¬
cocci and methicillin-susceptible strains of S. aureus
revealed patterns similar to that observed with the MRSA
strains (data not shown).
In summary, the susceptibilities of 100 clinical isolates of
MRSA to trimethoprim, as determined by the disc diffus¬
ion and agar dilution methods, were identical, with 87
strains being categorized as susceptible. The Vitek GPS-
AK card, on the other hand, incorrectly designated 32 of
these 87 strains as resistant—a major error rate of 37%.
Moreover, the results of susceptibility testing of a further
19 strains were not reproducible and, therefore, inconclu¬
sive. These observations suggest that the Vitek GPS-AK
card is an unreliable method of determining the suscepti¬
bilities of staphylococci to trimethoprim.
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High-Level Fluoroquinolone Resistance in Helicobacter pylori Caused by Three
Unusual Sequential Mutations in gyrA
Ciprofloxacin resistance in Helicobacter pylori is due to the alteration within the gyrA gene, encoding
the A subunit of DNA gyrase. To investigate the development of resistance in H. pylori, ciprofloxacin-
resistant mutants were selected in vitro by exposing a sensitive strain to serial increments of
ciprofloxacin in Columbia blood agar plate. The Quinolone Resistance-Determining Region (QRDR) of
gyrA gene was analysed for mutations. Gene amplification was performed by PCR and the resultant
fragments were sequenced. Reduced susceptibility (MIC 8-128 mg/L) to ciprofloxacin was associated
with either a single or double amino acid changes in gyrA gene. The first-step mutant (MIC 8 mg/L)
carried one gyrA mutation at amino acid 91 (Asp to Asn). The second-step mutant (MIC 64 mg/L) had
an additional gyrA mutation ht amino acid 85 (Gly to Cys) and the third-step mutant (MIC 128 mg/L)
showed the mutation at amino acid 91 (Asn to Tyr). A comparative in vivo study for ciprofloxacin
resistance was determined by a clinical ciprofloxacin resistant isolate with the MIC 32 mg/L. This strain
had a single amino acid substitution at codon 87 (Asn to Lys). After the in vitro selection mutation, no
further alteration in the QRDR was observed when the MIC was increased to 64 mg/L. This latter
observation demonstrates that gyrA mutations are not sole contributors for the mechanism of
ciprofloxacin resistance in H. pylori. As no parC gene has yet been identified in H. pylori, any
contribution from topoisomerase IV mutants cannot be quantified. High level resistance to
ciprofloxacin was associated with two mutation sites in the gyrA gene in laboratory mutant. Although a
single mutation at Asn-87, which is homologous to Ser-83 in E. coli, has been linked to high level
resistance to ciprofloxacin in H. pylori. In this study the mutations at amino acid 91 may be comparable
with the codon 87 mutation in E. coli gyrA but no direct comparison can be made with mutations in H.
pylori codon 85.
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Figure1Seq entialmutationsnthQRDRofGyrAlabo atorymut nts 3791 HP-7V1GKYHPHGDNAVYDALVRMAQDFSM(MIC0.032mg/L)NCTC11916VIGKYHPHGDNAVYDALVRMAQDFSM(MIC0.0 4mg/L) LaboratorymutantsfHP-7 37 11"stepmutant 2ndstepmutant 3'°stepmutantV1GKYHPHGDNAVYNALVRMAQ FS(MIC16mg/L) V1GKYHPHGDKAVYNALVRMAQDFSM(MIC128mg/L) VIGKYHPHGDKAVYNALVRMAQDFSM(MIC612mg/L) LaboratorymutantsfNCTC11916 *8791 1s'stepmutantVIGKYHPHGDNAVYNALVRMAQDFSM(MIC16mg/L) 2ndstepmutantVIGKYHPHGDNAVYMALVRMAQDFSM(MIC64mg/L) 3rdstepmutantV1GKYHPHGDKAVYNALVRMAQDFSM(MIC128mg/L) AspartioacidKW Conclusions ®High-levelciprofloxacinresistancen.pyloriw sas ciated witht omutationsi esinthgyrAenelabo atorymu an s. ®Thisist efirstreportshowingdoubleaminocidchanges AsnB7toLysandAsp9lsniH.pylori,lbeitthatyma manifestthemselvestdiffer nuta ionstag . ainadditiontogyrAmutations,otherec an smsfr s s a ce mayplaroleinthemechanismsfciprofloxacinr sistanceH. pylori.'* ®AparCgeneh snotybeenid ntifiedH.pylori,therefo e, mutationsintopoisomera eIVyotcontributth mechanismoffluoroquinolonesistance. References 1.MooreRA,BecktholdW ngSKureishiAanyanEL.N cl oti e sequenceofthgyrAeandcharacterizationiprofloxacin-resista t mutantsofHelicobac erpylori.Antlm crobgentChe oth s1995;3 :07- 111. 2.ChatsuwanT,ndAmyesSGB.Ch racteris tionofciprofloxaci resistanceinHelicob cterpylori.39lhICCACCo ference1999,S ssion 14.C1,Paper1386.
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HelicobacterpyloriIstheprincip lcauseofc on ca tiveg str t sandpep c ulcerdiseas .Multi-drugantim crobialtherap esincl dcombin ionsofpr ton pumpinhibitorsando erseve alantim crobialag nts.Resist nceofH.pylor






















Mutationsinthe23SrRNAgenw rexami edinthinemacrolide-resistant H.pyloristrains.Sevenofthninisolateshadmuta ionapositio2143(At G).Twoofthesev nisolateshadnadditionalTtCmut t onaeitherpo i ion 2182or1934.Mutationatposition2 82(TtC)hapreviouslybe nfoundno
tobeassociatedwithm cr lideresistance.Howev r,thmutatioap si i n 1934hasnotpreviouslybe nreported.Oftniisolat s,necar edo ly Tto,Cmutationap sition2182ando eh dnmu ationi'the23$rRNA implyingthatotherechanismsareresponsibfothresistan einth strains.Theresults owthatmacrolideresist nc ,occu ringbydiffe n mechanisms,iscurrentlyfoundIn13%fH.pylo iisolates Introduction Helicobacterpylorilaysanimportanr lenchronicactivegas tisa dpe ulcerdisease.1Multi-drugantimicrobialtherap esincl d ngcombin tionsf clarithromycin,metronidaz leoa oxycillinnpro npumpinhibit rsar widelyusedtoeradicateH.pylo i.2Thdevelopmentofantimicrobialresistance inH.pylorihasbeenassociatedwithtreatm ntfailur .Mutationsinth peptidyltransferaseregionofth23SrRNAfH.py/orfconfmacr lid resistance.3Ithisstudy,winvestig tedthantimicrob alsuscepti i ity patternsofamoxycillin,ciprofloxacin,clarithr m ci ,erythromycin,tetracy line andmetro idazoleinH.pyl ristrai sisolat dEdinburgh,Scotla d.Muta ions inthe23SrRNAgeneconferringmacrolideresistancw ralevalu ted.
Methods
Bacleriaistrains
Atotalf67H.pyloristrainsisolatedfr m243antralbi psys m lfpatients undergoingendoscopyattheCentrefoLiv raDig stivDis rde s,Royal Infirmary,Edinburgh,Scotland.Thesampleswecollect ddur gthpe iod December1999-August2000. Susceptibilityte ting MICsofamoxycillin,ciprofloxa n,clarithromycin,erythromycitetra yclineand metronidazolew redeterminedbyEt stwithColumbiaagarsupple entedith 7%horsebl od. PCRamplificationandsequenci gothe23SrRNAgen PrimersandCRamplificationconditionswereca riedoutasdescribby Occhialinietal.4TheDNAsequenci gw sdetermin dbyaautomatic sequencer. Results
Table2.Mut tionsinthe23SrRNAgenof3macrolid -resistantH.pyl i TC-18 TC-24 TC-40 TC-78 TC-19 TC-140 TC-175 TC-185 TC-215>256 >256 32 6 1.5 3 0.125 24 3>256 >256 >256 >256 >256 >256 >256 >256 >256
TheMIC50andI 90ofthesixantib oticsars owniT bl1.Resi t nto clarithromycinanderyth omycinw sfoundin12%(8/67)an39/ )fth H.pyloristrains,respectively.Alofthe est ainshaderythromycinMICof>256 mg/LSixisolateswerresistanttmet onidazolea dtwoofthalsh clarithromycinanderyth omycinresist ce.Tetracy l nresi tanc(intermediat , MIC1mg/L)wasfoundinonefthe67is lat s(1.5%).Resist cet amoxycillinndciprofl acinwasn tdete ted. Mutationsinthe23SrRNAof9macrolide-resistantisol tapresent din Table2.heAtoGmutationstposition2143wereidentif ed7isola s.T ofthemhadnadditionalmutatifromTtCaeith rp sition1934or2182. Mutationatpositi2182(TtC)hpreviouslybe nfoundnottassocia e withmacrolideresistance.5However,thmutationaposi ion1934hn t previouslybe nreported.Ofthninisolat s,nca riedlyTtC mutationapositi2182ando eh dnmutationithe23SrRNA,implying thatothermechanismsareresponsiblefothresi tancinth est ins. Theresultss owthatmacrolidresistance,occurringbydifferentm h ni ms,
iscurrentlyfoundn13%fH.pylo iisolates. Table1.Antimicrobialsusceptibilitypatte nsof67H.pylo iclini alisola es
A2143Q, A2143G, A2143G A2143G A2143G A2143G A2143G
T2182C T1934C T2182C
Conclusions
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Fluoroquinoloneresistancewasass c a edwithalterationsInthQRDRofgyrA gene.Mutationatposition91(A ptAsn)w sfoundinb thciprofloxacin1- resistantstrains(MIC16and32mg/L).Sevenofthnmacrolide-resistant isolateshadmutationsInt e23SrRNAapo ition2143(AtoG),Twfhe sevenisolateshadnadditionalTtCmut tioaeitherposition2182or1934. Oftheenisolat s,twocarriedinglmutationaei herpo ition2182or195. Mutationatposition2182hpreviouslybe nfoundnotbassociat dwith macrolideresistance.However,thmutationsaposi ion1934(TtC)and position2195(CtoT)havenotpre iouslybe nIdentifi d.Nomutati nw s detectedinonisolate.ThresultsImplythadiffer nmechanismsar responsibleformacr lideresistanceinOurH,pylo istrains. Introduction Multipleantimicrobialther piesincludingcombin tionsofclarithromyci , metronidazoleoramoxyc llinandpr tou pinhibit rsa ewid lyusedto eradicateH.pylori.How ver,antimicrobialresistanceinH.pyl rihaemerged andisconsidereatheprincipalc u eoftreatme tfailur .Inth sst dy,we investigatedtheantimicrobialsuscepti litypatt rnsofamoxy ill n,ciprofloxaci , clarithromycin,erythromycin,tetracycl neandmetro idazoleinH.pyl is r ins isolatednEdi burgh,Scotland.Muta io swithithepeptidyltr nsferasereg on ofthe23SrRNAandmutationsintheQRDRogy Aenwalsoevaluated
Methods
Bacterialstrains Atotalf100H.pyloristrainswereisolatedfr m4 8an lb op i sfp ient undergoingendoscopyattheCentrfoLivaDig stivDis rders,Royal Infirmary,Edinburgh,Scotland.Thespecim sw rcoll ct ddur gthperiod December1999-February2001. Susceptibilityte ting MICsofamoxycillin,ciprofloxacin,clarithromycin,eryth o ycin,tetracy lineand metronidazolew redeter inedbyEt s . Mechanismsofmacrolideandfluoroquinoloneresistan es Thepeptidyttranf raseregionof23SrRNAgeneanthQRDRofgy Ae wereamplifiedandsequencedinmacrolide-resistantandciproflox in-resistant strains,respec ively*1-2).
Table2MutationsInthe23SrRNAgenof10macrollde-reslstantH.pyl i
Results






























































Figure1MutationsintheQRDRofgyrAeninciprofloxacin-resistantisolates 91. NCTC11916VIGKYHPHGDNAVYDALVRMAQDFSM(MIC0.064og/L) TC-246VIGKYHPHGDNAVY;ALVRMAQDFSM(MI16mg/L) TC-413VIGKYHPHGDNAVY:(ALVRMAQDFSM(MI>32mg/W D■Aaapartioaoid ,HwAeja x giAe-;: Conclusions »Theprevalenceofmacrolidresistanc(10%)igreat rthan otherantibiotics. ®Mutationsinthepeptidyltransferaseregionofth23SrRNAin H.pyloriareassociatedwithmacrolideresistance. eFluoroquinoloner sistanceiassociatedwithmutati nsinth QRDRofgyrAene. References 1.Occhialini,A.,MUrdac ,F.Daucet-Populaire,C.M.Bebear,H.Lamouliatte,ndF. Megraud.1997.MacrolideresistanceinHelicobac erpylo i:rapiddetectionofpoint mutationsandassaysofm crolidebindi gtribosomes.Antimicr b.Age t Chemother.41:2724-28 2.MooreRA,Beckthold,W ngSKur is iA,andBryanEL.1995Nucleotide sequenceofthgyrAnandcharacterizationofciprofloxacin-resistanmutanto Helicobacterpylori.Antimicr b.Ag ntsChemothers.39:107-111.
AntimicrobialResistanceofHStrai s IsolatedinSc tl nd T.CHATSUWAN'.FRATON-,.C.HEADING1andS.GBAMYES' DepartmentofMedicalMicrobi logy.MedicalSch ol,Unive sityofEdinburgh.Edin rgh,UK:'Ce trefoLiveandDigest veisor ers.RoyalInfirm ry.Edinburgh,UK IntroductionTable1Antimicrobialsusceptibilitypa ternsof1 0H.pylo iisolates













































strainsisolatedinScotland. aToinvestigatemut tionswithinthpeptidyltransferase regionofthe23SrRNAgenandmutationsintheQRDR ofthegyrAgeneinmacrolide-resistantanciprofloxacin- resistantisolates,respectively. Methods Bacterialstrains Atotalf110H.pyloristrainswereisolat dfr m454antral biopsiesfpatientsundergoingendoscopyatthCentrefo LiverandDigestiveDisorders,Roy lInfirmary,Edinbur h, Scotland.Thespecimenswerecolle tedduringtheperi d December1999-March2001. Susceptibilitytesting TheMICsofamoxycillin,cipr floxacin,clarithromycin, erythromycin,tetracyclineandmetronidazolewe e determinedbyEt stwithColumbiaagasupplementedwith 7%horsebl od. Mechanismsofmacrolideandfluoroquinol neresista c Thepeptidyltranferasereg oofth23SrRNAgeneandth QRDRofthegyrAenew ramplifiedandsequenced
inmacrolide-resistantaciprofloxacin-resistantstrain , respectively'12).













































TheMICSofthesixantibioticsareshowninTable1. Fluoroquinoloneresista cewasdemonstr tedin2isolate (1.8%).Mutationatposition9(A ptAsn)ofthegyrAene wasdetectedinbothciprofloxacin-resistantstrai s(Figu e1). Resistancetoclarithromycinanderythromycinwafoundin 8.2%(9/110)and9.1%(10/1 0)oftheHpyloriisolates, respectively.Mutationsinth23SrRNAofmacrolide- resistantstrainsa edemon tratediTabl2.Sevenofth tenmacrolide-resistantisolateshadmutationsint e23S rRNAatposition2143(AtoG).Twofthesev nisolateshad anadditionalTtoCmut t oaeitherposition2182or1934. Oftheenisolat s,twocarriedsinglmutationaeithe position2182or2195,Mutati natposition2182ha previouslybe nfoundnottbassociatedwithmacr lid resistance.However,thmutationsaposition1934(Tto C)andposition2195(toT)haven tpreviou lybe n identified.Nomutationwasdetectedinonisolate. Metronidazoler sistancewasdemonstr tedin8isolate (7.3%).Twoofthemhadcl rithromycinanderythromycin resistance.Tetracycliner sistance(intermediate,MIC 1mg/L)wasfoundinneisolat(0.9%).Resistanceto amoxycillinwasn tdetected. Conclusions theprevalenceofrriacrolid ;resistance(9.1%)isgreater thanotherantibiotics. eMutationsinthepeptidyltransferasereg oofth23S rRNAgeneiH.pyloriaassociatedwithmacrolide resistance. qFluoro uinoloneresistanceisassociatedWithmut tionin theQRDRofthegyrAene. References 1.Occhialini.A..MUrdac ,F.Daucet-Populaire,C.M.Bebear,H.Lamouliatte;ndF Megraud.1997.MacrolideresistanceinHelicobacterpyl f.rapiddetectioofpoint mutationsandassaysofmacrolidebindingtoribosomes.Antimicrob.'Agents Chemother41:2724-28 2MooreRA,Beckthold,WongS,KureishiA,andBryanEL.1995Nucleotide sequenceofthgyrAgeneandcharacterizationofciprofloxacin-resist ntmutantsf Helicobacterpylori.Anbm r b.AgentsChemoth r.39:107-111.
